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Abstract. The effect of substituted phenothiazities was studied in 
three different  systems; bacteria and  cancer cells and  reverse  
transcriptase  enzyme  of  Moloney  leukemia  virus. F'lac and 
hemolysin  plasmids  were  elimirutled  by  some  substituted  
phenothiazities from E.  coli at  a  very  low frequency.  The  same 
phenothiazine  derivatives  also were synergistic  with  tetracycline  
in  bacteria and shown antimutagenic  effect in Arties test.  No 
mutagenic  effects  were observed in  TA 98 strain  of Salmonella 
typhimunium.  Chloroethyl-substituted  phenothiazines showed 
antimutagenicity equivalent  to  the parent compounds;  however,  
phthalimido-substituted phenothiazines  had  higher antimu-
tagenicity of  50%.  F-glycoprotein responsible for  multidrug  
resistance was also inhibited in tumor cells.  The accumulation of 
the  fluorescent rhodamine  123  in  the  phenothiazine  treated  
multi-drug resistant tumor cells was measured by flow cytometry. 
Some  of  the  substituted  phenothiazines  were  effective  P-
glycoprotein blockers, while  some  compounds  had moderate 
activity, but  others were without effect as  compared to  5  pM  
verapamil  On  the  basis of  computer analysis  there are some 
coirelations between  the  biological  activities  and  the  dipole  
moments,  and  entropy of  the  studied  molecules. Our  results  
suggest  that the inhibition  of Hly+  plasmid  replication  and P-
glycoprotein  function may  depend partly  on  similar  electronic  
properties  of  the studied phenothiazine  derivatives.  The activity  
of Moloney leukemia virus reverse transcriptase was inhibited by 
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the  substituted phenothiazines, however, no  basic  differences  
were found  in  the  activities of  phthalimido-  and  chbroethyl  
substituted phenothiazines. 
Resistance  to  chemotherapeutics  has  recently  been  observed  
to  be  emerging  among viruses,  bacteria,  fungi, protozoa  and  
cancer  cells.  The  basic  reason  for  the  development  of  this  
resistance  is  Darwinian  selection,  which  £ftsurek  the  
accommodation  of  the  living  organisms  to  an  altered  
environment.  The  genetic  basis  for  drug  resistance  can  be  
extrachromosomal  plasmids  in  bacteria  and  chromosomal  
mutations.  The  former  plasmid  makes  the  living  organism  
more flexible  in its adaptation  to the environmental  changes,  
ensuring  the  evolution  of  resistance  by  intercellular  transfer  
of  plasmids.  The  latter  is  less  frequent  and  mutations  are  
more conservative than  plasmid encoded DNA and  those can 
be tested  in  mutagenicity  assays. .The inhibition  of  mutations  
can  result  in  a chemopreventive  effect in cancer  induction  or  
resistance  development  in  bacteria  and  cancer  cells,  in  
addition  the  inhibition  of  ABC  transporter  related  effect  
pumps  of  multidrug-resistant  bacteria  and  cancer  cells  can  
restore  the  sensitivity  of  resistant  cells  as  well.  Such  efflux  
pumps  in  bacteria  and  cancer  cells reduce  the  effective drug 
concentration inside the cells to an ineffective level. 
P-glycoprotein  sequences  of: multidrug  resistant  cancer  
cells  have  a  substancial  degree'of'sequence  similarity  with  a  
family of bacterial transporter proteins, i.e., hemolysin (1). On 
the  basis  of  the  homology between bacterial  and  cancer  cell-
produced  ABC  transporters,  the  consequences  of  hemolysin  
plasmid elimination and mdr efflux inhibition were compared. 
This  paper  reports  the  reversal  <! of  .< similar  resistance  
mechanisms  in bacteria  and cancer  cells, via inhibition  of  the  
drug  efflux  mechanisms  by  certain  'phenothiazines.  The  
mutagenic and  antimutagenicity .studies were planned to give 
evidence for the effects on chromosomal DNA or for possible 
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Tabic I. Effect of phcnothiazines  (1,2,3,4)  on L-5J7S  cells with multidrug resistance. 
Compound's  (CH2)n  R  Concentration  Forward  
number  (M)  scatter  
height 
[cell size 
ratio] 
10-lN-(Phthalimido)alkyll-2-substituted-10H-phenothiazines 
[1]  3  CI  1  x  10-5  541.63 215.98 615.46 2.40 253.59 10.65 
2  x  10-5  538.05 219.75 704.47 2.75 564.72 23-72 
[2]  4  CI  1x10-5 535.16 220.48 595.62 2.32 212.14 8.91 
2  x  10-5  537.95 222.88 657.17 2.56 369.03 15.50 
]-(2-Chloroethyl)-3-(2-substituled-i0H-phenolhiazin-10-yl)alkyl-l-ureas 
[31  4  CI  1  x  10-5  535.93 210.71 520.21 2.03 107.66 4.52 
2  x  10-5  534.05 211.90 633.59 2.47 298.51 12.54 
[41  3  CF3  1  x  10-5  535.31 216.00 538.84 2.10 127.30 5.34 
2  x  10-5  532.75 226.20 599.29 2.34 219.26 9.21 
(-t-Jverapamil*" 4 Pg 545.74 '  216.62  451.14 1.76 57.84 2.43 
DMSOc) 10 pL 145.33 210.62 316.49 1.23 17.23 0.72 
par" control 504.86 184.75 732.17 2.86 724.50 30.44 
mdr  +  R123s)  control 552.95 211.52 352.41 1.37 23.80 1.00 
d  Ref  12. bx: Measured  fluorescence value at linear scale [mg, uptake of  R123],  
cThe  R-123 accumulation was calculated  from  fluorescence  of one height value using  1st equation  y=  10 256 
then the  fluorescence  activity ratios were calculated  according to the formula given below; 
^  _  (mdr treated/mdr  control)  
(parental treated/parental  control)  
d(±)vcrapamil:  a control for mdr reversal;  °DMSO (dimethylsulfoxide): solvent  control;  
fpar parental without  multidrug resistant gene;  emdr parental with multidrug resistant  gene.  
promethazine  [6]  were  purchascdirom  Sigma  Chemical  Co.  (St.  Louis,  
MO, U.S.A.). Chlorpromazine [7] was purchascd  fronvAldrich Chemical 
Co.  (Milwaukee,  WI,  U.S.A.)!' ' ( ^Verapami l  (Sigma, ' V  4629)  as  
calcium channel  blocker  (3,4) was'purchased  from'Sigma Chemical  Co.  
(St.  Louis,  MO,  U.S.A.).  Rhodaminc  123  hydrate  (R123)(Aldrich,  
28394-0)  was  purchased  from  Aldrich  Chemical  Co.  (Milwaukee,  WI,  
U.S.A.). 
Tissue  culture.  LS178  mouse  T .  cell  lymphoma  and  its  MDR1/A  
retrovirus transfected derivative were provided  by Prof. Aszalós.  •:  
•  •. '  J/'  •;:  •  ••.•'  .'  •  
Bacterial  strains.  E.  coli  IF  2571/Rm98  was  resistant  to  ampicillin,  
streptomycin,  sulphonamide  and  tetracycline,  Haemolysin  producing  
bacteral.  isolates  were  obtained'  fromi  clinical  specimens  and-  two  
laboratory strains  of  E.  coli-ON-22  and  CW-3S were  used  in the  studies  
(kindly  provided  by  L.  Emődy,  Institute  of  Microbiology,  POTE,  Pécs,  
Side scatter  Fluorescence one height'  Fluorcsccncc  
height  x  activity  
[granulation  b  x  ratio*  
of cell ratio]  x  
canccr  chemoprotective  effects.  The  mutagenic,  anti-
mutagenic and antiretroviral effects of some phthahmido- and 
chloroethyl-substituted  phenothiazines  will  be  studied  and  
reported  in  the  hope  that  new  chemotherapeutics  can  be  
developed. 
Materials and  Methods  
Chemicals.  Four  phenothiazine  derivatives,  i.e.,  10-[3-(phthalimido)  
propyl]-2-chloro-10H-phenothiazine  [i],  10-[4-(phthalimido)butyl]-2-
chloro-10/9-phcnothiazinc  [2],  l-(2-chIorocthyl)-3-(2-chloro-10//-pheno-
thiazin-10-yl)butyl-l-urca  [3]and  l-(2-chlorocthyl)-3-(2-trifluoromethyl-
I0f/-phcnothiazin-10-yl)propyl-l-urca  [4\,  used  in'  this  paper  were  
prepared  as  described  previously  [2],  Phenothiazine  [5]  and  
3538 
Motohashi  et  al: The Effect of Phenothiazines on the Antibiotic  Resistant  Bacteria  and Multidrug  Resistant Tumor  Cells  
Hungary).  The  bacteria  were  gro'wn  in  minimal  tryptone  yeast  extract  
broth  or  agar  (MTY)  as described  by Alföldi et al  (5). The TA 98 strain 
of  Salmonella  typhimunium  was  obtained  from  Prof.  Bruce  Ames.  The  
reverse  transcriptase  of  Moloney  leukemia  virus  was  a  recombinant  
enzyme produced  by New England  BioLabs.  
Plasmid  curing effect  of phenothiazines.  Plasmid  elimination  was carried 
out  as  describd  earlier  (6,7).  An  overnight  preculture  of  E.  coli  JF  
257I/Rm98 was diluted  10-4 fold and  SO pL (about  S  x  103) bacteria  was  
inoculated  of  this  dilution  into  5.0  mL  MTY  both.  Increasing  
concentrations  of  the  tested  drugs  were  added  and  the  tubes  were  
incubated  at  37*C  for  24  hours.  From  the  tubes  showing  growth,  
different  dilutions  were  prepared  and  0.1  mL  samples  were  plated  on  
MTY  and  blood  agar  plates.  The  plates were  incubated  at  37*C for  24  
hours  (hen  colonies were  counted  (master  plate). The  isolated  colonies  
were  replicated  with  Lederberg's  velvet  replica  plating  (8)  into  MTY  
plates containing tetracycline (5 pg/mL). After incubation  at  37*C for 24 
hours  the  number  of  colonies  was compared  to  the  number  of  colonies  
growing on the master  plate.  
Synergism  between  phenothiazines  and  tetracycline.  The  synergism  
between  phenothiazines  and  tetracycline  was  performed  on  hemolysin  
producing  and  non-hemolytic  E.  coli  strains. Tetracycline  hydrochloride  
36 pg/mL was  mLxed with  MTY agar and poured  into Petri  dishes, which 
contained  a filter paper strip 5  x  50 mm (imersed  into the  phenothiazine  
solutions  2500  pg/mL).  After  solidifying  of  the  nutrient  .agar,  the  
hemolysin  positive  and  negative  bacterial  cultures  were  inoculated  as  a  
line  perpendicularly  to  the  filter  paper.  Inocubation  was  37*C  for  16  
hours then synergism was evaluated. 
Cell  and  fluororescence  uptake.  MDR1/A  expressing  cell  lines  were  
selected  by  culturing  the  infected  cells  with  60  ng/mL  colchicine  to  
maintain  the  expression  of  the  MDR  phenotype  (9). The  L5178  MDR  
cell  line,  and  the  L5178Y  parent  cell  line  were  grown  in  McCoy's  5A  
medium  with  10%  heat-inactivated  horse  serum,  L-glutamine  -and  
antibiotics. The cells were adjusted to a concentration  of 2  x  10<>/mL and 
resuspended  in  serum-free  McCoy's  5A  medium  and  the  cells  were  
distributed  into 0.5 mL aliquot  to Eppendorf  centrifuge tubes. Then,  the  
tested compounds were added  in 2.0 mL  Of the 2.0 mg/mL stock  solution  
and  the  samples  were  incubated  for  10 minutes  at  room  temperature.  
Then,  50  pL  rhodamine  123  (R123)  as  an  indicator  was  added  to  the  
samples  (5.2  pM  final  concentration)  and  the  cells  were  incubated  for  
further  20  minutes  at  37*C,  washed  twice  and  resuspended  in  0.5  pi  
phosphate-buffered  saline  (PBS)  for  analysis.  The  fluorescence  of  cell  
population  was  measured  by  flow  cytometry  using  Beckton  Dickinson  
FACScan  instrument  (cell  sorter).  (±)Verapamil  was  used  as  a  
positive  control  in  the  RI23  accumulation  experiments  (10,11).  
The  RI23  accumulation  was  calculated  from „fluorescence  of  one  
height  value  using  the  2nd  equation  y=l()2»  (Table  I).  In  the  
case  of  logarithmic  transformation,  the  1024  digital  channels  are  
switched  to  one  decade  at  each  256  (=2*)  channels.  Then,  the  
percentage  of  control  mean  of  the  fluorescence  intensity  was  calculated  
for parental  and  indr  cell  lines, compared  to  untreated  cells. An  activity  
ratio was calculated  by the following equation (10,l2)(Tahle  I):  
(mdr  treated hndr  control)  
Ratio  =  
(parental  treated/parental  control)  
Mutagenicity assay.  Spot  test was performed as described  previously  (13).  
The  bacterial  strain  was  cultured  in  Oxoid  nutrient  broth  No.2  for  16  
hours for turbidity to reach the optical density of 0.5 at 600 nm. After 0.1 
mL  of  bacterial  culture  and  0.1M  sodium  phosphate  buffer  (piI  7.4)  
were  mixed  and  overlaid  onto  minimal  glucose  agar,  9  mm  in  diameter  
well  was  made  in  the  center  of  Petri  dish  and  ImL  of  5  mg/mL  test  
chemical  was applied.  All  tested  chemicals  were  dissolved  in DMSO.  10  
Table  II. The determination  of antibacterial and antiplasmid  effects of  some  
phenothiazines. 
Compound's  (CH2)n  R  Concentration  Plasmid  MIC  
number  (pg/mL)  elimination  pg/mL  
(%)  (MIC)0  
]0-[N-(Phthalimido)alkyl]-2-substituted-
10H-phenothiazines 
[1]  3  CI  160  
200 
[2]  4  CI  160  
200 
l-(2-Chloroethyl)-3-(2-substituted-10If-
phenothiazin- 10-yl)alkyl-1-ureas 
[3]  4  CI  80  
100 
[4 J  3  CFj  160  
200 
Phenothiazines 
[5]  160  
200 
[6]  40  
60 
80 
[7]  40  
60 
80 
0  Minimal  inhibitory  concentration 
pg/mL  4-nitro-l,2[-phenylenediamine  was  used  for  positive  control.  
After  48  hours,  the  presence  of  background  lawn  on  all  plates  was  
confirmed and the number  of back mutant  colonies around  the well were 
counted.  The  assay  was  performed  in  duplicate  in  two  separate  
occasions. 
Anti-mutagenic  assay.  TA  98  strain  of  Salmonella  typhimurium  was  
obtained  from  Prof.  Bruce  Ames.  The  plate  incorporation  test  was  
performed as described  previously (13) with some modifications for anti-
mutagenicity  assay. The  bacterial  strain  was  cultured  in  Oxoid  nutrient  
broth  No.2 for  14-1'6 hours  until  turbidity  reached  the optical  density  of  
0.3 at  600 nm. 0.1 niL of bacterial culture, 0.1 mL of phenothiazines  and  
0.5  mL  of  0.1M  s6dium  phosphate  buffer  (pH  7.4)  were  mixed  and  
incubated  for 20 minutes at 37*C in a turbulating incubator, then 0.1 mL 
>200 
>200 
150 
>200 
0 
0 
2.4 
14.9 
85.3 
3.2 
15.0 
26.0 
>200 
90 
85 
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Tabic  III.  The  determination  of  mutagenicity  and  anti-mulagenicity  of  
some  phenothiazines  
Compound's  (CH2)n  R  Mutagenicity  Anli-mulagc-
numbcr  (spot  test)  nicity (%) 
10-IN-(Phthalimido)alkyil-2-suhstituted-
iOH-phenolliiazines 
HI 
I2J 
CI 
CI 
]-(2-Chloroethyl)-3-(2-substituted-IOII-
plienotliiazin- 10-yl)alkyl-1-ureas 
CI 
C F j 
13]  4  
[4J  3  
phenothiazines 
15] 
16] 
[7] 
positive control 
4-nitro-l,2-phcnylcncdiaminc 
(mutagenicity) 
chlorpromazine  3  CI  
(antimutagcnicily) 
50 
48 
10 
20 
12 
33 
24 
24 
Table  IV.  The  synergistic effects  of  some  phenothiuzine  with  tetrmyelinc  
on haemolytic  and non-haemolytic  E. coli strains. 
Compound's  (Cll2)n  
number 
k Synergism with  tetracycline  i) 
liacmolytic 
/;. coli 
non-liacmolytic 
E. coli 
IO-lN-(Phlhalimido)alkyll-2-suhslituted-
101¡-phenothiazines 
UJ 
121 
CI 
C'l 
l-l2-(Chbroethyl)-3-(2-sul>stitutcd-IOII-
phenolhiazin-IO-yl)alkyl-l-ureus 
[3J 
14] 
phenothiazines 
[5] 
[6] 
[7] 
CI 
CI 
+ 
+ 
+ 
+ 
I) +: synergism.;  -  : no-synergism.;  w: weak synergism.  
of  10 pg/mLof  4-nitro-l,2-phcnylcncdiamine  was added  for the  mixture  
and  incubated  for  20  minutes  at  37"C  in  a  turbulaling  incubator.  The  
mutagenicity  of  the  4-nitro-l,2-phcnylcncdiaminc  derivative  was  
compared  in the  presence  of the compounds. The  samples were  poured  
into  minimal  agar  and  after  48  hours  incubation,  the  mutant  colonics  
were  counted  considering  in  the  presence  of  background  growth.  Anli-
inutagcnicity  assay was performed in triplicate  in two separate  occasions.  
Quantum-chemical  calculations.  The  molecular  orbital  calculations  by  
parametric  method  -3  (PM3)  were  performed  with  the  application  of  
MOPAC  program  (Version  6.01)  (14).  The  geometries  of  the  neutral  
species  [1, 2, 3,4,  S, 6,  7] were optimized  with respect  to  all  geometrical  
parameters  using  Broydcn-Flclclicr-Coldfarb-Shanno  algorithm  
incorporated  in  the program. For  these calculations, the  FACOM  M770  
computer  in the Josai University  Information Sciences Cenlqr was used. 
Antiretroviral  effect.  Moloney  murine  leukemia  vims  (M-MuLV)  reverse  
transcriptase  assay.  Test  compounds  and  3'-azido-3'-dcoxythymidinc  
triphosphate  (AZT-TP)  were  assayed  for  their  ability  to  inhibit  
recombinant  M-MuLV  reverse  transcriptase  (RT).  The  assay  was  
performed as follows; the poly(rA)noligo(dT)i2.ia  directed  incorporation  
of  [3H]dTTP  (Amcrsham)  into  cDNA.  The  lOx  reverse  transcriptase  
buffer contains 500 mM Tris-HCI (pH 8.3), 80 mM MgCI2,300 mM  KCI,  
and  100 mM  DTF.  In  all experiments  the  final volume of  reaction  assay  
was 20 mL. This contained water, 2 pL of  lOx buffer, 20 pg/mL template-
primer,  5  pM  dTTP  precursor,  0.2  pCi  tritiatcd  precursor,  compounds  
tested  (administered  into  the  medium  before  adding  the  enzyme)  and  
5U  reverse  transcriptase  initiating  the  reaction.  This  procedure  was  
followed by an  incubation  for 40 min  at  37*C.  15 pL of  the  mixture  was  
Table  V.  Calculated  di/mle  moments,  n-LUMO,  n-HQMO  energies, and 
distance between N10  and  nitrogen atom  on seven compounds  11, 2,  3,  4,  
5, 6,  7] by PM3  method.  
Compd's  (CII2)n  Dipolc  it-LUMO  JI-IIOMO  d'>  Antitumor  
number moment  (cV unit)  (cV unit)  
(Dcbyc  unit)  
activity' 
LU 3 3.31 -1.188 -7.997 5-04 
[2] 4 4.31 -1.195 -7.982 6.33 
[3] 4 2.92 -0.549 -8.162 6.30 
[4] 3 4.34 -0.972 -8.433 5.00 
[S] 0 2.42 -0.298 -7.968 -
16] 2 .  2.88  -0.265 -8.012 3.79 -
[7] 3 1.07 -0,447 -8.045 5.08 + 
' '  Distance  between  N10  and  nitrogen  atom  (in  A  units).  Rcf:  17;  
Antitumor  activity: +, positive: -, negative. 
then  transffercd  to  a  Whatman  DE  81 filter paper  disc, washed  by  5% 
dinatrium-hydrophosphatc  buffer,  water,  then  96%  ethanol,  and  after  
drying and  putting into  5  ml scintillation  cocktail  (OptiPhase  'HiSafc 3', 
Wallac)  radioactivity  was  measured  by  Packard'Tri-Carb  4530  liquid  
scintillation  counter. The residual  enzymatic activities were compared  to  
the  control  (no  drug  added).  The  IC50  of  AZT-AT  was 0.2  pM  in  our  
experiments.  :  1  
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Figure  I.  The  optimized  structures  of  seven  compounds  / / ,  2,  3,  4, 5,  6,  7] by PM3  method.  
Results  and  Discussion  
The  ring  substitutions  which  were  favourable  for  antitumor  
effect  (Table  I)  resulted  ineffective  molecules  in  plasmid  
elimination  (Table  II).  In  addition,  the  MIC  values  were  
higher  than  200  fig/mL  for  the  E.  coli  strains  tested.  These  
data  suggest  that  the  substitution  introduced  into  the  
phenothiazine  reduced  the  cell  wall  permeability  of  the  
compounds.  The  compounds  were  also  tested  for  mutagenic  
effects  in  the  direct  Ames  test  without  microsomal  fraction.  
As  is  shown  in  Table  III,  these  phenothiazines  were  not  
mutagenic. Considering  the  lack  of mutagenic activity  of  these 
phenothiazines  [1-7]  and  the  presence  of  antimutagenic,  
antiplasmid  and  synergistic  effect  with  tetracycline,  a  search  
for  structure-activity  relationship  was  promising  (Table  IV).  
Anti-mutagenic  activity  and  the  antitumor  effects  of  the  
derivatives  were  systematically  studied  and  the  effects  were  
compared  to  the  quantum-chemical  properties  of  the  
substituted  phenothiazines.  
We  calculated  the  dipole  moments  (in  Debye  unit),  ji-
L U M O  and  j t - H O M O ,  energies  (eV  unit),  and  the  distance  
( A  unit)  between  10th  nitrogen  on  phenothiazine  skeleton  
and  terminal  nitrogen  of  aliphatic  chain  group  for  the  
relationships  between  the  electronic  structures  and  antitumor  
activity  (Table V).  In  all cases, the  PM3 optimized  geometries  
were  slightly nonplanar,  and structures  are  shown  in  Figure  1.  
It  is  interesting  that  substituted  phenothiazines  had  different  
anti-mutagenic  activity,  however  none  exerted  mutagenic  
effects. The  reverse  transcriptase  enzyme  inhibition  of  murine  
leukemia virus shows that  the substituents  introduced  into  the  
phenothiazines  do  not  alter  significantly  the  antiretroviral  
effect  of  phenothiazines.  However,  the  reverse  transcriptase  
inhibition  makes  a  wider  perspective  for  phenothiazines  as  
anticancer compounds (Figure  2).  
Relationship  between distance from  NIO  to  nitrogen atom  with  
group, and  antitumor  activity: The  distance  of  the group  1, i.e., 
10-[3-(phthalimido)propy]-2-chloro-10/7-phenothiazine  [1],  
(n=3),  l-(2-chloroethyl)-3-(2-trifluoromethyl-10//-phenothia-
zin-10-yl)propyl-l-urea  [4],  (n=3)  and  chlorpromazine  [7],  
(n=3)  with  stronger  compounds  showed  5.04,5.00  and  5.08A,  
respectively.  Second,  the  distances  of  group  2,  i.e.,  10-[4-
(phthalimido)butyl]-2-chloro-10//-phenothiazine  [2],  (n=4),  
l-(2-chloroethyl)-3-(2-chloro-10//-phenothiazin-10-yl)butyI-1 -
urea  [3],  (n=4)  with  weaker  activity,  phenothiazine  [5],  
(n=0),  promethazine  (6,  n=4)  with  non-antitumor  activity  
showed 6.33,6.30 and  0, 3.19k,  respectively  (Table  V).  
Interestingly,  it suggested  that  a direction  of a lone  electron  
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Concentration  of compound  (100 x  pM)  
Figure  2.  The  inhibition  of  Moloney  leukemia  vims  reverse  transcriptase  by  
phenothiazine  compounds.  Activity  of  the  control  was  21500  CPM.  10-(4-
phthulimido)butyl-2-cliloro-10H-phenothiazine  ¡2/:  •,  l-(2-chloroethyl)-3-
(2-trifluorometltyl)-10H-phenothiazin-10-yl)propyl-l-urea  [4]:  O,  l-(2-
chloroethyl)-3-(2-chloro)-10H-phenothiazin-10-yl)butyl-l-urea  [3]:  U.  10-
(3-plithalimido)propyl-2-chloro-10H-phcnolhiazine  ¡1/:  • .  
pair  on  10th  nitrogen  of  phenothiazine  skeleton  and  the  
length  between  10th  nitrogen  of  phenothiazine  skeleton  and  
terminal  nitrogen  (3N or  4N)  of  methylene group  might  have  
a  role  on  the  activity  of  the  compounds  (Figure  1).  The  3-
(phthalimido)propyl  group  of  10-[3-(phthalimido)propy]-2-
chloro-10//-phcnothiazine  [1],  n=3),  and  a  l-(2-chloroethyl-
l-urca)-3-propyl  group  of  l-(2-chlorocthyl)-3-(2-trifluorome-
thyl-10//-phenothiazin-10-yl)propyl-l-urca  [4],  (n=3),  and  a  
3-dimethylaminopropylene  group  of  chlorpromazine  [7],  
(n=3)  have  the  bending  tendency  of  orientation  inside  the  
phenothiazine  skeleton  (Figure  1).  On  the  other  hand,  
(phthalimido)butyl  group  of  10-[4-(phthalimido)butyl]-2-
chloro-l()/7-phcnothiazine  [2], (n=4),  or  a  l-(2-chloroethyl-l-
urea)-3-butyl  group  of  l-(2-chlorocthyl)-3-(2-chloro-10/7-
phcnothiazin-10-yl)butyl-l-urea  [3], (n=4),  phenothiazine  [5],  
and  promethazine  [6]  have  the  orientation  outside  the  
phenothiaiznc  skeleton  (Figure  1). However,  pentamethylene  
derivative  of  phenothiazine  (n=5)  had  again  the  inner  
orientation  (data  not  shown).  This  is  an  apparent  difference  
between  group  1 compounds  and  group  2  compounds.  This  
active  conformation  of  group  1  compounds  might  be  very  
convenient  to  attack  the  cytosine  and  guanine  sites  of  DNA,  
or  electrostatic  P-glycoprotein  membrane  sites  (15).  
Additionally,  the  proposed  inner  orientation  can  be  
supported  by  the  C-C  bonds  of  phenothiazine  ring  1.390-
1.405A.  The  double  bonds  were  1.386-1.398A  except  for  the  
central  bonds  such  as  C4a-C10a  with  1.402-1.408A,  the  C9a-
N10  and  NIO-ClOa  were  1.437-1.449A  and  1.437-1.450A,  
respectively,  and  the  C4a-S5  and  S5-C5a  were  1.755-1.760A,  
respectively.  It  means  that  the  antitumor  activity  of  four  
phenothiazines  [1,  2,  3,  4]  depends  on  the  number  of  a  
methylene group (n=3,  4, 5). 
Relationship  between fluorescence  activity  ratio  and  electronic  
structures  on  phenothiazines  11,  2,  J,  4/:  The  fluoresccncc  
activity ratio  of  the group  1, i.e.,  10-[3-(phthalimido)propy]-2-
chloro-lO/7-phcnothiazinc  [1] (n=3)  and  l-(2-chloroethyI)-3-
(2-trifluoromethyl-107/-phcnothiazin-10-yl)propyl-l-urca  |4,  
n=3)  with  stronger  activity  at  concentration  of  1 x  10"'  M  
showed  10.65 and  5.34 , respectively. Second, the fluorescence 
activity  ratio  of  group  2,  i.e.,  10-[4-(phthalimido)butyl]-2-
chloro-10//-phenothiazine  [2] (n=4)  and  l-(2-chloroethyl)-3-
(2-chloro-10/7-phenothiazin-10-yl)bulyl-l-urca  [3) (n=4)  with  
weaker  activity  showed  8.91  and  4.52,  respectively  (Table  1).  
The  relationship  between  multi-drug  resistance  reversal  
effects  (fluorescence  activity  ratio)  of  phenothiazines  at  
concentration  of  2  x  10"5  M showed  also  the  similar  correla-
tion  with  the  concentration  except  l-(2-chlorocthyl)-3-(2-
chloro-10//-phcnothiazin-10-yl)butyl-l-urea  [3]  (n=4).  From  
the  measurement  of  fluorescence  activity  ration  by  R123,  
among four phenothiazines,  i.e.,  10-[3-(phthalimido)propy]-2-
chloro-l()//-phcnothiazine  [1]  (n=3),  10-[4-(phthalimido)bu-
tyl]-2-chloro-10/7-phcnothiazine  [2]  n=4),  l-(2-chlorocthyl)-
3-(2-chloro-107/-phenothiazin-10-yl)butyl-l-urea  [3]  (n=4)  
and  l-(2-chloroethyl)-3-(2-trifluoromcthyl-10//-phcnothiazin-
10-yl)propyl-l-urea  [4] (n=3),  a  good  relationship  was found 
between  multi-drug  resistance  reversed  effect  and  
fluorescence  activity  ration  (Table  I).  However,  a  significant  
relationship  between  dipole  moment,  Jt-LUMO,  or  n-
HOMO, and antitumor  activity could not be found (Table  V).  
Moreover,  four phenothiazines  [1, 2,3,  4] did  not  show any 
mutagenic  effect  but  were  antimutagenic  in  the  Ames  test.  
Therefore,  the  direct  antitumor  activity  of  phenothiazines  
(16,17,18)  can  possibly  be  exploited  for  experimental  drug  
design.  In  this  process,  other  beneficial  biological  effects like 
antimutagenic,  antiviral  (19),  antiplasmid  (6,7),  reversal  of  
multi-drug  resistance  in  cancer  cells  (20)  and  synergism  with  
antibiotics are considered  as well. 
We  could  therefore  conclude  from  these  results  that  
electron  relationship  contributions  arc  strongly  related  to  a  
lone  electron  pair  on  the  10th  nitrogen  of  the  phenothiazine  
skeleton,  and  the  length  between  the  10th  nitrogen  of  
phenothiazine  skeleton  and  the  terminal  nitrogen  (3N or  4N)  
of  alkylene  group.  Additionally,  we  propose  that  the  
inhibition  of  the  membrane-efflux mechanism  using  a  reverse  
transcriptase  enzyme  of  a  retrovirus  by  phthalimidophc-
nothiazines,  or  chloroethylphcnothiazincs  can  be  exploited  in  
the drug design  for anticancer  chemotherapy.  
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The Role of Stereoselectivity of Chemosensitizers  in the Reversal  of  
Multidrug Resistance of Mouse Lymphoma  Cells  
DIANA SZABÓ and JOSEPH MOLNÁR 
Department of Microbiology, Albert Szent-Györgyi Medical University, Szeged, Hungary 
Abstract.  Tlw effect of three different stereoisomer pairs  ofCNS 
(central  nervous  system) active compounds was sudied on the 
activity  of human  mdrl  p-glycoprotein.  The  methotrimeprazine, 
clopenthixol  and  butaclamol isomers had  an  antiproliferative  
effect (IDyi) on the mdrl  expressing cells at  O.250 ftg/ml,  while  
the parental cells were less sensitive having IDyo at 0.37-0.69 
ug/ml.  Enantiomers of methotrimeprazine and clopenthixol had 
similar effectivity  on  the  drug efflux of  mdr  cells.  However,  
(-)butaclamol  was found  to  inhibit  mdr  efflux-pump  activity  
much more than the CNS  active (+)  isomer. Based on  these  
results,Irityclic  compounds  does  not  seem  to  have  
stereoselectivity  in  methotrimeprazine  and  clopenthbcol  on the 
mdr reversal effect.  In general,  both active and inactive members 
of stereoisomers  had a similar effect  on the drug accumulation 
of  the  mdr  cells.  Therefore,  hypothetically  the  CNS inactive 
member  of  stereoisomer  pairs  can  be  used  as  a resistance 
modifier without any risk in patients suffering from drug resistant 
cancer. 
Multidrug  resistance  of cancer  cells  is associated  with  a  large  
number  of  ebemotherapeutic  medicines  due  to  the  over  
expression  of  a  membrane  localized  p-glycoprotein.  This  
protein  confcrs  drug  resistance  through  its  action  as  a  drug  
efflux-pump  by  reducing  the  intracellular  concentration  of  
anticancer  drugs.  Therefore,  the  medicines  (chemicals)  that  
block  the  action  of  mdr  p-glycoprotein  can  be  useful  in  
treating  cancer  patients  whose  tumors  are  resistant  to  
multiple chemotherapy. 
In  previous  studies  we  investigated  the  effect  of  a  large  
number  of  drugs  and  chemicals  including  antibiotics,  
psychopharmacons  and  beta-adrenergic  antagonists  on  the  
action  of  efflux-pump. The  most  effective compounds  were  
('oiiv.spoiulcncc  10:  Dr.  Diana  Szabó,  Faculty  of  Medicine,  
Imsiitulc  of  Microbiology,  Albert  Szent-Györgyi  Medical  
t Iniversily, Szegctl,  Dóm  tcr  10, H-6720  Hungary.  
Key  Won Is:  Multidrug  resistance,  blood  brain"  barrier,  
stereoselectivity, methotrimeprazine,  butaclamol, clopenthixol. 
the  promethazine,  amitriptiline,  propranolol  and  verapamil.  
While  the  verapamil  isomers  were  effective  in  the  same  
concentrations  remarkable  differences  were  found  in  the  
effect of two cyclosporin analogues (2,3). 
A  dissociation  of  the  mdr  reversal  effect  and  cancer  
specific  antiproliferative  effect  were  found  in  some  newly  
synthetised  compounds.  
Interestingly,  two  stereoisomers  of  three  medicines,  had  
practically  the  same  effect  on  bacterial  plasmid  replication  
(S). Although their biological  effects were entirely different in 
the central nervous system. 
Therefore,  we  suggested  that  minor  modifications  in  the  
chemical  structure,  such  as changes  in  stereosymmetry  could  
modulate  the  mdr  reversing  effects  of  methotrimeprazine,  
butaclamol  and clopenthixol  isomeres.  
The  effect of  six stereoisomers  was promising  is the  study  
of  the  action  of  mdr  p-  glycoprotein.  In  this  paper  we  will  
review  our  recent  studies  on  the  structure  activity  
relationships  of  tricyclic  psychopharmacons  as  chemosensi-
tizers,  and  present  a  working  hypothesis  on  how  the efflux 
pump  activity  is  modulated  in  response  to  comparative  
toxicity  of  different  substances  in  the  CNS.  The  results  
suggest  to  us  that  non-toxic  (CNS-  ineffective)  member  of  
stereoisomeric  pairs  can  reverse  the  multidrug  resistance  of  
cancer  cells. The chosen  drugs to  reverse drug resistance  has  
been compared to that of promethazine and verapamil. 
Materials and  Methods  
Chemicals.  Verapamil  and  promethazine  were  obtained  from  EGIS  
Works,  Hungarian  Pharmaceutical  Company,  Budapest.  D-
methotrimeprazine,  L-methotrimeprazine  (EGYT  Pharmacochemical  
Works  Budapest,  Hungary),  (-)  butaclamol,  (-F)butaclamol  (Research  
Biochemicals  Inc.  P.O.Box  181  Wayland),  trans(e)-clopenthixol,  cis(z)-
clopenthixol  (Lundbeck  CO.A/S.  2500  Kobenhavn-Valby,  Denmark)  
(Figure  1).  
Cell  cultures.  The  L5178Y  (parent)  mouse  T  cell  lymphoma  and  its  
transformed  subline  with  mdr  (MDR1/A)  were  grown  in  McCoy's  5AA  
medium supplemented  with  10 % heat- inactivated horse serum (6).  
Fluorescence uptake  assay. The  L5178Y mouse T  cell  lymphoma  cell  line  
was  transfected  with  the pHa  mdr HA  retrovirus  as  previously  described  
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L-methotrimeprazine 
L-IO|3-(Dimethylamino)-2-methylpropyl]-2-methoxyphenothiazine 
HCl 
D-methotrimeprazine 
D-10|3-(Dimethylamino)-2-methylpropyl]-2-methoxyphenothiazine 
eis -  Clopenthixol 
4-13-(2-Cldorothioxanthen-9-ylidene)propyl]-l-piperazineethanol 
trans  -  Clopenthixol  
4-[3-(2-Chlorothioxanthen-9-ylidene)propyl]-l-piperazineethanol 
Butaclamol 
3-( 1,1 -Dimethylethyl)-2,3,4,4a,8,9,13b,  14-octahydro-1H-
benzo[6,7]cyclohepta[ 1,2,3-de]pyrido-[2,1 -a]isoquino!in-3-ol 
Figure  I.  The  chemical  structure  of  methotrimeprazine,  clopenthixol  and  
butaclamol  enantiomers  and  stereoisomers.  
Table  I.  Determination  of  50  %  growth  inhibitory  dose  of  various  
stereoisomers  on  mdr  and  parent  cells of  mouse  lymphoma.  
Cell Compounds Cytotoxicity 
ID5 0  (pg/ml)  
Parental (-)butaclamol 0.375 
(+)butaclamol 0.400 
cis-clopenthixol 0.697 
trans-clopenthixol 0.325 
L-methotrimeprazine 0.450 
D-methotrimeprazine 0.375 
I D 5 o  ( p g / m l )  
M D R (-)butaclamol 0.285 
(+)butaclamol 0.290 
cis-clopenthixol 0.250 
trans-clopenthixol 0.252 
L-methotrimeprazine 0.250 
D-melhotrimeprazine 0.325 
Table  II.  Effect  of  methotrimeprazine,  clopenthixol  and  butaclamol  
stereoisomers  on  the  activity  of  multidrug  resistance  effux-pump  in  mouse  
lymphoma  cells.  
Samples Cone, 
pg/ml 
FL-1 Fluorescence 
Activity  Ratio  
PAR  treated  MDR  treated  
PAR  control  MDR  control  
Verapamil 5 0.65 8.43 12.97 
L-methotrimeprazine 0.5 0.89 3.20 3.60 
5 0.74 5.62 7.59 
D-methotrimeprazine 0.5 0.93 5.58 6.00 
5 0.86 8.32 9.67 
Trans(E)-Clopenthixol 0.5 0.93 11.63 12.51 
5 0.66 16.27 24.65 
Cis(Z)-Clopenthixol 0.5 0.90 14.47 16.08 
5 0.69 17.29 25.06 
(-)Butaclamol 0.5 0.83 6.60 7.95 
5 0.78 17.96 23.03 
(+)Butaclamol 0.5 0.93 2.27 2.44 
5 0.84 4.78 5.69 
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1: Verapamil  5 pg/ml  4:  L-methotrimeprazine  0.5;  5 pg/rnl 
2:  (-)Butaclamol  0.5;  5 pg/ml  5:  D-methotrimeprazine  0.5;  5  pg/ml  
3:  (+)Butaclamol  0,5;  5 pg/ml  6: Trans(E)-Clopentixol  0.5;  5  pg/ml  
7: Cis(Z)-Clopenthixol  0.5;  5 pg/ml 
Figure  2.  The  effect  of  butaclamol.  methotrimepramine  and  clopenthixol  isomer  on  the fuction  of  mdr  efflux-pump  in  mouse  lymphoma  cells.  
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(6).  Mdr!  expressing  cells were  selected  by culturing  the  transfccted  cells  
in  60  ng/nil  colchicine.  The  L5178Y  mdr  cell  line,  and  the  L5178Y  
parental  cell  line  were  grown  in  McCoy's  5AA  medium  with  10  %  heat  
inactivated  horse  serum,  glutamine  and  antibiotics.  The  cells  were  
adjusted  to  a  concentration  of  2xlOh/ml  and  resuspended  in  serum  free  
McCoy's  5AA  medium  and  were  distributed  into  a  0.5  ml  aliquots  in  
Eppenilorf  centrifuge  tubes.  Test  compounds  were  added  from  0.5  to  5  
pi  of  the  1.0  mg/ml  stock  solutions  and  the  samples  were  incubated  for  
III minutes  at  room  temperature. Then  10 pi of  the  indicator  Rhodamin-
123  (5.2  pM  final  concentration)  or  doxorubicin  was  added  to  the  
samples  and  the  cells  were  incubated  for  further  20  minutes  at  37  "C,  
washed  twice  and  resuspended  in  0.5  ml  I'BS  for  FACS  analysis.  The  
lliioresccnce  of  cell  population  was  measured  by  flow  cytometry  using  
Bccklon  Dickinson  FACScan  instruments.  
I way  for  anticellular  effects.  Greiner  %-well  Oat-bottom  microtrays  were  
used  throughout  the  study.  For  diluting  and  distributing  cells  and  
reagents,  an  8-channel  pipette  was  used.  L5178Y  parent  and  mdr  tumor  
cells  were  resuspended  in  the  growth  medium  and  seeded  into  the  
microtrays  at  appropriate concentrations  (4000/0.2  ml/well).  
I lie  growth  medium  was  McCoy's  5AA  medium  containing  10  %  
horse  serum.  Then,  from  0 to  50 pg/ml  of  the  compounds  were  added  to  
the  wells  (5  pl/well).  Cell  controls  and  medium  controls  were  set  up  in  
each  tray.  Cell  control  wells  received  0.2  ml/well  of  growth  medium,  and  
medium  control  wells  had  no  cell  suspension  but  0.2  ml  of  growth  
medium. 
The  total  volume  of  medium  per  well  at  this  point  was  0.2  ml.  The  
trays  were  incubated  further  at  37°C  for  3  days  after  cell  seeding  in  a  
('<  incubator.  
At  the  end  of  the  incubation  period,  the cells  in  the  wells were  stained  
by  20  pi  M IT  solution  for  4  hours  then  100  pi  SDS  treatment  for  24  
bonis  Inhibition  of  growth,  as  well  as  of  the  cytotoxic  effects of  the  test  
samples,  were  determined  and  quantitated  by  measuring  the  optical  
density  at  545  nm  with  a  Awareness  Stat  Fax-2100  Technology  Inc.  
vertical  beam  reader  (reference  630  nm).  
The  average  optical  density  of  2  wells  of  each  dilution,  as  well  as  the  
controls,  was  calculated  and  the  percentage  inhibition  was  determined  
according  to the  formula:  
(OD  sample  - O D  medium  control)  
1 ( H )  X L O O  
(OD  cell control  - O D  medium  control)  
Results 
Before the  reversal  of  multidrug  resistance  the  ID50 values of  
the  compounds  were  determined  and  it  was  found  that  the  
parent  cell  line  was  a  little  bit  less  sensitive  to  the  
stereoisomer  pairs  than  the  multidrug  resistant  cell  line.  
However,  we  have  to  consider  that  for  determination  of  
antiproliferative  effect  much  smaller  number  of  cells  (see  
materials  and  methods)  are  treated  for  much  longer  time,  
than  for  the  determination  of  reversal  of  mdr  efflux-pump  
(Tablel  I).  
The  effect  of  three  different  pairs  of  stereosimers  was  
studied  on  the  activity  of  mdr-glycoprotein  of  the  mouse  
lymphoma  cells  (Table  II).  The  methotrimeprazine  
enantiomers  tl  and  /  had  nearly  the  same  effect  by  inhibiting  
the  efflux-pump  activity  of  mdr  p-glycoprotein  in  mouse  
lymphoma  cells.  The  results  show  that  the  two  enantiomers  
do  not  differ  significantly  in  the  reversal  of  multidrug  
resistance. 
The  second  pair  was  the  butaclamols.  An  interesting  
correlation  was  found  between  mdr-reversing  effect  and  
molecule  configuration  of  the  butaclamol  stereoisomers.  In  
the  experiments  the  concentration  dependent  inhibition  of  
stereoisomers  on  the  efflux  pump  were  compared.  
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Interestingly  (-)butaclamol  was  more  effective  than  the  
biologically  important  (+)butaclamol  enantiomcr.  The  data  
indicate  that  there  are  no  general  rules  for structure  activity  
relationships  in the  inhibition  of  mdr  efflux pump  activity by 
tricyclic compounds. 
The third stereoisomer pairs are the clopenthixols. The cis-
and  trans-clopenthixol  had  similar  inhibitory  effects on  the  
indr  efflux-pump  of  mouse  lymphoma  cells  if  results  were  
compared to the verapamil as a control. 
Since the  CNS-inactive  members  of  the  tested  drugs were 
as  effective  on  the  mdr  p-glycoprotein  as  their  active  
neuroleptic  counterpart,  we  can  conclude  the  lack  of  
stereoselectivity  of  drug  binding  in  the  inhibition  of  mdr  
efflux-pump mechanism. However,  the remarkable  activity of 
(-)butaclamol  is an exception, which  is probably based on  the  
higher lipofilicity of the (-)butaclamol than (+)  stereoisomer.  
Discussion 
Cltiral  anticancer  drugs  are  known  since  pharmacological  
differences  have  been  found  between  stereoisomers.  The  
single  isomers  of  Icucovorin,  isofosfamide  buthionine  
sulfaxiinine  and  verapamil  are  used  in  the  medical  practice  
with better  results  than  the  racemic forms, however, the  role  
of chiralily was not reported  (71a,71b)  in the reversal effect of 
drugs  on  the  mdr.  Despite  similar  drug  targets  in the  cancer  
cells,  the  50  %  inhibitory  concentration  of  various  
antracyclins, vinca  alkaloids,  podophillotoxins,  topoisomerase  
inhibitors and  antibiotics varied to a great extent  in multidrug 
resistant  and sensitive cancer cells (8). 
In  the  mdr  cancer  cells  the  efflux-pump  mechanism  is  
responsible  for treatment  failures; therefore, the  inhibition  of  
efflux  mechanism  can  result  in  an  effective  anticancer  
chemotherapy.  However,  we  have  to  consider  that  normal  
cells  also  contain  ABC  transporters  eg.,  for  function  of  
detoxication.  To  avoid  toxic  side  effects  of  novel  resistance  
reversal compounds we need drugs with selective inhibition of 
the  mdr  efflux  in  cancer  cells.  To  achieve  this  effect  three  
classes  of  known  neuroleptic  drugs  with  active  and  inactive  
stereoisomers  were  tested  for  mdr  efflux  inhibition  and  
antiproliferative  effects on  sensitive  and  multidrug  resistant  
cancer  cell  cultures  and  results  were  compared  to  verapamil  
as a classic resistance modifier. 
The  (-)  isomer  of  verapamil  is  10 fold  more  potent  as  a  
calcium  antagonist  than  the  (+)  isomer,  both  enanthiomers  
are  equally  effective  in  increasing  cellular  accumulation  of  
anticancer  drugs  (9).  The  enantiomers  of  phcnylalkylamines  
equally  potent  in  inhibition  of  drug  transport  by  p-
glycoprotein  (10).  However,  the  potency  of  vinca  stereo-
isomers  in both  wild type and mdr cells was dependent  on the 
suhsliluents  of  stcrcoisomcric  form  due  to  modulation  of  
cytotoxicity  of  vinblastine  (11).  When  the  stereoisomers  of  
verapamil  and cyclosporines were compared  on pgp mediated 
efflux and  NK  cell  mediated  cytolysis verapamils  were  more  
potent  inhibitors  of  cytolysis  than  cyclosporines,  on  the  
Tabic  III.  Comparison  of  hiologicul effects of  some  slereoisomeric pairs  oj  
methotrimeprazine,  hutaclamol  anil ciopenthixoi. 
Name of  compounds 
Specificity of 
pharmacological 
effect 
Experimental  dose  
IDso(nM)* 
1 neuroleptic 3.5 x  10"4 M ** 
Methotrimeprazine 
d 3.5 x  10"4 M  ••  
(+) ucurolcptic 310* 
Butaclamol 
(") KM) 000* 
eis neuroleptic 26* 
Ciopenthixoi 
trans 440* 
* dopamine stimulated  adenylate cyclase activity in rat  striatal  tissue (13) 
** in vitro minimal  inliihitoiy concentration  for  /•.'. coli (26) 
contrary  cyclosporines  were  more  effective on  inhibition  of  
pgp mediated rhodamine efflux than verapamil  isomers (12). 
The  CNS  -  active  and  inactive  -  members  of  butaclamol  
enantiomers  differed  in mdr-  reversal  very much, that  means  
drug  binding  has  some  enantioselectivity  on  the  p-
glycoprotein.  On  the  contrary,  the  similar  effect of  levo-  and  
dextromethotrimeprazine  provides  idence  against  the  
enantioselective  inhibition  of  drug efflux-pump. How can  we  
explain  the  two different examples of enatiomer  effects ? The 
CNS  inactive  enantiomers  were  inhibitory  in  case  of  
methotrimeprazine  and  butaclamol  as  well.  Therefore,  the  
mdr  reversing  effects  of  CNS  inactive  members  of  
enantiomers  can  be  exploited  in  the  neoadjuvant  chemo-
therapy  of  cancer  to  increase  the  effectivity  of  several  
cytostatics. The remarkable  inhibitory effect of (- )butaclamol 
can be due to the higher log-P value, the increased lipofilicity. 
Surprisingly,  the  stable  stereoisomers  of  ciopenthixoi  had  
similar  concentration  dependent  inhibition  on  the mdr efflux 
mechanism,  for the  evidence  for the  lack  of  stereospecificity  
in  the  drug  binding  on  cancer  cells.  On  the  contrary,  the  
normal  cells  in  the  CNS  (13)  and  the  heart  (9),  in  bacterial  
plasmid  replication  (5),  inhibition  of  ATPase  or  Choline-
sterase  enzymes  (5)  show  that  the  stereoselectivity  and  
configuration of tricyclic compounds is essential (13). 
The  cis-clopenthixol  inhibited  the  dopamine  stimulated  
adenyl cyclase  10 fold compared to the trans isomer. 
In the case of methotrimeprazine enantiomers, a significant 
stereoselective  effect  was  observed  on  dopamine  and  5-
hydroxi  tryptamine  receptors,  whereas  the  opiate  receptors  
did  not  discriminate  between  the  levo-  and  dextrorotatory  
isomers (Table III)  (14).  
3042 
Szabó and Molnár: Multidrug Resistance  Reversal  in mdr Mouse  Lymphoma  
The  basis  of  selectivity  of  stereoisomers  may  be  due  to  a  
rigid configuration of the receptor sites. Another  reason  is the 
individual  members  of  stereoisomer  pairs  have  different  
energy  levels for binding. Indeed cis-stereoisomer  has a more 
stable  configuration  with  lower  energy  level  than  the  trans-
form  of  clopenthixol.  The  differences  in the  energy  levels  in  
the excited state can be even higher (15,16).  
Based  on the  relatively high concentration  of drugs used  in  
our experiments, a potential  non-specific effect was suggested 
to develop via interaction  at various drug receptors (Table I).  
As an example sigma receptors have high affinity binding sites 
for  several  psychotropic  drugs.  Similar  sites  are  located  not  
only  in  the  CNS  but  also  occur  in  various  periferal  tissues.  
The  ovcrexpression  of  these  receptors  is  found  in  human  
tumors  (17).  Different  neuroleptic  compounds  affecting  
sigma  receptors  produced  changes  in  cell  morphology.  Some  
neuroleptics  lacking sigma affinity such as (+)butaclamol  and  
clozapine  had  no  effect  on  cellular  morphology  (18).  
However,  (-)butaclamol  exhibited  morphological  changes  
(19)  resembling  apoptosis.  The  sites  are  distinguishable  by  
their affinity for stereospecific ligands (19). 
The  (H-)butaclamol  has  a  high  affinity  binding  site  on  
dopamine  D2  receptor  (20)  while  the  (-)butaclamol  was  300  
times  less  active.  Interestingly  the  (-)  enantiomer  was  more  
active  in  the  reversal  of  mdr  efflux-pump  than  the  
(+)butaclamol,  which  means that  mdr  reversal  effect was not 
mediated  by  D2-like  structures,  but  probably  mediated  by  
sigma  receptors.  5-hydroxy  tryptaminc  receptors  are  
suggested  to  play  a  role  in  certain  neuroleptic  disorders  the  
llierapculic effect of (-t-)butaclamol and clozapine  is localized 
on 5I-IT receptors  by inhibition some effects of 5I1T. However 
the (-)butaclamol and (-)propranolol were less effective (21). 
Considering  the  role  of  D4 receptor  or  D4-like  structures  
on  the  mdr  glycoprotein,  we can  exclude  D4 specific binding 
on  the  pgp  because  dopamine  receptor  antagonists  which  
showed  high  affinity  to  the  receptor  with  a  rank  order  
of  haloperidol  >  chlorpromazine  >  (+)butaclamol  >  
(-)butaclamol.  The  (-t-)butaclamol  bound  to  D4  receptors  in  
stereoselective  manner  showing  higher  affinity  than  its  
respective  (-) enantiomer. The (+)  enantiomer  was found  to  
be  nearly 20 fold more effective than  (-)butaclamol  (22). The 
lack  of  dopamine  receptor  specific stereospecificity  of  mdr-
reversal  excludes  the  involvement  of  D2  and  D4-like  binding  
sites on  the mdr p-glycoprotein,  rather our results refer to the 
sigma  receptor  involvement  for drug  binding  responsible  for  
inhibition  of drug efflux in the tumor cells. 
When  mdr  cells  were  exposed  to  tricyclic  stereoisomers  
with lipophilic characteristics the drug resistance was reversed 
due  to  the  inhibition  of efflux-pump  system.  However,  down-
regulation  of  the  mdr  gene  was  also  found  in  some  cases  
(23,24).  In  control  experiments  the  effect  of  verapamil  
stereoisomers  had  no  substantial  difference  in  the  potencies  
of (+)  and (-) enantiomers  in reversing mdr efflux-pump (10) 
and  in age related clearance (25).  
Theoretically  the  enantioselective  mdr-reversal  effect  of  
the pharmacologically  inactive (-)hutaclamol  can be  exploited  
in  the  combination  chemotherapy  based  on  the  different  
lipophilicity of the two stereoisomers. 
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Abstract.  Due  to  the  close  homology  between  bacterial and 
tumor cell transporter proteins,  some antiplasmitl and anticancer 
compounds were  tested for  their ability to reserse the  multidrug  
resistance (mdr)  of  lymphoma  cells.  Some  known anticancer 
medicines such as platidiam, novantron, fluorouracil,  bleomycin  
and methotrexate were ineffective/while vinca alkaloids exerted a 
strong  reversal  effect  on  the  mdr  of  lymphoma < cells.  The  
structurally  related reserpine  and  yohimbine  do  not  affect the 
activity of efflux pump. Some selected antitumor phenothiazines 
and  benzofajphenothiazines,  including trifluoperazine  inhibit  
the ¡'-glycoprotein  (pgp) function. This fact  is independent from 
the antiproliferative- or differentiation inducing effects.  Since the 
polylactosamine specific tomato  lectin prevents the action of the 
cliemosensitizers  tested, it  is supposed that the site of  action of 
phenothiazines can  be  at  the  1st  loop  in  the transmembrane 
glycoprotein.  The  efflux pump  activity  of  the  pgp  in  brain  
capillary  endothel which is  responsible for  blood  brain  barrier  
IBBB)  was also inhibited by some phenothiazines.  However,  the  
tomato lectin sensitivity of pgp was different in mouse lymphoma 
and  human  brain  capillary  endothelial  cells.  The mdr-gene 
expression  of the mouse lymphoma cells (which were transfectetl 
with the human mtlr-1 gene) could be reduced by phenothiazines 
such as promethazine  and  trifluoperazine,  when the  cells  were  
cultured in the presence  of  0.5 fig mL  phenothiazines.  Further  
synergism was  found  between  two  resistance  modifiers  i.e.  
verapamil  and  trifluoperazine  on  the  inhibition  of  mdr-
dycoprotein. 
Cancer  is  the  3rd  most  important  cause  of  death  worldwide,  
and  lung cancer  of questionable  origin  is the  most  frequent of 
these  malignancies.  However,  WHO  has  estimated  that  over  
I Unespondence  a>: Dr.  Joseph  Molnár,  (-"acuity  of  Medicine,  
Institute  of  Microbiology,  Albert  Szent-Gyorgvi  Medical  
Universilv,  Szeged.  Dom  ter  10,  H-6720  Hungary.  TEL:  (+)36-
02-15-51  15:  Fax:(+)36-62-45-5113.  
Key  ll'on/.v:  Multidrug  resistance,  blood  brain  barrier,  pheno-
thia/incs,  tomato  lectin.  
1.5  million  of  the  total  of  ten  million  new  cancer  cases  per  
year  are  associated  with  infections such  as Helicobacter pylori, 
human  papillomaviruses  and  hepatitis viruses,  not to  mention  
others,  such  as  HTLV  infections.  Approximately  40%  of  
cancer  patients  can  be  treated  by  surgery  and  the  great  
majority  of  patients  need  chemotherapy.  The  effectiveness  
chemotherapy  is limited  by the emergence  of drug  resistance,  
especially multidrug resistance  (mdr).  
mdr  is associated  with increased  expression  of  170 kD mdr-
1  P-lycoprotein  (pgp)  (1),  which  extrudes  anticancer  drugs  
from  the  cells.  Apart  from  mdr  (pgp),  other  resistance  
mechanisms  exist, e.g., the wi/r-associated  protein (MRP)  (2),  
which  is  mediated  by  a-190  kD  membrane  glycoprotein  (3),  
and  the  lung  resistance  protein  (LRP)  which  a  110  kD  
protein  involved  in  nuclear  cytoplasmic  drug  transport  (4).  
Enhanced  glutathione-S-transferase  (5)  vesicular  drug  
binding  and  compartmentization  of  drugs,  e.g.,  mitoxantrone 
(6) and  DNA topoisomerase  mutation-related  resistance  have  
been  also  observed  in  tumor  cells.  The  wide  spread  use  of  
anticancer  drugs underlines the importance  of  the  elucidating  
the  various  mechanisms  of  resistance,  especially  the  
characterization  of  different  mdr  phenotypes.  New-
compounds  could  be  introduced  to  overcome  multidrug  
resistance  by blocking the  enhanced  drug  efflux with  the  help  
of  new  resistance  modifiers  (7).  by introducing  more  specific  
antitumor  drugs  against  various  cancer  cell  lines  (8).  or  
molecules  targeting  phosphorylation,  protein  kinase,  
differentiation and telomerase  (9).  
The  new  information-intensive  approach  to  cancer  
chemotherapy (8,10,11,12)  has also been  used  to search for  
candidate  anticancer  drugs  that  are  specific for certain  types  
of  cancer  (13).  Our  recent  studies  have  focused on  the  most  
important  mrfr-glycoprotein  mediated  drug  resistance  which  
can  be  considered  the  most  widely  distributed  form  of  
resistance  in bacteria  (14,15,  16,  17,  18), fungi (19),  helmints  
(20),  and  cancer  cells  (14,  21,  22).  Considering  the  close  
homology  between  these  ABC  transporter  proteins,  a  
systematic  study  was  initiated  to  develop  new  mdr  reversing  
compounds  from  anticancer-  and  antiplasmid-  and  
0250-7005/98 S2.00+.40  3033  
ANTICANCER  RESEARCH  is.-  3033-303R <I99S) 
Table  I.  The  effect  of  some  anticancer  drugs  and  resistance  modifiers  on  
rhodamine-  J23 accumulation  by mdr  mouse  lymphoma  cells.  
Compound Concentration 
(Hg'mL) 
Fluorescence 
activity  (ratio)  
verapamil 8.0 2.29 
platidium 2.0 0.53 
20.0 0.60 
novantron 2.0 0.67 
20.0 0.70 
flnorouiucil 2.0 0.47 
20.0 0.73 
bleomycin 0.5 0.88 
5.0 O.SO 
methotrexate 5.0 1.00 
Table  II.  flic  effect  of  some  vincu  alkaloids  und  snvcnirally  related  
Compounds  on  K123 accumulation  ly  mdr  mouse  lymphoma  cells.  
Compound Concentration 
(lig'ml.) 
Fluorescence 
activity  (ratio)  
thalihlasiine 2.0 20.3S 
20.0 13.50 
vinblastine 2.0 22.33 
20.0 23.89 
vincristine 2.0 16.65 
20.0 34.51 
reserpine 2.0 0.8 5 
211.(1 1.43 
yohimbine 2.0 0.49 
20.0 0.68 
immunomodulatory  agents.  The  possible  synergistic  action  
with anticancer drugs also will be  discussed.  
Materials  and  Methods  
Chemicals.  CJiloipromazine  (CJ'Z), 6.9-dioxochlorpromazine,  7.S- dioxo-
7-semicaiba?one-clilnrpromazine.  5-oxo-57/-6-hydro.xybenzo[a]pheno-
thiazine  and  6-methyl-5-  oxohenzo[a]phenoihiazine  were  svnthetized  as  
described  previously  (2?).  7.8-Dihydroxychlorpromazine  and  7.S-
dioxncltlorproniazirie  were  syntlietized  as  described  previously  (24).  
Verapamil  and  promethazine  were  obtained  EG IS  Works.  Hungarian  
Pharmaceutical  Company,  Budapest.  Platidium  (Lachemu  Brno),  
iiovantron.  Iluorouiacil  (I.a  Roche  Ltd  Basel),  bleomycin,  methotrexate  
(Eacliema-Brno).  trifluoroperazine,  thaliblusline  (TBI.),  vincristine  
(Ricliter-Gcdeon).  vinblastin  (Richter-Gedeon),  reserpine,  yohimbine,  
cyclosporin  A (Sandimmune,  Cs-A) and cyclosporin  D (PSC-833,  Cs-D).  
Cell  cultuie.  l"or  the  cytotoxicity  assay,  HEp-2  cells  were  cultivated  in  
RPM1  supplemented  with  10%  fetal  calf  serum.  The  L517SY  (parent)  
mouse T  cell  Ivmplionia  and  its transformed subline with mdr  (MDRl/A)  
were  grown  in  McCoys  5AA  medium  supplemented  with  10%  heat-
inactivated  horse  serum  (25).  HEp-2  cells  for  immunofluorescence  
studies  were  grown  on  a  glass  coverslip  in  Petri  dishes  in  Eagle  MEM  
supplemented  with 5%  new horn  calf  serum.  
l-'lunie.sccnce uptake  assay, 'lite  L5178Y mouse  T  cell  lymphoma  cell  line  
was  infected  with  the  P11A  mdr-MA  retrovirus  as  previously  described  
(25). 3hlr-1  expressing  cells  were  selected  by culturing  the  infected  cells  
in  60 ng'ml. colchicine.  The  1.5178Y  mdr cell  and  E5178Y  parental  cell  
line  were  grown  in  McCoys  5AA  medium  with  10%  heat  inactivated  
horse  serum,  glulamine  and  antibiotics.  The  cells  were  adjusted  to  a  
concentration  of  2  x  106/ml.  and  resuspended  in  serum  free  McCoys  
5AA  medium  and  the  cells  were  distributed  into  a  0.5  mL  aliquot  in  
Eppemloif  centrifuge lubes. Test  compounds were added  to  1.0-10 pi. of 
the  1.(1 mg'inl.  stock  solutions  and  the  samples  were  incubated  for  10  
niiii  at  room  temperature.  Then  10 pi.  of  the  indicator  rhodamin-123  
(5.2  pM  final  concent rat ion)  was  added  to  the  samples  and  the  cells  
weie  incubated  Tor  a  further  20  min  at  37*C,  washed  twice  and  
resuspended  in  0.5  ml.  phosphate-buffered  saline  (PBS)  for  analysis,  
l i t e  lluorescence  of  cell  population  was  measured  by  flow  cytometry  
using Bccklon  Dickinson  FACScan  instruments.  
The  effect  of  lectins  on  ¡'-glycoprotein.  This  was  studied  by  fluorescence  
uptake  assays. Tomato lectin was added to mdr  cell line or brain  capillary  
endothelial  cells  at  different  concentrations  in  the  presence  of  I  m.M  
MeCI; and  0.1  m.M CaCI;. 
The  inhibition  of  mdr gene  expression. The  par  and  mdr-1  cell  lines  were  
incubated  in  the  presence  of  0.5-2.0  pg/mL  trifluoperazine  and  
promethazine  for 48 hours  at 37 'C  in  5%  CO2  as  usual.  For  isolation  of  
the  total  cellular  RNA.  the  cells  were  washed  in  ice  cold  sodium  
chloride,  centrifuged  and  RNA  was  prepared  from  drug  treated  and  
control  cells with miniprep-RNA  protocol cDNA  was prepared  of the  1.0  
pg isolated  RNA  by reverse  transcriptase  (26). The  reverse  transcriptase  
(RT)  assay  was run at 42 'C for fill min followed  bv denaturalion  al  95*C  
for  5  min  and  a  cooling  step  at  5*C  for  5  min.  The  amplification  was  
performed  in  polymerase  chain  reaction  (PCR)  at  94"C  for  5  min  and  
continued  for  37  cycles  of  melting 94 'C  for  30  seconds  and  annealing  
extending  with  Taq  polimerase  62 "C 50 seconds  followed by  a final  step  
at  72 'C  60 seconds. The  PCR  products  were  separated  in  2.0%  agarose  
in  the  presence  of  cthidium  and  semiquantitated  by  densitometry  
NVayne-Rasband,  NIMH.  Bethesda,  U.S.A.  The  trifluoperazine  and  
promethazine  apparently  inhibited  (he  synthesig  of  mdr-1  RNA  by  the  
inhibition  of gene expression  primers for PCR were mrfr-1 and  B-actin.  
Results 
First  of  all, some well  known anticancer  drugs were tested  for  
multidrug  resistance  (mdr)  reversing  activity.  Platidiam,  
novantron,  fluorouracil, bleomycin  and  methotrexate  did  not  
affect the efflux pump activity (Table I). However, some vinca 
alkaloids,  i.e.,  vinblastine,  vincristine  and  thaliblastin  
enhanced  the  rhodamine  123 accumulation  in  the  mdr  cells.  
The  structurally  similar  reserpine  had  very  slight  effect  and  
yohimbine  was  ineffective  (Table  II).  Some  ring  substituted  
chlorpromazine  derivatives  had  moderate  effect  or  were  
ineffective.  Benzo[a]phenothiazines  were  effective  at  
relatively  high concentrations from 2.0 to 20 pg/ml, and  in this 
study  5-oxo-5H-benzol[a]phenothiazine  was  the  most  active  
compound  (Table III). Some phenothiazine  compounds  were  
more  effective  on  the  drug  efflux  of  human  brain  capillary  
endothelial  cells  than  on  mdr  cells  (Table  IV),  but  the  
inhibition  was  low.  While  the  Cs-A  and  Cs-D  were  much  
more inhibitory on the pgp function of mouse lymphoma  cells  
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Table  III.  The  effect  of  some  phenothiazines  and  benzofajphenothiazines  
on  R123 accumulation  by mdr  mouse  lymphoma  cells.  
Compound  Concentration  Fluorescence  
(pg/mL)  activity  (ratio)  
7,8-dioxochlorpromazine 2.0 0.89 
20.0 0.70 
6,9-dihydroxychlorpromazine 2.0 0.82 
20.0 0.79 
6,9-dioxochlorpromazine 2.0 0-79 
20.0 2.38 
5-oxo-5//-bcnzo[a]phenothiazine 2.0 0.85 
20.0 1.40 
6-hydroxy-5-oxo-5f/-benzo[A]phenothiazine 2.0 1.20 
20.0 1.00 
6-methyl-5-nxo-benzo[a]phenothiazine 2.0 3.44 
20.0 2.92 
verapamil 8 3.81 
than  the  previously  tested  phenenothiazines.  Cs-D  had  a  
higher  activity  than  Cs-A  (Table  V),  which  gives  an  
opportunity  to  improve  the  mdr  reversal  effect  by  further  
changes  in  the  chemical  structure  of the  polypeptide  (Figure  
The mdr reversal  effect of  promethazine  was decreased  by  
tomato  lectin  treatment  (Table  VI).  The  binding  of  
promethazine  or  trifluoperazine to the pgp  of  the  tumor  cells  
and  to  brain  capillary  endothelia  was  determined  by  the  
interaction  of  tomato  lectin  with  polylactosamine  moiety  of  
the first  loop of pgp, meaning that  the  1st loop has a  key role 
in the biological effect of pgp. The tomato lectin  itself was not 
able  to  affect the  efflux pump  activity  in the  tumor  cells,  but  
the  inhibition  of  promethazine  (or  trifluoperazine)  was  
rcduced.  An  opposite  effect was  observed  on  human  brain  
capillary endothelial cells. 
The  tomato  lectin  reduced  the  inhibitory  effect  of  
promethazine  (or  trifluoperazine);  however,  the  lectin  was  
able  to  inhibit  the efflux pump activity of the pgp  of the  brain  
capillary  endothelial  cells  (Table  VI)  showing  that  the  
localization  (or accessibility)  of the pgp  is not exactly the same 
in the  two cell lines. 
In  the  experiments,  the  presence  of  pgp  in  drug  treated  
brain  capillary  endothelial  and  lymphoma  cells  were  
examined  in  trypsinized  and  acetone  fixed cells  by using  two  
monoclonal  antibodies.  One  of  the  mab  4E  3.16  (SIGNET  
Laboratories,  Inc, Mass, U.S.A) requires the epitope  of  mdr-\  
on  the  exterior  surface of  the  cell membrane. The  2nd,  C219  
( S I G N E T  Laboratories)  recognizes  an  internal  highly  
conserved  sequence  found  in both  mdr-3 and  mdr-1 isoforms 
of  pgp,  and  was  studied  under  the  fluorescent  microscope.  
The  external  and  internal  fragments of pgp were identified  in  
both  cell  lines.  Trypsin  treatment  (0.25%  trypsin  for  5  min)  
markedly  decreased  the  specific  expression  binding  of  mab  
for external  fragment of pgp on  the  surface of  brain  capillary  
Table  IV.  The  effect  of  substimted  phenothiazines  on  R123  accumulation  
by human  brain capillary endothelial  cells.  
Compound Concentration Fluorescence 
(pg/mL) activity  (ratio)  
capillary endothel  (control)  - -
verapamil 8 0.81 
6,9-dihydroxychlorpromazine 2 1.06 
20 1.03 
7,8-dioxochlorpromazine 2 1.11 
20 0.85 
6,9-dioxochlorpromazine 2 1.05 
20 0.80 
5-oxo-5//-benzo[a]phenothiazine 2 1.10 
20 0.69 
FC-1884 2 1.18 
20 1.11 
Table  V.  The  effect  of  cyclosporins  on  RI23  accumulation  by  mdr  mouse  
lymphoma  cells.  
Compound Concentration Fluorescence 
0'g/mL) activity  (ratio)  
cyclosporin-A 2 12.72 
(Sandimmune) 4 24.87 
8 50.04 
10 51.00 
cyclosporin-D 2 99.29 
(PSC-833) 4 100.47 
S 102.78 
'  10  112.57 
endothelial  or  lymphoma  cells.  The  binding  of  mab  to  the  
internal  compartments  of pgp  was not  changed.  It  is  possible  
that  more  than  one  mechanism  is  involved  in  the  action  of  
phenothiazines  and  tomato  lectin  on  the  efflux  pump  of  
tumor cells. 
At any rate, phenothiazine  and  trifluoperazine reduced  the  
gene  expression  in  the  tumor  cells,  when  the  cells  were  
cultured  in  the  presence  of  low  concentrations  of  the  drugs  
for  48  hours  (Figure  2).  The  results  show  that  at  least  two  
independent  biological  processes  are  responsible  for  reversal  
of mdr of tumor cells such as the reduced  activity of the efflux 
pump and the down regulation  of mdr gene. 
Since  the pgp  responsible  for  the  mdr  of  the  tumor  cells  
also  has  a  physiological  function,  (i.e.  maintain  the  blood-
brain  barrier  (BBB)),  it was reasonable  to  search for specific 
mdr  reversing  compounds  and  selective  antitumor  drugs  
(Table  VII).  For  improving  the  selectivity  of  anticancer  
compounds,  some  phenothiazines  were  synthetized  with  
alkylurea  and "half- mustard  type" phenothiazines  and  tested  
on  sixty  cancer  cell  lines  (27).  There  were  some differences 
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Figure  1.  Chemical  structure  of  cyclosporin  A  (Sandimmune)  and  cyclosporin  D  (I'SC  833).  
between  the  growth  inhibitory potencies  of the compounds  on  
the  various  cancer  cell  lines  showing  that  specificity  of  
anticancer  agents can be increased  by substitutions  (12,13,27).  
However,  the  mdr  reversing  effect-of some  representatives  
ill  the  newly  synthesized  "half-mustard  type"  plienothiazines  
was nearly  the same  (8,  11,  13).  
Furthermore,  the  specificity  of  mdr  reversal  effect  was  
analysed  by  using  stereoisomers  of  some  active  compounds  
(28).  As  a  result  of  these  experiment'  the  selectivity  of  the  
inhibition,  on  the  mdr  efflux  pump  was  improved  (29).  
Putting  the  two  findings together,  we  realized  that  their  is an 
opportunity  to  improve  the  perspectives  of  cancer  
chemotherapy  by  combination  chemotherapy  (Table  VIII).  
I'lie  combination  of  trifluoperazine  and  Verapamil  was found 
lo  In* the  most  effective in this system. 
I tiscussinn 
1  lie large  number  of  cancer patients and  the emerging mdr  of  
cancer cells leads to  the  ineffectiveness of chemotherapy.  The  
majority of anticancer  chemotherapy medicines do not  inhibit  
mdr  but  can  induce  the  expression  of  the  mdr  gene.  
Therefore,  physicians  have  to  change  the  strategy  of  
chemotherapy.  One  way  is  to  improve  the  effectiveness  of  
chemotherapy  is  to  inhibit  the  resistance  mechanism,  the  
second  is to  prevent  the  induction  of  mdr  and  the  third  is  to  
develop  new types of anticancer  drugs.  
Since  mdr  pgjt  is  involved  in  the  acquired  mdr  of  tumor  
cells,  the  selective  killing  of  cancer  cells,  and  expression  of  
pgp, could be  improved  by the simultaneous  administration  of  
anticancer  drugs  and  resistance  modifiers  in  combination  
3036 
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Figure  2.  Reverse  transcriptase-polymerase  chain  reaction  (RT-  PCR)  
analysis  of  mdr-1  messenger  RNA  expression  in  the  presence  of  
trifluoperazine  (TFP).  Lane  1 .DNA  molecular  weight  markers  (Boehringer;  
Mannheim,  Germany).  Lane  2.  mdr  cells  grown  in  the  presence  of  0.5  pg  
TFP  (mdr  without  p-actin  band).  Lane  3.  mdr  cells grown  in  the  presence  
of  0.5  pg  TFP  (mdr-1  and  P-actin  bands).  Lane  4.  mdr  cells  untreated  
(mdr-1  and  p-actin  bands).  Lane  5.  mdr  cells grown  in  the presence  of  2.0  
pg  promethazine  (P-actin  primer  without  mdr-1  primer).  Lane  6.  mdr  
control  primer  (without  p-actin  primer).  Lane  7.  control  parent  cells  (with  
P-actin  primer).  L a n e e g y e g n t m l ,  parent  cells  only  (mdr  primer).  
Lane  9.  mdr-1  cells gfowh  in  the  ftesfgee  of  2.0 pg  promethazine  (P-actin  
and  mdr-1  bands).!  
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Table  VII.  Theoretical  applications for  general  efflux-pump  inhibitors  and  
organ-specific  efflux-pump  inhibitors  in  combination  with  chemothe-
rapeutics. 
Type Specificity of 
indr-reversing Anticancer  drug  Expected  results  
compound's effect accumulation of  combination 
A  GENERAL efflux SPECIFIC for: synergy 
pump  inhibitors:  tissue or organ 
quinidinc GENERAL for:  toxic or general 
cyclosporin uniform immuno-
distribution  in  suppresion 
the  body 
It  SPECIFIC for tissue  ororgan:  SPECIFIC for: strong synergy 
verapamil  (cardial)  affinity to CNS 
trifluoperazine  (CNS)  kidney, liver etc 
thiazinamium  (lung)  GENERAL for synergy or 
cytotoxic organ-specific 
uniform toxicity 
distribution  in  
the  body 
chemotherapy.  However,  side effects of  resistance  modifiers  
on normal  cells, expressing the pgp, should  also be considered 
because of the organospecific toxicity depends on the  amount  
of pgp  in the various tissues. Mdr pgp  is also present  in various 
normal  cells  (like  capillary  endothel  in  brain,  colon,  kidney  
and  liver cells) and  is associated with  physiological functions. 
The  pgp,  expressed  in  these  tissues,  is  responsible  for  the  
transport  of  toxic  compounds  into  the  cerebrospinal  fluid  
(CSF),  bile  or  urine,  etc.  Consequently,  the  reduced  blood-
biliary,  blood-urine  or  BBB blood  brain  barrier  can  increase  
the  organotoxicity  of  antitumor  drugs.  Therefore,  cancer  or  
organospecific  efflux inhibitors  can  be  used  to  increase  the  
cytostatic  drug concentration  in malignant  cells to  avoid  side  
effects  in  other  essential  organs.  For  example,  if  there  were  
drugs  which  affect  the  BBB  selectively  then  they  could  be  
used  for  a  different  purpose.  Such  drugs  would  be  able  to  
increase  the  concentration  of  cytostatics  in  the  tumor  cells  
localized  in the brain. 
Mdr  reversing  drugs  could  increase  the  concentration  of  
C'NS targeted  medicines of any kind  simultaneously.  
On  the  other  hand,  even  a  general  chemosensitizer  can  
enhance  the  uptake  of  the  organospecific  medicines, that  are  
subjects  of  mdr  efflux pump.  Cancer  or  organ  specific efflux 
inhibitors theoretically  can  reduce the general  toxic effects of 
cytostatic  compounds,  due  to  the  increased  accumulation  of  
cytostatics  in  the  cancer  cells  even  at  reduced  administration  
doses. 
In  our  experiments,  the  physiological  function  of  one  
expressed  in  brain  capillary  endothelial  and  lymphoma  cells  
from  mice  was  compared  in  the  transport  of  R-123  as  an  
indicator  in the presence  of CNS active  medicines.  
The  results  show  that  there  are  some  differences  in  the  
Table  VIII.  The effect of  dntg  combinations  on  the  mdr  reversal in  mouse  
lymphoma cells. 
Compound Concentration Fluorescence 
(pg/mL) activity (ratio) 
verapamil - -
melipramin 5 7.35 
trifluoperazine 5 23.40 
amitriptilin 1 3.76 
5 5.66 
verapamil  -1- melipramin 2.5  +  5  1.54 
verapamil  +  trifluoperazine  2.5 +  2.5  15.21 
verapamil  +  amitriptilin  2.5  +  0.5  3.69 
trifluoperazine  +  amitriptilin  2.5  +  0.5  2.44 
Table  VI.  Effect  of  tomato  lectin  on  the  mdr  of  mouse  lymphoma  and  
human  brain capillary endothelial cells in the presence of  promethazine.  
Compound  Concentration  Fluorescence  
(pg/mL)  activity (ratio) 
mouse lymphoma  (control)  - -
promethazine 5 3.80 
tomato lectin 50 0 90 
tomato lectin  +  promethazine  50  +  5  2.56 
human brain capillary endothel  (control)  - -
promethazine 5 0.71 
tomato  lectin  50 1.17 
tomato lectin  +  promethazine  50 +  5  0.82 
lectin  sensitivities  of-the  two  cell  lines. We  suppose  that  the  
difference could  be  the consequence  of  different  localization  
of the two efflux proteins in the membrane  lattice.  
.  If there are differences in drug sensitivity  of different  cells,  
one  can  improve  the  activity  or  selectivity  of  a  given  
compound  with rational  drug design,  e.g.,  the modification of  
phenothiazine  ureas  and  "half-mustard  type"  phenothiazines  
(8)  or  by introducing changes into  Cs-A resulting  in a  higher  
mdr  reversing  effect  with  Cs-D  than  Cs-A  based  on  the  
modified  structure  (28).  When  many  structurally  related  
phenothiazines  were  tested  for  their  antiproliferative effects 
on  60 different cancer  cell  lines,  a  wide  range  of  biological  
activity  was  observed  on  a  large  variety  of  cancer  cell  lines  
(12,13,27,  29).  Based  on  the  measured  antiproliferative  
effects, some correlations were found  between  the  sensitivity  
on  different  types  of  cancer  cell  lines  and  the  structures  of  
substituted  phenothiazines  (11,  13, 30),  meaning that  certain  
types of cancer cell lines are more  sensitive than others. 
The  selectivity  of  mdr  reversing  compounds  can  be  
improved  by  combination  with  other  chemosensitizers  e.g.,  
trifluoperazine  plus  verapamil,  or  by  exploiting  the  
stereoselectivity  (28, 29). In this case, the  inactive member of  
a  pair  of  stereoisomers  should  be  considered  to  inhibit  the  
mdr pgp. 
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Since  promethazine  and  trifluoperazine  are  able  to  
downregulate  mdr  gene  expression,  the  pretreatment  of  
cancer  cells  with  these  (or  less  toxic)  compounds  make  the  
cells  more  sensitive  to  anticancer  drugs  by  preventing  the  
induction  of  mdr.  
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6,12-Dihydro-l-benzopyrano [3,4-ft] [1,4] benzothiazin-6-ones: 
Synthesis and mdr Reversal in Tumor Cells 
ANAMIK SHAH1, YOGESH NALIAPARA1, DINESH SUREJA1, NOBORU  MOTOHASHI2,  
MASAMIKAWASE3,  CSILLA MISKOLCI4, DIANA SZABO4  and JOSEPH  MOLNÁR4  
lDepartment of Chemistry,  Saurashtra  University,  University Road, Rajkot-360 005,  India; 
¿Meiji College of Pharmacy, Tanashi-shi,  Tokyo 188, Japan; 
3Faculty of Pharmaceutical Sciences, Josai University,  Saitama, 350-0290; 
^Faculty ofMedicine,  Institute of Microbiology, Albert Szent-Györgyi Medical  University,  Szeged, H-6720 Hungary 
Abstract.  Six  6,12-dihydro-l-benzopyrano[3,4-b][l,4]benzothi-
azin-6-ones and three coumarins were systematically investigated 
for reversal of multidrug resistance of bacteria and cancer cells in 
model experiments.  7-Methylcourharin  was able to eliminate the 
E.  coliplasmid  significantly;  however, the other derivatives were 
ineffective.  Four  of  6,12-dihydro-l-benzopyrano[3,4-b][l,4]  
benzothiazin-6-ones had  a  moderate  effect  on  the multidrug 
resistance efflux pump  of mouse lymphoma cells in vitro.  Despite 
of the similarity of resistance mechanisms of bacteria and tumor 
cells,  the  reversal of  drug resistance in  bacteria and  in cancer 
cells is not  uniform because the stmcture- activity  requirements 
are apparently different, 
i 
In  cancer  therapy,  the  development  of  resistance,  including  
multidrug resistance for traditionally used medicines, is now a 
major  problem.  Patients  need  new  type  of  medicines  or  
special  drugs to  reduce the  drug resistance. Therefore,  some 
benzo[«]phenothiazines  were  planned  for  synthesis  in  our  
laboratories.  As  shown  earlier,  benzo[a]phenothiazines  have  
antitumor  activity  against  some  tumor  cells  (1),  induce  
significant  apoptosis  on  human  myelogenous  leukemic  cell  
lines  such  as  ML-1,  U-937  and  THP-1  (2),  and  affect  the  
element  content  of  tobacco  tissue  culture  and  hormone  
requirement  (3).  6,12-Dihydro-l-benzopyrano[3,4-fc][l,4]ben-
zothiazin-6-ones  are structurally very similar to the  structures  
of  benzo[a]phenothiazines  (Figure  1).  Some  6,12-dihydro-l-
benzopyrano[3,4-b][l,4]benzothiazin-6-ones  showed an  effect  
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Saurashtra  University,  University  Road,  Rajkot-360 005,  India.  
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Key Words:  6,12-dihydro-l-benzopyrano[3,4-6][l,4]benzothiazin-
6-ones, mdr reversal on tumor cells. 
on the multidrug resistance  efflux pump  of  mouse  lymphoma  
cells  in  vitro  (4). The  coumarins  which  are  included  in  these  
compounds  have  also  shown  antitumor  activity  by  the  
inhibition  of  HIV  integrase  (5).  Based  on  our  estimated  
structure-activity  relationship,  it  was  expected  that  6,12-
dihydro-l-benzopyrano[3,4-6][l ,4]benzothiazin-6-ones  may  
have  some  antitumor  activity  and  may  cause  reversal  on  
resistant tumor cells. The purpose of this paper  is to show the 
mdr  reversal  activity  of  seven  6,12-dihydro-l-benzo-
pyrano[3,4-b][l,4]benzothiazin-6-ones  on  tumor  cells  with  
multi-drug resistance.  
Materials and  Methods  
Melting  points  were  determined  in  open  glass  capillaries  in  a  paraffin  
bath  and  are uncorrected.  1H-NMR spectra were performed on  a  JEOL 
JNM-GSX 500 (500 MHz) spectrometer  using TMS as internal  standard  
(6=0). Aromatic  protons  are  represented  as ArH. Infrared (IR)  spectra  
were  recorded  on  a  JASCO  IRS 10  spectrometer.  Mass  spectra  (MS)  
were  recorded  on  a  JEOL-JMS-DX300  spectrometer  with  direct  inlet  
system  at  70eV. TLC  (Thin  layer  chromatography)  was performed on  a  
Merck Kiesclgel  60 F254 (Merck 5549, USA). 
Chemicals.  Phenols  were  purchased  from  SISCO  Chem  Industries,  
Bombay,  India.  Phosphorus  oxychloride  was  purchased  from  
Spectrochem  private  limited  Bombay,  India.  Zinc  chloride  was  made  
anhydrous  by  fusion  and  then  used.  6-Methylcoumarin  [13](Aldrich,  
M3,620-3);  7-methylcoumarin  [14](Aldrich,  22,032-9);  ethyl  3-
coumarincarboxylate  [15](A!drich,  39,080-1) and  rhodamine  123 hydrate 
(R123)(Aldrich,  28394-0)  were  purchased  from  Aldrich  Chemical  Co.  
(Milwaukee,  WI,  U.S.A.).  (±)-Verapamil  (Sigma,  V  4629)  as  calcium  
channel  blocker  (3,5)  was  purchased  from  Sigma  Chemical  Co.  (St.  
Louis, MO, U.S.A.).  
General  method  of  preparation  of  4-hydroxycoumarins  [1-6].  4-Hydro-
xycoumarins  [1-6] were prepared  according  to  the methods  of  Shah  and  
Bose  (6,7).  Phenol  or  substituted  phenol  (0.1 M)  and  malonic  acid  (0.1  
M) were  added  to  q mixture  of  30 mL phosphorus  oxychloride and  36 g 
anhydrous zinc chloride,  which  was preheated  to  60*C and  the  reaction  
mixture  was  heated  on  a  water  bath  at  70*C for  16-36 hours. After  the  
reaction  had  finished,  it  was  cooled  and  decomposed  with  crushed  ice,  
0250-7005/98  $2.00+.40  3001 
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the  product  was  crystallized  and  was  filtered,  followed  by  washings  with  
water.  The  product  was  dissolved  in  10%  sodium  carbonate,  warmed  if  
neccessary  and  filtered. The  filtrate was  slowly acidified with  3  M  HC1 till 
complete  precipitation,  then  filtered,  washed  with  water,  dried  and  
rccrystallized  from ElOH  or AcOH  (Scheme  1).  
The  following compounds  were  obtained:  
a)  4-Hydraxycoumarin  / / / .  Yellow  powders  (EtOH).  mp:209-210*C  (Lit.  
6: mp  201-203°C).  
b)  6-Metliyl-4-hydroxycoumarin  [2],  Yellow  powders  (EtOH).  mp:251-
253 °C (Lit.  8:  mp240"C) .  
c)  5,7-Dimethyl-4-hydroxycoumarin  [3J.  White  powders  (AcOH).  
mp:210-211 "C (Lit. 7: mp 210-211 °C). 
d)  5,8-Dimethyl-4-hydroxycoumarin  [4],  Yellow  powders  (EtOH).  
mp:261-262°C  (Lit.  9.  mp  261-262'C).  ' H - N M R  (60  MHz,  TFA)  6:  
2.47  (s, 3H,  CH3) ,  2.49  (s, 3H, CH3) ,  6.22  (s,  1H, H-3),  7.41  (br  s,  1H,  
ArH),  7.60 (br  s,  1H,  ArH).  
e)  7,8-Dimethyl-4-hydroxycoumarin  [5],  Yellow  powders  (EtOH).  
mp:236-237°C (Lit.  7: mp  236-237'C).  
f)  6-Chloro-7-methyl-4-hydroxycoumarin  [6j.  Yellow  powders  (EtOH).  
mp:229-230°C (Lit.  7: mp  229-230"C).  
General  method  of  preparation  of  6,12-dihydro-l-benzopyrano[3,4-
b][ l,4]benzothiazin-6-ones  [7-12],  6,12-Dihydro-l-benzopyrano[3,4-
b][l,4]benzothiazin-6-ones  [7-12]  were  prepared  according  to  the  
method  of  K.Tabakovic  el  al  (10).  A  mixture  of  appropriate  4-
hydroxycoumarin  [1-6] (0.01M)  and  2-aminothiophenol  (0.01M)  in  25-30  
rnL  DMSO  was  stirred  and  heated  at  140-150°C  for  10-13 hours. At  the  
stage  when  the  reaction  mixture  became  dark,  heating  was  stoped  and  
the  mixture  slowly  distilled  in  an  excess  of  approximately  15-17.  mL  
DMSO  at  atmospheric  pressure.  The  reaction  mass  was  then  cooled  to  
obtain  dark  colored  crystallized  product.  This  product  was  washed  with  
MeOH  and  purified  by three  time washings and  its purity was checked  by  
TLC using CH 2 CI 2 -McOH  (10:1) system  (Scheme  1).  
The  following compounds were  obtained:  
a)  6,12-Dihydro- l-benzopyrano[3,4-b][l,4]benzotliiazin-6-one  [7],  
Reddish  brown  crystals.  mp:337-340"C  (MeOH)  (Lit.  10:  mp  337-
340 °C). 
b)  2-Metliyl-6,12-dihydro-  1-benzopyrano[3,4-b][l,4]benzothiazin-6-one  
¡8],  Dark  orange  crystals.  mp:340°C  (MeOH).  yield:  50%.  ' H - N M R  
(DMSO-df,)  6:  2.40  (s,  3H,  CH3) ,  6.82-6.88  (m,  2H,  ArH),  6.95-7.20  
(m,  2H,  ArH) ,  7.26  (d,  1H, 7=8.2  Hz,  ArH),  7.44  (d,  1H, 7=8.5  Hz,  
ArH),  7.92  (s,  1H,  ArH),  8.94  (s,  1H,  NH).  IR  (Nujol)  cm"1:  3350  
(NH),  1655 ( C = 0 ) .  MS  m/c:  281  (M+,  100%).  High-resolution  MS:  
Calcd  for C i 6 H n N 0 2 S :  281.0511.  Found:  281.0506.  
c)  1,3-Dimethyl-6,12-dihydro-  1-benzopyrano  [3,4-b]  [1,4]benzothiazin-6-
one  [9],  Green  crystals.  mp:290°C  (MeOH).  yield:  52%.  ' H - N M R  
(DMSO-d6)  6: 2.33 (s, 3H, CH 3) ,  2.65  (s, 3H, CH 3) ,  6.68-6.73 (m,  1H,  
ArH),  6.79-6.85  (m,  1H, ArH),  6.87-6.98  (m, 3H, ArH),  6.98-7.40  (m,  
1H,  ArH),  10.10  (br  s,  1H,  NH).  IR  (Nujol)  cm"1:  3300  (NH),  1630  
( C = 0 ) .  MS  m/e:  295  (M+,  100%).  High-resolution  MS:  Calcd  for  
C i 7 I I | 3 N 0 2 S :  295.0667. Found:  295.0653.  
d)  1,4-Dimethyl-6,12-dihydro-  1-benzopyrano  [ 3,4-b]  [1,4]benzothiazin-6-
one  110].  Light  green  crystals,  mp:  170°C  (MeOH).  yield:  50%.  'H-
NMR  (DMSO-dg)  6:  2.26  (s, 3H,  CH3) ,  2.53  (s,  3H,  CH 3) ,  6.35-6.45  
(m,  1H, ArH),  6.65-6.76  (m,  1H, ArH),  6.80-7.10  (m,  3H, ArH),  7.28-
7.37  (m,  1H,  ArH),  7.96  (br  s,  1H,  NH).  IR  (Nujol)  cm"1:  3300  (br,  
NH),  1670 ( C = 0 ) .  MS  m/e:  295  (M+,  100%).  High-resolution  MS:  
Calcd  for C i 7 H ] 3 N 0 2 S :  295.0667. Found:  295.0654.  
e)  3,4-Dimethyl-6,12-dihydro-  1-benzopyranof3,4-b][1,4]benzothiazin-6-
one  ¡11].  Orange  crystals.  mp:>300"C  (MeOH).  yield:  50%.  ' H -
N M R  (DMSO-ds)  6:  2.24  (s,  3H,  CH3) ,  2.35  (s,  3H,  CH 3) ,  6.82-6.87  
(m,  2H, ArH),  6.96-7.02  (m,  2H, ArH),  7.24 (d,  1H, 7=8.2  FIz,  ArH) ,  
7.86 (d,  1H,7=8.2  Hz, ArH),  8.94  (s,  1H, NH).  IR  (Nujol) cm"1:  3340  
Benzo[a]phenothiazine  6,12-dihydro-l-benzopyra[3,4-
4]benzolhiazin-6-oucs[7-12| 
Figure  1.  13enzo[a]phenothiazine  and  6,12-dihydro-  1-benzopyrano[3,4-
b][l,4]benzothiazin-6-ones  ¡7-12],  
(NH),  1655 ( C = 0 ) .  MS  m/e:  295  (M+,  100%).  High-resolution  MS:  
Calcd for C n H 1 3 N 0 2 S :  295.0667. Found:  295.0667.  
f)  2-Chloro-3-methyl-6,12-dihydro-  1-benzopyrano[3,4-b//  1,4]  benzotliiazin-
6-one  [12],  Reddish  brown  crystals.  nrp:328°C  (MeOH).  yield:  45%.  
' l l - N M R  (DMSO-df,)  6:  2.40  (s, 3H,  CH 3) ,  6.83-6.87  (m,  2H,  ArH),  
6.94  (d,  1H, 7=7.6  Hz,  ArH),  6.97-7.01  (m,  1H,  ArH),  7.42  is,  III,  
ArH),  8.25  (s,  1H, ArH),  8.98  (br  s,  1H,  NH).  IR  (Nujol)  cm"1:  3350  
(NH),  1660 ( C = 0 ) .  MS  m/e:  315  +  317  (3:1)  ( M + ,  100%:  38.6%).  
High-resolution  MS:  Calcd  for  Ci 6 H 1 0 3 7 CINO 2 S:  315.0121.  Found:  
315.0129.  Calcd for C ]6Hio37C1N02S:  317.0091.  Found:  317.0085.  
Biological  evaluation  
Measurement  of  antiplasmid  activity.  The  F'lac  plasmid  of  E.  coli  served  
as  a  convenient  model  in  this  study  because  the  plasmid  carrying  
colonics  were  easily  differentiated  from  the  plasmidless  colonies  on  a  
simple  eosinum  methylene  blue  (EMB)-differential  media.  The  
antiplasmid  activity  of  test  compounds  was  measured  on  E.  coli  K12  
LE140  F'lac  strain  in  MTY  broth  which  contained  various  
concentrations  of  test  compounds  (11,12).  After  24  hours  of  incubation  
at  37°C,  various  dilutions  of  samples  were  plated  on  EMB  agar.  The  
lactose-positive  (plasmid  earring)  colonies  and  lactonc-ncgativc  
(plasmidless)  colonies were counted  (Table  I).  
Tissue  cultures.  L5178  mouse  T  cell  lymphoma  and  its  MDR1/A  
retrovirus  transfected  derivative  were  provided  from  Prof.  Aszalos  
(Table  II).  
Cell  and  fluororescence  uptake.  MDR1/A  expressing  cell  lines  were  
selected  by  culturing  the  infected  cells  with  60  ng/mL  colchicine  to  
maintain  the  expression  of  the  mdr  phenotype.  The  L5178  M D R  cell  
line, and  the L5178Y parent  cell line were grown  in McCoy's 5A  medium  
with  10% heat-inactivatcd  horse  serum,  L-glutamine  and  antibiotics.  The  
cells were  adjusted  to  a concentration  of  2  x 106/mL  and  resuspended  in  
serum-free  McCoy's  5A  medium  and  the  cells  were  distributed  into  0.5  
mL aliquots  to  Eppendorf  centrifuge tubes. Then,  the  tested  compounds  
were  added  in  2.0  pL  of  the  2.0  mg/mL  stock  solution  and  the  samples  
were  incubated  for  10  minutes  at  room  temperature.  Then,  50  pL  
rhodamine  123  (R123)  as  indicator  was  added  to  the  samples  (5.2  pM  
final  concentration)  and  the  cells  were  incubated  for  a  further  20  
minutes  at  37°C,  washed  twice  and  resuspended  in  0.5  mL  phosphate-
buffered  saline  (PBS)  for  analysis.  The  fluorescence  of  the  cell  
population  was  measured  by  flow  cytometry  using  Beckton  Dickinson  
FACScan  instrument  (cell  sorter).  (±)Verapamil  was  used  as  the  
positive  control  in  the  R123  accumulation  experiments  (13,14).  The  
R123 accumulation  was calculated  from fluorescence of one height  value  
x 
using  the  2nd  equation  y=10  256  (Table II).  In  the case  of  logarithmic  
transformation,  the  1024 digital channels were  switched  to one decade  at  
each  256  (=28)  channels.  Then,  the  percentage  of  control  mean  of  the  
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Sr0 H 
0 
¿ H  ZnCl2,POCl3  
60-70° 
several hrs 
1: R ] = H ,  R 2 = H ,  R 3 = H ,  R 4 = H  
2: R I = H ,  R 2 = C H 3 ,  R 3 = H ,  R 4 = H  
3: R I = C H 3 ,  R 2 = H ,  R 3 = C H 3 ,  R 4 = H  
4: R ] = C H 3 ,  R 2 = H ,  R 3 = H ,  R 4 = C H 3  
5: R ] = H ,  R 2 = H , R 3 = C H 3 I  RACILY  
6: R , = H ,  R 2 =CI, R 3 = C H 3 ,  R 3 = H  
D M S O 
140-150° 
7:  RI = H, R 2 = H , R 3 = H ,  R 4 = H  
8:  RI = H, R 2 = C H 3 ,  R 3 = H ,  R 4 = H  
9: R | = C H 3 ,  R 2 = H ,  R 3 = C H 3 ,  R 4 = H  
10: RI=CH 3 ,  R 2 = H ,  R 3 = H ,  R 4 = C H 3  
11: R | = H, R 2 =II ,  R3=C1I3 J  R 4 = C H 3  
12: R | = H ,  R2=C1,  R 3 = C H 3 ,  R 3 = H  
Scheme  1. Synthesis  of  6,I2-dihydro-l-benzopyrano[3,4-b][l,4]henzothiazin  -6-ones[7-12],  
fluorescence  intensity  was  calculated  for  parental  and  mdr  cell  lines,  
compared  to  untreated  cells.  An  activity  ratio  was  calculated  by  the  
following equation  (13,!5)(Table  II):  
(mdr  treated Imdr  control)  
Ra t io= 
(parental  treated/parental  control)  
Results  and  Discussion  
Antiplasmid  activity  by  elimination  of  F'lac.  Antiplasmid  
activity  by  elimination  of  F'lac  was  tested  and  only  one  
compound  the  7-methylcoumarin  [14]  had  a  remarkable  
effect,  while  three  other  derivatives  [8],  [11]  and  [12]  had  
slight  effect.  The  other  coumarins  [7,  9,  10,  13,  15]  were  
ineffective (Table  I).  
The  activity of 7-methylcoumarin  [14] is probably related  to  
the  electrophilic-superdelocalization  induced  by  methyl  
substitution  at  7 position.  If this correlation  were true  then  we  
would  expect  similar  effects in case  of compounds  [9,11,  12];  
however,  these  compounds  were  weak.  The  effect  of  [9]  was 
reduced  by  methylation  at  position  1 due  to  a  compensating  
electronic  distribution.  
mdr  Reversal  on  tumor  cells.  The  effect  of  6,12-dihydro-l-
benzopyrano[3,4-6][l,4]benzothiazin-6-ones  [7-12]  and  
coumarins  [13-15]  was  tested  on  the  mdr  reversal  on  tumor  
cells. The  coumarins  used  in  this  study were  slightly effective 
(Table  II).  Three  6,12-dihydro-l-benzopyrano[3,4-6][l,4]ben-
zothiazin-6-ones  of  [8] (Fluorescence  activity  ratio,  1.56),  [9]  
(Fluorescence  activity  ratio,  1.43)  and  [10]  (Fluorescence  
activity  ratio,  1.11)  at  20  pg  concentration  had  a  moderate  
activity  on  mdr  reversal  (Fluorescence  activity  ratio>l).  
However, three  6,12-dihydro-l-benzopyrano[3,4-6][l,4]benzo-
thiazin-6-ones  [7,11,12]  (Fluorescence  activity  ratios,  0.57,  
Table  I.  Antiplasmid  activity  of  6,I2-diliydro-l-benzopyrano[3,4-
b][l,4]benzothiazin-6-ones  [7-12]  and  related  coumarins  [13-15],  
Compd's  RI  R 2  R 3  R4  Elimination  Antiplasmid  
No.  of  F'lac  effect  
(pg/mL)  ( % )  
200  0  
>200  0.05/at  160  pg  
200  0  
200  0  
200  0.1/at  160  pg  
>200  0.9/at  180  pg  
200  0  
95  32.0/at  70  pg  
200  0  
7 11 H H H 
8 H CH 3 H H 
9 CH 3 H CH 3 H 
10 CH 3 H H CH 3 
11 H H CH 3 CH 3 
12 H CI CH 3 H 
13 
(6-methylcoumarin) 
14 
(7-methylcoumarin) 
15 
(ethyl  3-coumarin-hyphen  
carboxylate)  *C  
CHjCHJO'  O  
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Table II.  The  effect of  6,12-diliydro-l-benzopyrano[3,4-b][l-4]benzothiazin-6-ones  [7-12]  and  related coumarins  [13-15]  on  the  indr  reversal on  L-5178  
tumor cells with multidrug resistance. 
Compound's Concentration Forward Side scatter Fluorcsccnce one  height"  Fluorescence 
number (Fg) scatter count activity 
count (granulation X  256  ratio
0 
(cell size) of cell) xb 256  y='o  
1.00 
8.49 
0.49 
0.57 
0.57 
1.56 
0.78 
1.43 
0.74 
1.11 
0-44 
0.60 
0.51 
0.63 
0.53 
0.52 
0.58 
0.57  1  
0.64 
aRef.l5.  bx: Measured  fluorescence  value at linear scale [pg, uptake of R123],  "  
T h e  R-123 accumulation was calculated from fluorescence of one height value using 1st equation»  10 256  ;  the  fluorcsccnce  activity  ratios  were  
calculated according to the formula given below; 
(mdr  treatedimdr control) 
Ratio  =  
(parental treated/parental  control)  
"par: parental without multidrug resistant gene;0mdr. parental with multidrug resistant gene. 
f(±)-vcrapamil:  a control for mdr  reversal.  
par") control 501.31 335.65 781.9520 3.0545 1133.80 
mdr  +  R123c)  control 552.47 385.44 326.0672 1.2737 18.78 
(±)-vcraparnil° 8pg 540.50 -  381.20  563.8161 2.2024 159.37 
7 2(ipg 
551.31 
533.43 
375.07 
400.03 
246.9632 
263.5264 
0.9647 
1.0294 
9.22 
10.70 
8 2(ipg 557.39 541.54 375.09 388.52 263.6261 375.3984 1.0298 1.4664 10.71 29.27 
9 2<Tpg 553.48 544.72 379.05 375.61 298.3680 366.0288 1.1655 1.4298 14.64 26.90 
10 2<ipg 
551.91 
543.69 
385.77 
380.65 
291.9680 
337.7408 
1.1405 
1.3193 
13.82 
20.86 
11 2(Jpg 540.58 553 07 368.60 374.34 235.6851 269.1072 0.9206 1.0512 8.33 11.25 
12 2<Jpg 550.50 544.76 386.64 382.16 251.5712 275.4304 0.9827 1.0759 9.61 11.91 
13 2<Tpg 558.61 559.92 396.64 389.56 254.8736 252.8512 0.9956 0.9877 9.90 9.72 
14 21'g 559.13 393.86 265.9840 1.0390 10.94 
15 2  Pg  522.56 397.48 264.1408 1.0318 10.76 
20 pg 513.96 371.64 275.8144 1.0774 11.95 
0.60 and 0.63, respectively) without  methyl or benzo group at 
positions  1  or  2  together  reduced  the  rhodamine  
accumulation  in  tumor  cells,  probably  by inducing  the efflux 
pump  mechanism  or  by  causing  a  direct  membrane  injury  
(Table II).  Position  4 must be free or  low in electron  density  
for the mdr reversal effect. The one exception is [10], in which 
the substitutions at positions 1 and 4 neutralized each other. 
The ineffectivity of ihe compounds was probably correlated 
with the lower or  reduced  cell  size, however, granulation  did  
not  change remarkably  in the cells. There was no toxic effect 
in the applied concentration,  and the  cell size did not  change  
in flow cytometry. 
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Nitric Oxide Production and MDR Expression by Human Brain 
Endothelial  Cells  
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and J O S E P H  M O L N A R 1  
department  of Microbiology,  department  of Biochemistry, Albert Szent-Györgyi Medical University,Szeged, Hungary; 
Department of Microbiology and Immunology,  Oregon Health Sciences University,  U.SA.  
Abstract.  The endothelium both  initiates and  responds  to  a  
cascade of events triggered by cytokines.  Enhanced formation of  
NO,  especially by  inducible nitric oxide- synthase  (i  NOS),  is  
largely stimulated  by  tumor  necrosis factor  (TNF).  Nitrogen  
oxides are reactive intermediate molecules functioning in neural 
transmission, and  vasodilatation. The aim  of our study  was  to  
investigate the effect of  TNF and Staphylococcus aureus,  a TNF 
inducing agent on the NO production of brain endothelial cells 
in  vitro.  The effect of  the same  agent  was investigated on  the  
MDR  expression  of  endothelial  cells.  Both  TNF  and  
Staphylococcus aureus resulted in  enhanced  NO  production.  
Western blot  analysis showed  enhanced  expression of iNO.S, 
which could be inhibited by pentoxifylline,  an inhibitor of TNF 
synthesis.  Flow  cytometric  analysis  revealed  that  the  brain  
capillary  endothelial  cells  exerted  P-glycoprotein  expression,  
which was not influenced  by  TNF. However, the mdr function 
itself in these cells  was decreased by  TNF. Cultured endothelial 
cells  are  excellent tools  for  the  investigation of  the  possible  
connection between  the NO production and MDR Junction,  and  
for  the estimation  the effect of different agents influencing these 
activities,  which  might  be  important  in  blood-brain  barrier  
function. 
Brain  endothelial  cclls  possess  a  unique  structure  which  is  
responsible  for  their  anatomical  barrier  properties.  
Substances  entering  or  leaving  the  brain  must  pass  through  
the  endothelial  cells.  The  multidrug  resistance  protein  in  
brain  capillary  endothelium  may  be  one  of  the  functional  
components  of  the  blood  brain  barrier,  functioning  as  a n  
active efflux pump  (1).  
O n  the other hand,  cytokines can  penetrate  the blood  brain  
barrier  at  specific  sites.  One  of  the  most  important  actions  of  
the  tumor  necrosis  factor  (TNF),  a  pluripotent,  
proinflammatory  cytokine,  is  that  it  can  increase  the  
permissivity of  the  barrier  (2).  It is interesting  that  endothelial  
cells  (EC)  both  initiate  and  respond  to  a  cascade  of  events  
triggered  by  cytokines.  Enhanced  formation  of  niric  oxide  
(NO),  especially  by  the  inducible  nitric oxid  synthase  (¡NOS),  
is  largely  stimulated  by  T N F  (3).  Nitric  oxides  are  reactive  
intermediate  molecules  functioning  in vasodilatation,  or  even  
in neural  transmission  (3).  
The  aim  of  our  studies  was  to  investigate  the  TNF.;'and  
Staphyloccus aureus,  as  a  TNF  inducing  agent  on  the  NO  
production  of  brain  endothel  cells  (EC)  in  vitro.  T h e  effect  of  
the  same  agents  were  studied  o n  the  M D R  expression  and  
M D R  function in cultured  endothelial  cells.  
Materials and  Methods  
Cells. Brain  capillary  endothelial  cells of  a  BB19 cell  tine  were  cultured  
in monolayers,  in RPMI  medium supplemented  with  10% FCS and  10%  
human AB serum, and  SO pg/ ml endothelial growth factor (SIGMA) 
Measurement  of  nitrite/nitrate  concentrations.  For  the  dctcrmiation  of  
total  nitrite/ nitrate concentrations  in cell supernatants,  nitrate  was first 
converted  to  nitrite,  by  incubation  with  nitrate  reductase  and  NADPi-1  
(Total  NO  kit,  Caymann  Chemicals,  U.SA),  and  then  nitrite  was  
measured  by  the  Griess  reaction  (4).  Adsorbance  at  540  nm  was  
measured  by use  of  a  StaFax ELISA plate reader. The  nitrite  present  in  
each well was quantified  by a comparison  with  a standard  curve of  serial  
dilution of a  10 mM solution  of sodium  nitrite.  
Western blot  analysis.  For  analysis  of  iNOS  content  of  EC,  3x10®  EC  
were  cultured  for  18  h  in  the  presence  or  abscence  of  1000 IU/  ml  of  
hrTNF  (Genzyme)  or  with  10° heat  killed  S.  aureus.  Cell  lysates  in  2X  
Laemmli  reducing  sample  buffer  were  boiled  fo r .5  min  at  100'C.  
Samples  were  loaded  onto'  SDS  polyaciylamide  gel  electrophoresis  
consisting of  10 %  running  gel. After electrophoresis,  the proteins  were 
transferred  to nitrocellulose  and probed  with  a  1:1000 dilution  of  rabbit  
anti-iNOS  polyclonal  antibody  (Affinity,  U.K.)  followed  by  a  1:1000  
diluton of goat anti- rabbit IgG conjugated to HRP (Bio Rad). The  color  
was  developed  with  diaminobenzidine  (DAB,  SIGMA)  and  hydrogen  
peroxide. 
Indirect  immunofluorescence  analysis  of  P  glycoprotein. Endothelial  cells  
(2x10® cells  in  50 pi) were  incubated, for 45 min on  ice with 50  pi  of  a  
1:50 dilution  of  Monoclonal  antibody  C219,  specific  for  P-glycoprotein  
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biology, Albert Szent-Györgyi Medical University, Szeged, Dóm 
tér  10, H-6720 Hungary. Tel: (+)36  62 455  115, Fax:  (+)36-62  
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Key  Words:  Multidrug  resistance,  endothelial  cells,  TNF,  nitric  
oxide. 
0250-7005/98 S2.00+.40 3049. 
A N T I C A N C E R  R E S E A R C H  IS.- 3049-3052  (1998)  
+  nitrate  
reductase 
-  nitrate  
reductase 
medium 
TNF 
S.aureus 
S.aureus+PTX 
8  10  12  
Nitrite  uM  
14 16 18 20 
Figure  1. A'O production  by human  brain  endothelial  cells.  Endothelial  cells grown  in  monolayers  were incubated  in  the  presence  of  1000  IU/ml  rhTNE.  or  
10°lml  heat  killed  S.  aureus  respectively,  and  in  the  presence  of  the  S.  aureus  with  100  pg/ml  pentoxipltylline  (PTX),  for  18  hours.  Nitrite,  (N02)  was  
measured  in  culture  supematants  by  the  Griess  reaction,  with  the  Total  NO  kit  (Caymann  Chemicals),  where  nitrate  was  first  converted  to  nitrite  by  
incubation  with  nitrate  reductase.  Thereafter,  nitrite  irax  measured  by  the  Griess  reaction,  and  determined  by  measuring  absorbance  at  550  tint  in  a  
STATFAXELISA  reader.  
(ID  Labs).  Cells were washed  three  times with  ice-cold  PBS containing  1  
%  FCS  and  stained  for  45  min  on  ice  with  a  1:200  dilution  of  
fluoresceinated  F(ab')2  fragments of  goat  anti-mouse  Ig (DAKO).  Cells  
were  washed  three  times  with  ice-cold  PBS-  1%  FCS  and  fluorescence  
analysis  was  performed  with  FACStar  plus  (Bccton-  Dickinson)  at  488  
nm  excitation.  Background  fluorescence  was  measured  by  incubation  of  
the cells with buffer only, instead  of with  C219  mAb.  
Fluorescence  uptake  assay.  Brain  endothelial  cells  grown  in  monolayer  
were  adjusted  to  a  concentration  of  2x10fy  ml  after  trypsinisation,  and  
resuspended  in  serum  free medium.  Test  compounds  were  added  to  the  
cell  suspensions  and  the  samples were  incubated  for  10 minutes  at  room  
temperature,  then  50  pM  of  the  indicator  Rhodamine  123 was  added  to  
the  samples  and  the  cells  were  incubated  for  a  further  20  minutes  at  
37 'C,  washed  twice  and  resuspended  in  0.5  ml  PBS  for  analysis.  The  
fluorescence  of  cell  population  was  measured  by  flow  cytometry  using  a  
Beckton  Dickinson  FACScan  instrument.  
Results 
Effect  of  TNF  on  NO  production  by  endothelial  cells.  
Endothelial  cells  were  incubated  with  1000  U/ml  TNF  or  in  
the  presence  of  heat  killed  St.  aureus  for  18 hours  thereafter,  
the  NO  production  was  estimated.  Nitrite,  (N02),  a  rapidly  
formed  stable  metabolite  of  NO,  was  measured  in  culture  
supematants  by  the  Griess  reaction,  with  the  Total  NO  kit  
(Caymann  Chemicals),  Nitrate  and  nitrite  are  the  primary  
oxidation  products  of NO,  reacting with water.  Therefore,the  
total  nitrite  concentration  in the  supematants  was  used  as  an  
indicator  of  changes  in  NO  production.  Nitrate  was  first  
converted  to  nitrite,  by  incubation  with  nitrate  reductase.  
Thereafter,  nitrite  was  measured  by  the  Griess  reaction,  and  
determined  by  measuring  absorbance  at  540  nm  in  a  
STATFAX ELISA  reader.  
The  detection  of  nitrite  content  of  the  supernatant  was  
much  more  sucsessful  if  the  nitrite  reductase  was  applied  
(Figure  1). TNF  induced  nitrite  production,  which  was  more  
pronounced  if  the  inducing  agent  was  the  heat  killed  S.  
aureus.  This  induction  could  be  inhibited  by  the  addition  of  
pentoxifylline  (PTX,  100  pg/ml)  which  is  able  to  inhibit  the  
TNF production  (5).  So we suppose that  the NO  induction  by  
Staphylococcus  is  due  to  the  TNF  inducing  abilty  of  the  
bacteria. 
Detection  of  iNOS  by  Western blot  analysis.  Not  only  the  the  
NO  production  also  but  the  expression  of  the  protein  of  the  
inducible  NO  synthase  (iNOS)  itself  could  be  detected  in  
endothlial  cells, by Western blot technique  (Figure 2).  
Using  a  polyclonal  antibody  which  specifically  detect  the  
protein  of  iNOS  of  a  molecular  weight  of  130  kD,  a  positive  
band  was appeared  with the positive controls  provided  by the 
manufacturer  (Figure  2.  upper  compartment).  The  results  
shown in the  lower compartment  of Figure  2. demonstrate  the  
same  band  at  the  same  Mw  position  when  applying  
endothelial  cells.  After  incubation,  of  EC  with  TNF,  the  
inducible  enzyme  protein  could  be  detected,  and  also  after  
the  incubation  of  cells with  S.  aureus.  However,  the  effect  of 
pentoxifylline proved  to be  inhibitory  even  on  the  expression  
of  the  enzyme.  In  addition,  incubation  of  endothelial  cells  
with  granulocytes  also  led  to  the  expression  of  iNOS.  Note  
3050 
Mandi  et al:  NO  and mdr  in Endothelial  Cells  
130 kD posit ive  controls  
106 kD 
1  2  3  4  5  6  
Figure  2. iNOS  expression  by brain  endothelial  cells  (EC).  EC  lysate protein  separated  by  10  %  SDS  PAGE.  EC  were  cultured  for  18 hours  in  the  presence  
(lane  3)  or  absence  (lane  2)  of  lOOOIU/ml  of  lirTNF  (Genzyme)  or. with  l(ft  heat  killed  S.  aureus  (lane  5).  or  with  Iffiiml  human  granulocytes  (lane  4)  
respectively.  Lane  6:  100 pglml  pentoxifylline(PTX)  were  added  together  with  S.  aureus.  Western  blot  was  incubated  with  antibody  to  iNOS.  Pound  antibody  
was  visualized  by horse  radish  peroxidase  mediated  color  development  of  diaminobenzidine.  
that  we  could  not  detect  this  enzyme  in  human  macrophages  
(lane  2).  
Next  we  investigated  the  effect  of  these  nitric  oxide  
inducing  agents  on  the  expression  and  function  of  MDR  in  
endothelial  cells.  
The  expression of  the  P-glycoprotein.  This  was  evaluated  with  
monoclonal  antibodies  directed  to the  intracellular  epitope  of  
the  protein.  Endothelial  cells  were  investigated  by  means  of  
indirect  immunoflourescency  and  flow  cytometry  analysis,  
(Figure  3).  Flow  cytometry  analysis  revealed  the  presence  of  
the  P-glycoprotein  on  the  cells  after  staining  with  the  
monoclonal  antibody  C  219. TNF  and  Staphylococcus  aureus  
did  not  significantly  influence  the  mdr  expression,  only  a  
slight  increase  can be seen  on  the  histogram.  
Effect  of  TNF  on  mdr  function.  Modulation  of  the  mdr  
function  itself  was  investigated  by  the  rhodamine  exclusion  
test.  The  fluorescence  intensity  depending  on  the  rhodamine  
intake was measured  by flow cytometry  (Table I). There  was a 
moderate  increase  in  fluorescence  intensity  when  cells  were  
incubated  in  the  presence  of TNF,  which  might  be  due  to  the  
decrease  of  the  mdr  function.  The  most  pronounced  effect  
was  observed  in  the  case  of  treatment  with  7,8  dioxo  
Tabic  I.  Rhodamine  123  accumulation  by  brain  endothelial  cells.  Flow  
cytometric  analysis  was performed  as  described  in  Materials  and  methods.  
Treatment  FT-1  
control  1269.29  
T N F  K W / m l  1477.63  
7,8 O : CPZ  lug'ml  1414.06  
Chlorpromazine  which  proved  to  be  an  effective inhibitor  of  
mdr  in other cell systems (6).  
Discussion 
The  gene  responsible  for multidrug  resistance,  termed  mdrl,  
encodes  a  membrane  glycoprotein  (P-glycoprotein)  that  acts  
as  a  pump  which  transports  various  drugs  out  of  the  cell  (7).  
The  amount  of  P-  glycoprotein  expression  was  found  to  be  
elevated  in  drug  resistant  cancers  (8).  In  addition  to  tumor  
cells,  the  P-glycoprotein  is  also  expressed  in  various  normal  
tissues  such  as  capillary  endothelium  in  brain  (9).  P-
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Fluorescence  intensity  
Figure  3.  Effect  of  TNF  and  S.  aureus  on  ¡'-glycoprotein  expression  of  
human  brain  endothelial  cells.  EC  were  incubated  for  18  hours  in  the  
presence  of  (b)  no  stimulant,  (c)  1000  IU/ml  rhTNF,  or  (d)  S.  aureus.  Cells  
were  incubated  with  C219  ni4b  then  with  F(ab')2  anti-mouse  FITC-
conjugated  antibody.  The  background  fluoresccnce  of  cells  incubated  with  
medium  only  is  shown  in  graph  (a).  The  result  is  a  representative  of  three  
independent  experiments  with  similar  results.  
glycoprotein  in  brain  capillary endothelium  may be one  of  the  
functionar components  of the blood brain  barrier.  
The  mAb  C219  used  in  this  study  is  able  to  detect  P-
glycoprotein on cultured human brain endothelial  cell line. 
Brain  endothelial  cells are  also one'of  the sources of  iNOS, • 
which  can  be  expressed  following  the  exposure  to  various  
inflammatory  mediators  such  as  cytokines  (3).  In  addition,  
TNF  is  able  to  increase  the  blood  brain  barrier  permeability  
(2), which  in turn  might be mediated  through  nitric oxide  and  
cyclic nucleotide formation (10). There  is no data  as yet  about  
the  connection  of  mdr  function  and  the  roduction  of  nitric  
oxide  by  brain  endothelial  cells  in  the  presence  of  different  
drugs.  We  suppose  therefore  that  human  endothelial  cell  
cultures  might  be  a good  tool  for the  in  vitro investigation  the  
effect of different drugs influencing these  functions which  arc  
essential  in the  blood  brain  barrier,  or  even  in cancer  therapy  
of tumors originating front the central  nervous  system.  
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The Inhibition of SOS-Responses  and MDR by 
Phenothiazine-Metal  Complexes  
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Abstract.  The gene of multidrug resistance  (mdr) is inducible by 
different  environmental  stresses  (SOS  gene).  We  tested  the  
inhibitory  action  of  some  new  metal  complexes  of  
phenothiazines  on megacin encoding bacterial gene induced by 
mitomycin-C as  an example of  "SOS  induction" and  on  efflux  
pump  of mouse lymphoma cells. The interaction of compounds 
to  DNA  war  measured by  thermal stability  of  DNA.  If  was  
found  that  metal  co-ordination  complexes  of trifluoperazine 
(TFP)  and  chlorpromazine  (CPZ)  added  before  mitomycin  
administration have an inhibitory action on megacine induction. 
The TFP-V(IV)  complex was effective  at  a  lower concentration 
than  TFP  alone.  The  inhibitory  effect  of  some  metal  co-
ordinating complexes (TFP-Cu(II) and  TFP-  V(IV)) exceeded 
the action of  TFP alone on efflux pumps.  We propose  that these 
compounds can form  a  complex with the  regidatory protein or 
DNA resulting in the inhibition  of SOS response and inhibit the 
mdr function by inactivating the P-glycoprotein as well. 
The  multidrug  resistance  gene  can  be  considered  as  a  
member  of  the  family  of  stress-induced  genes.  Due  to  some  
similarities,  the  mdr  gene  promoter  can  also  be  activated  by  
various  environmental  stresses,  carcinogens  and  anticancer  
drugs.  Therefore,  it '  was  suggested  that  the  mdr  gene  
promoter  can  be  a  target  for  stress-induced  gene  regulation  
(1,  2,  3,  4,).  Bearing  this  in  mind,  it  is  not  unlikely  that  
phenothiazines  (known  as  mdr  efflux  pump  reversal  
Correspondence  to:  Dr  János  Nacsa,  Department  of  
Microbiology,  Albert  Szent-Györgyi  Medical  University,  Szeged,  
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Key  Words:  mdr,  SOS,  stress  respons  gene,  thermal  stability  of  
DNA,  phenothiazine,  trifluoperazine,  chlorpromazine,  metal  
complex,  mitomycin.  
compounds)  can  stabilise  the  drug  sensitivity  in bacteria  and  
cancer  cells.  It  is  possible  that  phenothiazines  reduce  the  
cancerous  transformation  (and  mutation  rate  of  bacteria)  via  
the inhibition  of SOS functions. It  is known that  mitomycin-C  
induces  SOS  response  in  bacteria  either  by  causing  DNA  
damage  due  to  intercalation  or  by  inhibition  of-'•DNA  
replication.  The  stabilisation  of  repressor  protein  (lex-A)-
DNA  complex  blocks  the  SOS  response.  Some  tricyclic  
compounds  (e.g.  TFP  and  CPZ)  are  able  to  inhibit  both  the  
inducing  effect  of  mitomycin-C  and  the  efflux pump  of  mdr  
(5,  6).  It  was  proposed,  that  metal  ions,  coordinating  to  the  
hetero  atoms  of the middle  ring,  induce  some changes  in  the  
structure  of  the molecule  and  in the binding features to  DNA 
or the repressor protein  of the SOS gene promoter and  the P-
glycoprotein  (by the efflux pump mechanism).To improve  the  
effect  of  TFP  and  CPZ  metal  co-ordination  complexes,  -
namely  CPZ-Pt(II).  CPZ-Sn(IV),  TFP-Sn(IV),  TFP-Cu(II),  
TFP-Ni(II),  TFP-Pd(II)  and TFP-V(IV)  - were prepared  and  
studied. 
Materials  and  Methods  
The  phenothiazines  (promethazine  (Pz).  CPZ.  TFP)  and  the  
dimethyltin(IV)-dichloride  were  purchased  from  Aldrich.  the  di-n-
butyltin(IV)  oxide and  the  metal  salts  used  were  purchased  from Fluku.  
The  CPZ  complexes  with  di-n-butyltin(IV)  oxide  and  piatinum(II)  and  
the  TFP  complexes  with  di-n-butyltin(IV)  oxide,  coppcr(II),  nickel(II)  
and vanadium(IV)  in  1:1 ratio of the components were prepared  by Nagy 
el at  (7) .The complex of palladium(II)  and TFP was prepared  also in  1:1  
ratio,  by  dissolving  the  metal  chloride  in concentrated  HC1 and  adding  
the  aqueous  solution  of  the  ligand.  The  complcx  precipitated  
immediately  was  filtered  off  and  reciystallised  from DMF  solvent.  The  
analytical data showed that complexes with  1:1 metal to ligand ratio  have 
been  formed.  
Detection  of  SOS  signal  by  megacin  induction.  The  plasmid  in  B.  
megaterium  216  encodes  a  bactericidal  substance  called  megacine,  but  
only  when  the  plasmid  DNA  and  the  repressor  protein  complex  are  
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Figure  1. Effect  of pre-treatment  of  phenolhiazincs  and  tlicir  metal  complexes  on  growth  rate  and  induction  of  megacin  by  mitomycin-C  in  II.  megalctium  
216. 
separated  by  mitomycin-C.  YT  (yeast  extract  tryptone)  medium:  
tryptone  (Oxoid),  10 g; yeast  extract  (Oxoid),  2.5  g; K ; H P 0 4 ,  1 g,  NaCI,  
5  g; distilled  water,  1000 ml; pH  7.5. YP  (yeast  extract  peptone)  medium  
was  prepared  as  described  previously  [12].  From  a  standing  culture  in  
YT  medium  incubated  overnight  0.2  ml  was  transferred  to  10  ml  YT  
medium  pipetted  into  a  100  ml  Erlcnmeyer  flask. The  flask  was  shaken  
in  water  bath  at  37  °C.  When  an  O D  value  of  0.25  had  been  reached  
(number  of  colony  formers,  5xl06/m!  average  chain  length,  4-5),  the  
cultures  were  supplemented  with  phenolhiazincs  and  after  10  minutes  
with  mitomycin  (0.5  pg/ml)  and  the change  in O D  on  further  incubation  
was  recorded.  YP  broth  culture  of  B.  mcgalerium  KM  was  diluted  1 : 4 
with  YP  medium  and  1 ml was  mixed  with  1 ml  molten  (47  ' C )  nutrient  
agar  and  poured  on  a  basic  layer  of  the  saipe  medium.  The  basic  layer  
was prepared  with  1.5 %  agar. The  upper  soft  layer contained  half  of  this  
concentration.  Serial  dilutions  of  the  mcgacinc  containing  lysatcs  were  
prepared  with  saline  containing  20  %  YP  broth.  By  means  of  a  loop  
equal  amounts  of  the  serial  dilutions were  placed  onto  the  surface  of  the  
indicator  plates  (highest  litre  was  128x).  The  reciprocal  of  the  highest  
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Figure  2. Mdr  reversal  effect  of phenothiazines  and  tlielr  metal  complexes.  
dilution  causing  clear  zones  or  lysing  at  least  half  of  the  bacteria  at  the  
corresponding  site  was regarded  as one  unit  of  megacin/ml  (8,  9).  
Reversal  of  efflux  pump  indicated  by fluorescence  uptake  assay.  The  cells  
from  L5178Y  mouse  T-ccll  lymphoma  parent  cell  line  and  from  its  
multidrug  resistant  subline  L5178YvMDR  (kindly  provided  by  Prof  
Aszalos.  FDA.  Washington  DC)  were  adjusted  to  a  concentration  of  
2x10  /ml  in  McCoys  5A  medium.  This  medium  with  10%  heat-
b/ 
Concentra t ion  of compounds  (u  M)  
d / 
Concent rat ion of compounds  (a  M)  
inactivated  horse  serum.  L-glutatninc,  penicillin,streptomycin  was  used  
for the  L5178Y  cell  line. The  medium  for the  L5  1 78vMDR  cell  line  was  
supplemented  with  60  ng'ml  colchicine  to  maintain  expression  of  the  
MDR  phenotype.  In  0.5  ml  aliquots  of  cells  were  distributed  into  
Eppendorf  centrifuge  tubes.  To  assay  the  test  compounds  they  were  
added  to  cells  and  incubated  for  ID minutes  at  room  temperature,  and  
then  with  indicator  Rhodamine  123  (5.2  pM  final  concentration)  for  
another  20  minutes  at  37°C.  After  washing  twice  with  PBS.  the  
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Tabic  I.  Effect  of  pre-treatment  of  metal  complexes  of  phenothiazines  on  
growth rale and  induction  of megacin  in B.  megaterium  216.  
Concentration  of compounds  (10-5 M) 
Table  II.  'Hire of  mcgacin  after  the  inhibition  of  mitomycin  induction  hr  
phenothiazine  and  metal  complexes.  
0 1,1 11 3.3 
Compounds  Time of  
incubation 
(hour)  Optical  density of culture (620 nm) 
TFP-Cu(II) 
0 0.38 0.38 0,33 0,31 
0.5 0.65 0.55 0,36 0,24 
1 0.S3 0,7 0.36 0.25 
3.25 0.32 0.25 0,2 0.25 
15.2 0.24 0.17 0.11 0.19 
TFP-Pd(ll) 
0 0.3S 0.36 0.35 0.25 
0.5 0.65 0.51 0.4 0.24 
1 0.83 0.64 0.36 0.23 
3.25 0.32  .  0.24 0.23 0.2 
15.2 0.24 0.17 0.17 0.17 
TFP-Ni(ll) 
'0 0.38 0.4 0,35  .  0.3 
0.5 0.65 0.58 0,48 0,3 
1.5 0.S3 0.74 0.58 0.26 
3.25 0,32 0.32 0.24 0,22 
15.2 0.24 0.3 0,17 0,18 
CPZ-PI(II) 
0 0,38 0,35 0,32 0,23 
0.5 0,65 0,41 0,3 0,18 
1,5 0,83 0,5 0,37 0,16 
3,25 0,32 0,26 0,27 0,14 
15.2 0,24 0,2 0,2 0,12 
Concentration  of compounds  (x I0-5M) 
0 1,1 2.2 3.3 
Compounds Tilrc  of  mcgacinc  
TFP 12S.\ 12Sx •Sx Ox 
TFP-V(IV) 12Sx 64x 4x Ox 
TFP-Cu(II) I2S.V I28x I23x Ix 
TFP-Ni(II) !2Sx 12Sx I28x •Ix 
TFP-Pd(II) 128.x 128.x 64x Ox 
CPZ-Pl(II) 128.x I28x S.v 8x 
fluorescence  of  1x10  cclls was measured  by the flow cytomcter  (Bccklon  
Dickinson.  FACScan  Instrument).  The  percentage  of  control  mean  
fluorescence  was  calculated  for  untreated  parental  and  multidrug  
resistant  cclls. Verapamil  was used  as a positive control. An  activity  ratio  
(R)  was. calculated  by  the  following  equation:  R=(Mdr  treated  /  Mdr  
untreated  control).  
DNA  thermal  stability  studies.  To  study  the  interaction  of  compounds  
with  DNA;  one  of  the  most  convenient  methods  is  to  measure  the  
thermal  stability  of  the  DNA  (10).  Melting  can  be  monitored  by  an  
increase  in  absorbancc  (hyperchromic  effect)  that  results  from  the  
disruption  of  base  stacking. The  mid-point  of  the  thermal  dcnaluration  
curve  is  referred  to  as  the  "melting  temperature,  (Tni)"  of  the  DNA.  
Highly  polymerised  lypc-l  calflhymus  DNA  sodium  salt  was  purchased  
from  Sigma.  Stock  solutions  of  DNA  and  the  phenothiazines  wctc  
prepared  as follows: DNA  (10 mg) was suspended  in  10 ml  Q.03 M TKIS 
buffer containing 0.01S M NuCI adjusted to  pi I 7.0 and  the solution  was  
kept  at 4"C  for at  least  three  days. The  slock solution  was diluted  to  the  
working  conc  immediately  before  use.  The  concentrations  the  DNA  
solutions were determined  spcctropliotomctrically  in terms  of  nucleotide  
phosphate  and  calculated  from  an  extinction  coefficient  at  260  inn  of  
6600/M/cm  for calf  thymus  DNA  (11,  12). The  phenothiazines  and  their  
inctal  complexes  were  dissolved  in  DMSO  at  a  concentration  of  10°  M  
immediately before  use.  
Measurement  was  recorded  on  a  Cary  Varian  Model  IE  
spectrophotometer  using  a  Cary  temperature  controller  connected  to  a  
Cary  1/3 multicell  block. The solutions were .allowed  to equilibrate  for 20 
minutes  before  increasing  the  temperature  and  the  temperature  was  
then  increased  at  a  rale  of  0.5  'C/minulc.  A  cell  containing  DNA  
solution  alone  was  always  measured  along  side  cclls  containing  
Drug/DNA  mixtures  to  act  as an  internal  standard. The  blank cclls  in  all  
measurements contained TRIS solution  and  all cclls were stoppered  with  
teflon  caps.  The  mid  point  of  the  thermal  dcnaluration  profile  of  the  
solutions  (Tin)  was  determined  by  calculating  the  average  absorbancc  
using the instruments thermal  application software  (13,14).  
Results 
On  adding  promethazine  alone  to  the  culture  of  B.  
megaterium  216  no  megacine  production  was  observed  
(Figure  la).  Promethazine  pre-treatment  was  able  to  inhibit  
megacine  production  by  inhibition  mitomycin  induction  
(Figure  2b).  The  Pz  had  concentration  dependent  
antibacterial  effect from 6.7 to 26.67xl0'5  M (Figure  la).  The 
compounds  had  no  cffcct  on  the  production  of  mcgacinc  if  
the  culture  was  treated  by  promethazine  10  minutes  after  
mitomycin-C  induction.  The  quantity  of  mcgacinc  was  
followed  by the  growth-lysis curve (depending  on  the  time  of  
incubation). As a result  of  the bactericidal  cffcct of  mcgacinc  
in  the  culture  the  cells  lysed.  Similar  cffcct was found  in  the  
case  of  CPZ.  Since  the  membrane  cffccts  of  Pz  and  CPZ  
cannot  be  excluded  on  bacteria,  some  newly  prepared  mclnl  
complexes  were  tested  to  avoid  the  dircct  membrane  injury  
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caused  by  the  phenothiazines.  TFP  one  of  the  most  potent  
phenothiazines  had  a  concentration  dependent  inhibitory  
action  on  the  megacine  production  (Figure  lc).  The  most  
effective complex of TFP was the vanadium  complex  (Figure  
2d),  while  other  metal-coordination  complexes  e.g.  copper,  
nickel, palladium were less effective (Table I, II) showing that  
these three metals do not modify the biological action  of TFP. 
The  platinum  complex  of  CPZ  had  similar  effect  to  TFP  
(Table  I,  II).  It  was  noted  that  the  compounds  do  not  
neutralise  the  antibacterial  action  of  preformed  megacine  
(results not shown). 
Induction  of  the  mdr  efflux pump  can  be  considered  as  a  
unique  type  of  SOS  function; therefore,  the  phenothiazines  
and  their  metal  co-ordination  complexes were  also  tested  on  
the  activity  of  mdr  of  mouse  lymphoma  cells.  None  of  the  
metal  ions  had  a  reversal  effect on  mdr  at  all!  The  TFP,  
TFP-Cu(ll),  TFP-V(IV)  and  the  TFP-Sn(IV)  complex  were  
the  most  effective on  reversal  of  mdr  of  mouse  lymphoma  
cells  (Figure  2a,  b,  c,).  The  Ni(II)  and  Pd(II)  complexes  of  
TFP  had  activity,  but  less  than  the  TFP  itself  had  (data  not  
shown). The  less effective compounds  were  the  Sn(lV)  and 
Pt(il)  complex  of  CPZ7  but  this  action  noticeably  exceeded  
that  of CPZ (Figure 2d). It was interesting that some of metal 
complexes  were  effective; however,  the  biological  action  did  
not  greatly  exceeded  the  mdr  reversal  action  of  the  parent  
compounds. 
The  measurements  of  thermal  stability  of  DNA  showed  
some interaction between the phenothiazine metal  complexes  
and  DNA.  The  increased  melting  temperatures  of  DNA  in  
the presence  of metal  complexes indicates an interaction with 
DNA and stabilisation  of the helix. CPZ and TFP can be seen 
to  stabilise  the  DNA  helix  by  intercalation  causing  a  slight  
increase  in  the  thermal  denaturation  temperature.  A  similar  
effect was seen with the TFP-Sn(lV)  the CPZ-Sn(IV)  and the 
TFP-Cu(ll)  coordination  complexes  indicating  an  interaction  
with  the  DNA  helix  whilst  metal  ions  alone  showed  no  
significant  stabilisation  of  the  helix. The  chlorides  of  Pt,  Pd  
and  V  degraded  the  DNA  resulting  in  a  linear  thermal  
stability  profile. The  coordination  complexes  of  these  metals  
with CPZ and TFP however decreased  the thermal  stability of 
DNA. The  phenothiazines  appear  to  be  exerting  a  protective  
effcct, protecting  the  DNA  against  total  degradation  caused  
by the metal ions alone (Tabic III). 
Discussion 
Apparently  the  phenothiazines  and  their  metal  co-ordination  
complexes  were  able  to  reduce  the  SOS function  in  bacteria  
(reducing  the  bacteriocin  induction)  and  tumour  cclls  
(reducing the ABC transporter  activity). It has suggested,  that  
the  inhibition  of  the  two different SOS function  is due  to  the  
complex  formation  between  the  phenothiazines  and  the  
inducible SOS gene or some regulator proteins.  Based on this  
working  hypothesis,  the  complex  formation  with  native  B  
Table III. Change in Thermal  Denaturation Temperature  (T)  of  C  TDM  
in the presence of  phenothiazines  and metal  complexes.  
Compounds  DNA:  ATm  DNA:  
comp.  enmp.  
=  10:1  =5:1  
ATm  DNA:  Aim  
comp. 
=  2.5:1  
CPZ 
TFP 
CPZ-Pl(II) 
Pt(II) 
CPZ-Sn(lV) 
Sn(IV) 
TFP-Cu(II) 
Cu(ll) 
TFP-Ni(II) 
Ni(II) 
TFP-Pd(Il) 
Pd(II) 
TFP-V(IV) 
V(IV) 
TFP-Sn(IV) 
Sn(IV) 
0.2 
0.91 
1.2 
0.2 
0.93 
0.70 
2.38 
0.1 
-2.3 
0.44 
1.22 
-2.7 * 
1.9 
0.1 
1.4 
-0.1 I 
0.95 
0.5 
-5.4 * 
-in.! 
v 
l.o 
1.0 
(I  (|7 
l.o 
1.34 
0.23 
I.51 
II.51 
2.3 
0.31 
I.I 
0.23 
'  Resulted  in dcunidiitioii  of the  DNA  
form  DNA  was  studied  by  measuring  thermal  stability  of  
DNA. 
The  results  suggest  that  the  co-ordinating  metals  alter  the  
fine  chemical  structure  (superdclocalizibility  of  it-electrons)  
and biological action  of phenothiazines. 
The  CPZ-V(IV)  complex  has  been  shown  to  he  a  tiiou:  
effective inhibitor  of  the  SOS  function  in  the  cultures  of  II.  
inegaterium  than TFP  and  it  had  a  reversal  action  on  mdr  of  
tumour  cells. The Tm  values  suggest  that  an  explanation  for  
this  action  may be  an  interaction  between  the  DNA  and  the  
phenothiazinc-metal  co-ordination  complexes.  
Metal  ions  react  with  a  variety  of  electron  donor  sites  on  
polynucleotides. There arc three main sites of  interaction,  the 
phosphate  moieties  of  the  ribosc-phosphatc  backbone,  the  
electron  donor  groups  of  the  basis  and  the  sugar  part  of  the  
polynucleotides.  The  fourth  but  still  significant  interaction  
could occur  by the intercalation  of metals or  metal  complexes  
and  altering  the  hydrogen-bonding  network.  Interaction  with  
ribosc  moieties  under  such  experimental  conditions  is  
neglible. Reactions with  the  phosphate  means  stabilisation  of  
ordered  structure  or  the  cleavage  of  phoshodicstcr  bonds  at  
high  temperature.  Although  the  binding  is  not  specific,  the  
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result  is the neutralisation  of the array of negative charges on 
the  double  helix  thus  stabilising  it.  This  stabilisation  is  
accompanied  by  an  increase  in  the  melting  temperature  of  
DNA.  Concerning  the  metal  ions,  the  preference  for  
phosphate  over  the  base  association  decreases  in  the  order  
Mg(II)  >  Co(II)  >  In(II)  >  Mn(II)  >  Zn(ll)  >  Cu(ll)  (15).  
Reaction  with  bases  means  déstabilisation  of  ordered  
structures, since metal  ions or complexes can bind to the  base  
stacking  interactions  that  hold  together  the  two  strands  of  
DNA.  This  interaction  is  accompanicd  by  a  dccreasc  in  the  
melting temperature. 
It  may be suggested  from the  thermal  denaturation  studies  
(Table  III)  that  the  SOS inhibitory  function and  the  reversal  
action  on  mdr  of  tumour  cclls  is due  to the denaturing cffcct 
of  Pd,  Pt  or  V  ions  on  the  cellular  DNA.  Co-ordination  of  
these  ions with CPZ or TFP provides a means  by which  these  
ions  may  be  selectively  carried  to  the  DNA  helix,  as  the  
phenothiazines  are  known  to  interact  with  the  DNA  helix  
(16). At  the  helix the  Pt,  Pd  and  V  ions act  to destabilise  the  
helix,  as  cvidcnccd  by  the  observed  decrease  in  the  thermal  
stability  of the DNA. A possible mechanism  for this might  be  
by  the  Pt,  Pd  or  V  ions  interfering  with  hydrogen  bonding  
between  the  nitrogenous  base  pairs,  or  the  metal  complexes  
interact  with basés and destabilised  the ordered  structures.  
The  inhibitory  effect  on  megacine  induction  and  on  the  
mdr  can  be  improved  by  complex  formation  of  
phenothiazines  with  various  metal  ions.  Therefore,  we  can  
conclude, that the specific action  of phenothiazine ring system 
can  be  basically  modified  by  multivalent  co-ordinating  metal  
ions. 
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Abstract 
Anti-psychotic  drugs are used in cancer patients undergoing chemotherapy  frequently and the concomitantly  used drugs  may 
alter  the  pharmacokinetics  of  each  other.  One  reason  for  the  alteration  of  pharmacokinetics  may  be  the  modulation  of  the  
function  of  P-glycoprotein,  whose  efflux pump  occurs  in  resistant  cancer  cells,  in  human  intestine  and  in  the  blood-brain  
barrier. For this reason we tested the effect of several anti-psychotic  drugs on the multidrug-resistant pump, P-glycoprotein.  We  
found that in the MDR  gene transfected L121C MDR,  L5178 MDR  and  in the  KB-V-1 cells  selected  for resistance  some  anti-
psychotic  drugs  block  the  function  of  P-glycoprotein.  Blood  cells  of  two  treatment-resistant  leukemic  patients  also  showed  
increased  uptake  of  daunorubicin  if  treated  ex  vivo  with  the  anti-psychotic  drugs.  Our  results  suggest  that  pharmacokinetic  
studies  should  be  performed  prior  to  concomitant  clinical  use  of  such  drugs  which  block  P-glycoprotein  function.  ©  1999  
Elsevier  Science  Ireland  Ltd.  All  rights  reserved.  
Keywords:  Reversal; Multidrug  resistance; Amitriptyline;  Fluphenazine;  Maprotiline;  Trimipramine;  Desipramine; Imipramine;  Haloperidol;  
Cyclosporin A ;  In  vitro; In  vivo; In  patients  
1. Introduction 
Resistance  to cytotoxic drugs is a major problem in  
cancer  chemotherapy  [1],  Different  mechanisms  are  
involved  in  cytotoxic  drag  resistance.  One  of  the  
most  important  mechanisms  is  the  P-glycoprotein  
(P-gp)  mediated  multidrug  resistance  [2].  P-gp  is  
responsible for accelerated  efflux of chemically  unre-
lated  drags  from cancer  cells.  Interference  with  the  
function of P-gp, can promote effectiveness of cancer 
*  Corresponding  author. Faculty of Medicine, Institute of  Micro-
biology,  Albert  Szent-Györgyi  Medical  University,  Szeged,  D ó m  
tér  10, H-6720  Hungary.  Tel.:  +  36-62-455115;  fax:  +  36-62-
455113. 
chemotherapeutic  drags.  Several  compounds  are  in  
clinical trials for modulation of P-gp related resistance 
in  cancer  [3].  
It  is  not  uncommon  to use  anti-psychotic  drugs  in  
cancer patients  [4-6J. The concomitantly  used cancer 
chemotherapeutic  and  anti-psychotic  drags  may  alter  
each  other's  pharmacokinetics  in  cancer  patients.  If  
the  anti-psychotic  drag  also  effects  P-gp  function  
then  the  pharmacokinetics  of  the  anticancer  drugs  
may  change  in  cancer  cells  and  also  through  the  
blood-brain  barrier  [71.  
Tricyclic  anti-psychotic  drags  were shown  to exert 
a  variety  of  biological  effects on  the  subcellular  and  
cellular  levels.  For  example,  chlorpromazine  (CPZ),  
0304-3835/99/$  -  see front  matter  ©  1999 Elsevier  Science  Ireland Ltd. Al l  rights  reserved.  
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trifluoperazine and clozapine inhibit certain proteases, 
acetylcholine esterase and affect Ca2+ metabolism [8]. 
Fluphenazine;  a?: phenothiazine  type  anti-psychotic  
drug, some of its analogues  [9], butaclamols  stereoi-
somers [10] and the chemically related thioxanthene-
type  compounds  [11]  were  shown  to  inhibit  P-gp  
function in  some  MDR1  gene  expressing  cell  lines.  
Most  of  these";tricyclic>nd :the other  anti-depressive  
drug molecules  are lipophilic  and possess a positive 
charge  due  to  their  nitrogen  atom.  These  chemical  
characteristics were shown to be important for agents 
that affect the function of P-gp [1,12]. Prochlorpera-
zine, the tricyclic  anti-emetic  drug  was  shown to be 
effective as a  resistance  modifier in  phase I  clinical  
studies [13].  
For the above reasons we have studied the effect of 
some anti-psychotic drugs on the function of P-gp.  In  
our study, we used the transfected leukemia cell lines 
L1210 MDR, L5178 MDR and the human adenocar-
cinoma  cell  line  KB-V-1  selected  for resistance  and  
peripheral  blood  lymphocytes  obtained  from  
leukemic patients. 
rs  139  (1999)  115-119 116 
temperature  10 min before the fluorescent substrate, 
106 cells/ml, in glucose containing PBS. 
Fluorescence histograms were obtained of  104 cells 
with a Becton Dickinson FACScan (Mountain View, 
CA) or with a FACStar Plus instrument (Becton Dick-
inson).  The  laser  was  tuned  to  488  nm  and  fluores-
cence  was  detected  at  525  nm  (FL-1  channel)  or at 
585  nm  for  R123  and  daunorubicin  (DR),  respec-
tively. Mean fluorescence intensities  were calculated 
by the C30 software of the instrument. Results repre-
sent  one  typical  of  two  or  three  experiments  
performed with new cell preparations. 
2.3.  Chemicals  
All  anti-psychotic  drugs,  Rhodamine  123 (R123), 
Cyclosporin A (CsA) and daunorubicin were obtained 
from Sigma (St. Louis, MO). 
2.4.  Patients  
2. Materials and  methods  
2.1.  Cells  
Peripheral  human  blood  (PBL)  samples  were  
obtained  from  volunteer  cancer  patients  and  PBL  
was  prepared  by  Ficoll-Hypaque  density  gradient  
centrifugation as described earlier  [14]. The sensitive 
leukemia cell lines, L1210, L5178 and its MDR1  gene 
transfected  resistant  pair  were  obtained  from  Dr.  
Gottesman  of NIH, and were maintained as described 
earlier  [15].  MDR expressing  cells  were  cultured  in  
the  presence  of  colchicine  up  to  48  h before  being 
used in the drug uptake assay. The sensitive KB-3-1 
and  the  resistant  KB-V-1  cells  were  cultured  as  
described  previously  [16].  
2.2. Flow cytometric drug uptake assay 
The flow cytometric drug uptake assay was carried 
out essentially as described earlier [17]. In brief,  fluor-
escent  substrate,  Rhodamine  123 (R123)  (0.08 |xM),  
or  daunorubicin  (DR)  (1  |xM)  uptake  was  assessed  
after 30 min incubation  time at 37°C. Anti-psychotic 
drugs  were  added  to  cell  suspensions  at  room  
Patients were consent blood donors at the University 
Medical  School  of  Debrecen.  Patient  SzL was diag-
nosed as having acute myeloid leukemia (AML). The 
first  regiment of treatment was with DR (45 mg/m2 for 
3  days)  and  Alexan  (100  mg/m2  for 7  days). After 
relapse, the  second regiment  of  treatment  was TAD/ 
COAP (Tioguanin,  Alexan,  Daunorubicin/Cyclopho-
sphamide, Vincristine, Alexan, Prednisolone).  At the 
time  of  the  blood  sample  the  WBC  was  28.5 X  109  
cells/1 and  the blast  count  was  38% as  measured by 
Giemsa staining. This patient was in complete relapse 
at  the time  of  the flow cytometric  analysis  and later 
became  diseased.  Patient  PL  was  diagnosed  with  
AML. The first regiment of treatment was adriamycin 
(AM), (45 mg/m2 for 3 days) and Alexan (10 mg/m2 
for 7  days).  After relapse,  the  second  regiment  was  
TAD/COAP.  At  the  time  of  the  blood  sample  the  
WBC  was  2.2 X109  cells/1  and  blasts  were  not  
detected.  At the present  time the patient  is asympto-
matic. Patient NV was diagnosed with AML. The first 
regiment of treatment was DR (45 mg/m2 for 3 days) 
and  Alexan  (100 mg/m2  for 7  days).  This  treatment  
was repeated after objective improvement. At the time 
of  the blood  sample  WBC  was 7.1 X  109  cells/1 and 
the blast count was 9.8%. This patient later died. 
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Table  1  
Influence of anti-psychotic drugs on the uptake of Rhodamine  123, the P-gp substrate, into L1210, L5178 cells  and the MDR derivatives,  KB-3-
1  and KB-V-1  (MDR)  cells'  
Anti-psychotic  drugs  Cone,  (p.g/ml)  Relative  fluorescence  intensity  
Cells 
L1210 L1210  MDR  L5178 L5178  MDR  KB-3-1 KB-V-1 
Amitriptyline 0.5 1.19 3.02 0.62 3.27 _b _ 
1 - - 0.67 3.50 - 1.96 
5 1.19 5.87 0.54 4.81 0.86 5.98 
Fluphenazine 0.5 1.49 4.02 0.75 4.45 - -
1 - - 0.76 7.44 - 1.37 
5 1.16 8.45 0.68 13.30 •0.73 2.89 
Maprotiline 0.5 1.13 2.54 0.68 3.22 - -
1 - - 0.60 3.08 - -
5 1.02 4.63 0.50 8.05 0.71 1.68 
Trimipramine 1 1.22 2.91 - - - 1.37 
5 1.15 6.30 - - 0.81 2.05 
Desipramine 1 - 1.73 - - - 1.37 
5 - 2.80 - - 0.78 1.55 
Imipramine 0.5 - 1.28 0.82 3.04 - -
1 - - 0.74 3.45 - -
5 - 2.82 0.70 4.80 - 1.98 
Haloperidol 0.5 1.03 5.39 0.71 2.28 - -
1 - - 0.64 2.04 - 1.99 
5 1.15 13.20 0.51 2.11 0.89 3.37 
Doxepin 0.5 - 1.19 0.96 2.40 - -
1 - - . 0.81 2.67 - -
5 - 2.95 0.57 4.48 - -
Cyclosporin  A  5 1.21 7.05 0.85 12.08 0.90 4.51 
° Fluorescence  intensities  are ratios of  means of  histograms  obtained  with  and without  drugs.  Each histogram  was obtained from  104  cells  
using  flow  cytometry  as described  in Section  2. Typical  results of  three independent experiments.  Rhodamine  123 concentration  was 5.2  p.M  
and that of  daunorubicin was  3  p,M.  
b - ,  not  tested.  
3. Results and  discussion  
Previous reports by Ford et al. [9,18] and structural 
features of  several  anti-psychotic  drugs prompted us 
to test them as blockers of P-gp, the multidrug efflux  
pump. Initial  testing  of  the  anti-psychotic  drugs was 
done  in  L1210,  L5178  parental  and  L1210  MDR,  
L5178  MDR  cells  and  with  the  substrate  R123.  
Table  1 shows relative  mean fluorescence intensities 
of  histograms  obtained  in  the  absence  and  the  
presence of 0.5, 1  or 5 |xg/ml of the drugs. Treatment 
of L1210 MDR cells with CsA (5 |xg/ml), a known P-
gp blocker,  increased the relative fluorescence inten-
sity  about 7-fold in the L1210 MDR cells. All tested 
anti-psychotic  drugs  increased  the  relative fluores-
cence  intensity,  uptake  of  R123,  into  LI 210  MDR  
cells,  haloperidol  and fluphenazine being  the  most  
active, In the L5178 MDR cell line fluphenazine and 
maprotiline were the most effective compounds. None 
of the tested drugs significantly changed R123  uptake 
into the parental  cells.  Similar  results  were obtained 
with  KB  cells  using  DR  as  fluorescent  substrate  
(Table  1).  
Again, relative fluorescence intensities are ratios of 
mean fluorescence of  histograms  obtained  of  drug  
treated and untreated cell populations. In these experi-
ments DR was used as a fluorescent substrate of P-gp 
since it was also used as a chemotherapeutic agent in 
the  patients.  The  anti-psychotic  drugs  increased  the  
relative fluorescence of  KB-V-1  but  not  of  the  KB-
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Table  2  
Influence of  anti-psycholic  drugs on  the  uptake of  daunorubicin,  as P-gp substrate,  into PBL of  patients*  
Anti-psychotic  drugs  Cone.  (p.g/ml)  Relative  fluorescence  intensity  
Patients 
SzL PL NV 
Amitriptyline 1 
5 
_!> 
1.48 1.39 1.10 
Fluphenazine .  1  
5 1.24 1.53 0.90 
Maprotiline 1 
5 1.86 1.32 1.03 
Trimipramine 1 
5 1.53 
— — 
Desipramine 1 
5 1.65 
— 0.90 
Imipramine 1 
5 1.42 1.00 1.00 
Haloperidol 1 
5 1.44 1.37 0.98 
Cyclosporin  A  5 1.39 1.32 0.90 
* Results are expressed as in the legend to Table  1. A description of the patients (SzL, PL and NV) is given in Section 2. Typical results of two 
independent  experiments.  
' - ,  not tested.  
3-1, parental cells. The increase was close to that with 
CsA,  the  known  P-gp  blocker,  for  amitriptyline,  
fluphenazine and  haloperidol.  However,  efflux  of  
DR from KB-V-1 cells  was not blocked  to the same 
extent  as in the L1210 MDR and L5178 MDR cells, 
relative  to  CsA  (Table  1).  We attribute  this  lack  of  
correlation between the three cell lines to the fact that 
we used different substrates,  R123 and DR, with the 
L1210, L5178 and the  KB cells, respectively,  which 
can contribute to differential sensitization  with CsA. 
In addition, a differential effect of  the anti-psychotic 
drugs  on  the  membranes  of  these  three  cell  lines  is  
possible.  It  was  shown  previously  that  some  P-gp  
blockers  may  exert  their  effects  indirectly  through  
the plasma membrane without being a substrate  [15].  
Because of the above-demonstrated blocking effect 
of the tested anti-psychotic  drugs on P-gp, we tested 
these drugs in peripheral blood lymphocytes (PBL) of 
drug treatment resistant patients using DR as a  fluor-
escent substrate. Table 2 shows the uptake of DR into 
PBL of patients. 
Relative to L1210 MDR, L5178MDR and to KB-V-
1  cells,  the  known  P-gp  blocker,  CsA  had  a  small  
effect on  DR  efflux in  the  PBL  of  the  patients  SzL  
and  PL.  However,  most  of  the  tested  anti-psychotic  
dings had a comparable effect to CsA in PBL of both 
of  these patients (Table 2). 
Cells from AML patient  NV, although resistant  to  
treatment in the clinic, could not be sensitized by CsA 
or  with  the  anti-psychotic  drugs  for  uptake  of  DR  
(Table  2).  The  reason  for  the  difference among the  
three PBL for sensitization  could not be established, 
for example,  by  mAb staining. Future  investigations  
are planned to include more detailed characterization 
of  clinically  resistant  AML  cells,  which  do  not  
respond to P-gp blockers. 
Anti-psychotic drugs are used at a blood level of 10 
to 500 ng/ml, depending on the drug used and on the 
sensitivity of the patient [11,19]. A double concentra-
tion  of  the  highest  clinical  blood  level,  1  |xg/ml,  
showed  small  but  significant  blocking  of  P-gp  in  
L1210 MDR, L5178 MDR and KB-V-1 cells  (Table 
1). PBL of the patients could not be tested at the 1  |xg/  
ml dose level, due to an insufficient amount of blood 
samples.  However,  based  on  results  with  CsA  at  a 
comparable  dose level  (5  jig/ml)  it  is  expected  that  
uptake of  DR into PBL would be enhanced by  1  and  
0.5  p.g/ml of some of the anti-psychotic drugs. 
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Taken  together,  using  the  model  cell  lines LI 210 
MDR, L5178 MDR and KB-V-1  and the  fluorescent  
indicator R123 and DR, we could show that the clini-
cally  used  anti-psychotic  drugs  may  significantly  
modulate the uptake of  substrates  of P-gp into MDR 
cells.  We have  also  tested  this  possibility  in  a pilot  
study, using PBL prepared from blood  of drug-resis-
tant leukemic patients. Resistance was based on clin-
ical experience and was verified on PBL by the effect 
of  CsA on the uptake  of  DR. In  these PBL cells we 
compared the effects  of the anti-psychotic drugs with 
that of CsA for the uptake of DR, the drug used for the 
treatment  of two of the patients. The ex vivo results 
indicate that treatment with some of the anti-psychotic 
drugs result in as much change in DR uptake as CsA 
does  into the  PBL of  two  out  of  three  patients.  Our  
results point  in the direction  of  necessary  pharmaco-
logical  studies when anti-psychotic  drugs and cancer 
chemotherapeutic  agents are used  in combination. 
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Chemical  Structure and Tumor Type Specificity 
of "Half-Mustard Type" Phenothiazines 
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Abstract.  The antiproliferative activity of six "half-mustard type" 
phenothiazines against a total of 54 tumor cell lines: 4 leukemia, 
9 non-small-cell lung,  7 colon-,  5 CNS-, 8 melanoma, 6 ovarian-, 
8 renal-,  1 prostate and 6 breast cancer was determined by NCI-
Information  Intensive-Approach.  The  C-2  position  of  
pherwthiazines were substituted with H, CI and CFj groups.  The  
half-mustard and ring system was linked either by a propylene or 
a  butylene  bridge.  Colon-cancer  cell  showed  the  highest  
sensitivity  against  "half-mustard  type" pherwthiazines,  followed  
by  leukemia, melatwtna,  prostate-,  CNS-,  breast-, lung-,  renal  
and  ovarian cancer celts. These data  suggest the  "cancer-type-
specific"  antitumor  action  of  "half-mustard  type"  pheno-
thiazines. 
Phenothiazines  interact  with  various  macromoleculcs  and  
cells (1-6). Some of them prevent chemical carcinogenesis  (7),  
due  to  their  antimutagenic  (8)  or  differentiation-inducing  
action  (9),  synergise  the  antitumor  activity  of  1,3-Ws(2-
chloroethyl)-l-nitrosourca  (BCNU) and hyperthermia  (6,10),  
and  show  the  radiosensitizing  effect  (11).  BCNU  enhanced  
the antiproliferative action of the phenothiazines  (11-15).  
Phenothiazines  exert  antitumor  activity  in vitro and  in vivo 
(1,  12,  13,  16).  Introduction  of  different  substituents  into  
phenothiazine  skeleton  might  alter  their  antitumor  (1,12-14)  
and antiretroviral  (15,17)  activity. Based on previous  studies,  
more  potent  "half-mustard  type"  phenothiazines  with  
alkylamino  side  linkers  were  synthetized  (16).  In  the  
preliminary experiments, the phthalimidophenothiazincs  [1-6]  
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Medicinal  Chemistry,  Meiji  Pharmaceutical  University,  2-522-1  
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were  found  to  be  inactive  (Figure  1)  (18).  However,  a  new  
information-intensive  study  of  NCI  (19)  has  displayed  the  
antiproliferative  activity  of  the  alkylurea  derivatives  [7-12]  
against  54  cell  lines  (nine  cancer  ccll  types).  The  "half-
mustard  type"  phenothiazines  with  butylene  linker  were  
active against  leukemia,  non-small  cell  lung cancer  and  colon \ 
cancer,  but  ineffective against  renal  and  ovarian  cancer  cells.  
The  structure-activity  relationship  studies  has shown  that  the  
sensitivity  of  AIDS-relalcd  leukemia  and  lymphoma  is  
different  from  (20)  that  of  other  types  of  cancer  ccll  lines  
(18).  The  "half-mustard  type"  phenothiazines  with  butylene  
linker  were  more  effective than  those  with  propylene  linker.  
Therefore,  the  role  of  multidrug  resistance  efflux pump  and  
cancer  type  specific antiproliferative  action  of  "half-mustard  
type" phenothiazines  were  promising  to  be analyzed  in  more  
details. Therefore, we investigated  here the antitumor  activity  
of  six  "half-mustard  type"  phenothiazines  against  various  
cancer cell lines to design more effective anticancer drugs.  
Materials and  Methods  
Chemicals.  All  related  phenothiazines  [1-12J  were  synthesized  as  
previously described  (16) (Figure  1).  
Assay  for  antitumor  activity.  The  50%  growth  inhibitory  concentration  
(GI50),  100%  tumor  growth  inhibitory  concentration  (TGI)  and  50%  
lethal  concentration  (LC50)  values  of  six  l-(2-chloroethyl)-3-(2-
substituted-10A/-phenothiazin-10-yl)alkylurcas  [7-12]  were  determined  
by  the  dose-response  curve,  using  4  leukemia,  9  non-small  cell  lung  
carcinoma, 7 colon cancer, 5 CNS-cancer,  8 melanoma, 6 ovarian  cancer,  
8  renal  cancer,  1 prostate  cancer  and  6 breast  cancer  ccll  lines as  target  
cells. The  mean  values  of  GI50, TGI  and  LC50 were calculated  in  each  
tumor group for the  six tested  compounds  [7-12], The  logic values were 
converted  to  molar  concentration  (x  10'5  M)  using  the  previous  data  
(18) for compounds  [7-12] (Table la),  and compared  to each other. The 
compounds  acting  at  the  lowest  concentrations  were  considered  to  be  
the most effective ones on  the particular  tumor  ccll  types. The GI50 and 
TGI  were  considered  as  values  corresponding  mainly  to  cytostatic  
effects, while  the  LC50 values were  thought  to  represent  the  ccll  killing  
capacities of the "half-mustard type"  phenothiazines.  
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Compound R n NSC  No.1 '  ST No.2» Compound R n NSC  No.1»  ST  No.2»  
10-[N-(Phthalimido)alkyl]-2-
substituted-10H-phenothiazine 
l-(2-Chloroethyl)-3-(2-substituted-
10H-phenothiazin-10-yl)alkylurea 
O 
—N I (CHj)n 
I  0  
CI 
R 
(CHj)n 
/ 
II  II  
-NHCONH 
1 H 3 D681647 ST50000 7 H 3 D681653 ST50006 
2 H 4 D681648 ST50001 8 H 4 D681654 ST50007 
3 Cl 3 D681649 ST50002 9 Cl 3 D681655 ST50008 
4 Cl 4 D681650 ST50003 10 Cl 4 D681656 ST50009 
5 CF, 3 D681651 ST50004 11 CF3 3 D681657 ST50010 
6 CFJ 4 D681652 ST50005 12 CF3 4 D681658 ST50011 
Figure  1.  Structures  of  10-[N-(phthalimido)alkyl-2-substituted-10H-phenothiazines  [1-6].  and  l-(2-chloroethyl)-3-(2-substituted-10H-phenotliiazin-10-
yl)alkylureas  17-12],  1) NCI  code  number.  2)  SCR1PTGEN  code  number.  
Table  la. Anticancer  activity  of six  l-(2-chloroethyl)-3-(2-substituted-10H-phenothiazin-10-yl)alkylureas  [7-12]  against  nine  different  groups  of cancer  lines.  
Compd Anticancer  activity  
Leukemia  Non-small  Colon-
(4)  cell  lung (9)  cancer  (7)  
CNS-  Melanoma  Ovarian  
cancer(5)  (8)  cancer  (6)  
Renal  Prostate  Breast-
cancer  (8)  cancer(1)  cancer(6)  
7 
8 
9 
10 
tl 
12 
7 
8 
9 
10 
It 
12 
7 
8 
9 
10 
It 
12 
-4.98 
-5.32 
-5.73 
-5.81 
-5.72 
-5.80 
-4.54 
-4.75 
-5.34 
-5.38 
-5.28 
-5.37 
-4.12 
-4.23 
-4.85 
-4.68 
-4.39 
-4.86 
logio  (GI50)  
-4.84 
-5.12 
-5.40 
-5.60 
-5.45 
-5.53 
-4.55 
-4.68 
-4.97 
-5.19 
-5.01 
-5.10 
-4.26 
-4.31 
-4.55 
-4.69 
-4.58 
-4.60 
-4.98 
-5.40 
-5.69 
-5.85 
-5.69 
-5.78 
-4.62 
-4.95 
-5.33 
-5.55 
-5.32 
-5.44 
-4.30 
-4.56 
-4.99 
-5.24 
-4.94 
-5.08 
-4.86 
-5.06 
-5.59 
-5.71 
-5.84 
-5.70 
I 
-4.57 
-4.66 
-5.10 
-5.28 
-5.07 
-5.23 
-4.88 
-5.23 
-5.70 
-5.78 
-5.61 
-5.74 
log,«  (TGI)  
-4.58 
-4.76 
-5.40 
-5.49 
-5.25 
-5.48 
log io (LC50) 
-4.27 
-4.31 
-4.61 
-4.73 
-4.51 
-4.70 
-4.28 
-4.39 
-5.04 
-5.22 
-4.84 
-5.16 
-4.86 
-4.99 
-5.25 
-5.51 
-5.21 
-5.41 
-4.57 
-4.62 
-4.74 
-4.93 
-4.72 
-4.83 
-4.27 
-4.29 
-4.34 
-4.37 
-4.31 
-4.29 
-4.96 
-5.13 
-5.33 
-5.56 
-5.31 
-5.53 
-4.97 
-4.70 
-4.89 
-5.15 
-4.86 
-5.02 
-4.29 
-4.34 
-4.49 
-4.69 
-4.47 
-4.50 
-4.97 
-5.27 
-5.60 
-5.68 
-5.59 
-5.61 
-4.65 
-4.74 
-4.92 
-5.09 
-4.87 
-4.92 
-4.33 
-4.37 
-4.45 
-4.52 
-4.42 
-4.44 
-4.84 
-5.23 
-5.44 
-5.68 
-5.58 
-5.58 
-4.56 
-4.76 
-5.07 
-5.30 
-5.09 
-5.15 
-4.25 
-4.32 
-4.57 
-4.86 
-4.62 
-4.68 
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Table  Ib./i/i/iai;ice/- effects of six J-(2-chloroclliyl)-3-(2-substitute<l-i0H-plienothiazin-10-yl)alkylureas  /7-12J  on nine different groups of cancer lines."* 
Coinpd  Anticanccr  activity  
Leukemia 
(4) 
Non-small 
cell lung (9) 
Colon-
cancer  (7)  
CNS-
canccr(5) 
Melanoma 
(8) 
Ovarian 
cancer(6) 
Renal 
cancer(8) 
Prostate 
cancer(1) 
Urcusl-
canccr(6) 
GI50 (x  10'5 M) 
7 1.06 1.44 1.06 1.37 1.32 1.39 1.11 1.07 1.46 
8 0.48 0.76 0.40 0 87 0.59 1.02 0.74 0.54 0.60 
9 0.19 0.40 0.20 0.26 0.20 0.56 0.47 0.25 0.37 
10 0.16 0.25 0.14 0.20 0.17 0.31 0.28 0.21 0.21 
11 0.19 0.35 0.21 0.14 0.24 0.62 0.49 0.26 0.26 
12 0.16 0.29 0.17 0.20 0.18 0.39 0.29 0.25 0.26 
TGI(x lO ' 5 M) 
7 2.91 2.81 2.39 2.72 2.64 2.72 1.07 2.24 2.77 
8 1.77 2.11 1.13 2.21 1.76 2.39 2.02 1.82 1.74 
9 0.45 1.07 0.46 0.80 0.40 1.81 1.30 1.20 0.85 
10 0.42 0.64 0.28 0.52 0.32 1.18 0.71 0.81 0.50 
11 0.52 0.97 0.48 0.85 0.57. 1.93 1.37 1.35 0.81 
12 0.43 0.79 0.36 0.59 0.33 1.50 0.95 1.20 0.71 
LC50 (x 10'5 M) 
7 7.59 5.52 5.03 5.37 5.22 5.33 5.11 4.68 5.68 
8 5.96 4.85 2.75 4.92 4.10 5.15 4.60 4.27 4.83 
9 1.41 2.83 1.03 2.47 0.92 4.54 3.23 3.55 2.68 
10 2.11 2.04 0.57 1.86 0.60 4.25 2.07 3.02 1.39 
11 4.04 2.62 1.14 3.09 1.45 4.88 3.42 3.80 2.40 
12 1.40  '  2.53 0.83 1.99 0.69 5.11 3.17 3.63 2.08 
a ) Transformation:  IOlax  105  =  lb  
Results  and  Discuss ion  
For  improving  the  antitumor  cffects  of  phenothiazines,  we  
have  newly synthesized  "half-mustard  type" phenothiazines  by  
modifing  the  alkylamino  side  chains  and  investigated  their  
antitumor  activity  against  a  total  of  54  tumor  cell  lines  (18)  
such  as  leukemia,  melanoma,  lung,  colon,  ovarian,  breast,  
renal  and prostate cancer,  and brain tumor cell  lines.  
The  present  study  shows  that  the  substituent  at  position  2  
in  the  phenothiazine  ring  and  the  number  of  linker  are  
important  factors  for  antitumor  activity.  Obviously,  the  
configuration  of  the  lone  pair  localized  in  the  ring  nitrogen  
(N)  of  phenothiazine  and  the  length  between  the  
phenothiazine  ring  nitrogen  (N)  and  terminal  nitrogen  (N)  of  
methylene  group might  play  a role  in the antitumor  activity  of  
the  new  compounds.  The  compounds  with  butylene  bridge  
yielded  more  potent  compounds  than  those  with  the  
propylene  bridge.  The  active  domain  of  the  derivatives  might  
attack  the cytosine  or more  likely guanosine  residues  in  D N A  
by  electrophilic  covalent  binding  or  by  polarizability  of  
compounds.  On  the  basis  of  computer  aided  studies,  some  
correlations  were  found  between  the  biological  activities  and  
values  of  dipole  moments  and:  entropy  of  the  newly  
synthetized  phenothiazine  alkylureas  (8a).  Additionally,  the  
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Tabic Ha. Sensitivity of nine types of cancer cells against five l-(2-cliloroelhyl)-3-(2-substituted-l0H-pbcnotliiazin-10-yl)alkylureas  I7-I2J.  
Cancer ccll  type GI50  (x 10"5 M) Canccr ccll  type TGI  (x  10 s  M)  Canccr ccll  type I-C50 (x  III"5 M) 
colon canccr  0.36 colon canccr  0.85 colon  canccr  1.86 
leukemia 0.37 melanoma 1.00 melanoma 2.16 
prostate  canccr  0.43 leukemia 1.08 brcast-canccr 3.18 
melanoma 0.45 brcast-canccr 1.23 CNS-canccr 3.28 
CNS-canccr 0.51 renalcanccr 1.23 non-sinall ccll  lung  3.40 
breast-cancer 0.53 CNS-canccr 1.28 renal  canccr  3.60 
renal canccr 0.56 non-small cell  lung 1.40 leukemia 3.75 
non-small cell  lung  0.58 prostate canccr 1.44 prostate canccr 3.82 
ovarian  canccr  0.71 ovarian  canccr  1.92 ovarian  canccr  4.88 
Table lib. Sensitivity of nine types of cancer cells against five l-(2-cldoroetliyl)-3-(2-substituted-l0H-phenothiazm-10-yl)alkylureas  /8-l2f  
Cancer cell  type G150 (x  10"5 M) Canccr ccll  type TGI  (x 10'5 M) Canccr ccll  type LC50 (x  I0"5  M) 
colon-canccr 0.22 colon-cancer 0.54 colon-canccr 1.27  !"  
leukemia 0.23 melanoma 0.68 melanoma 1.55 
melanoma 0.28 leukemia 0.72 brcast-canccr 2.68 
prostate canccr 0.30 brcast-cancer 0.92 CNS-canccr 2.86 
CNS-cancer 0.33 CNS-canccr 0.99 non-small  ccll  lung  2.97 
brcast-canccr 0.34 non-small  ccll  lung 1.12 leukemia 2.98 
non-small  ccll  lung  0.41 renal canccr J .27 renalcanccr 3.30 
renal canccr 0.45 prostate canccr 1.28 prostate  canccr  3.05 
ovarian  canccr  0.58 ovarian  cancer  1.76 ovarian canccr 4.78 
1) The values of compound  [7J arc omitted.  
urea  portion  of  "half:mustard  type"  phenothiazines  have  
shown  significant variability  in  the  energy  (eV)  of  lone  pair  
orbital (n) and a lone pair electron density (p") in n orbital of 
Nl, O, and N3 atoms (data not shown) (8b) (Figure 2). 
When  the  logio  values  of  GI50,  TGI  and  LC50  of  6  
compounds. [7-12]  against  54 different cancer  cell, lines were 
compared,  an  interesting  correlation  was  found  (Table  la).  
Then,  the  logarithmic  values  were  converted  to  molar  
concentrations  (Table lb). The mean value of  GI50, TGI and 
LC50 concentrations  of  compounds  [7-12] was  calculated  at  
first. Then, the nine main tumor groups were ranked from the 
lowest  values  (more  sensitive)  of  GI50,  TGI  and  LC50  
towards  the  highest  values  (more  resistant)  (Table  Ha).  
Secondly, compound  [7] was omitted from Table lib,  because  
of  its  extremely  low  antitumor  activity  probably  due  to  the  
permeability  barrier,  as  compared  to  other  five  compounds  
[8-12]. The compound  [7] has the  lowest  ground  state  dipole  
moment  (2.63  D)  and  enhanced  the  radical  intensity  of  
sodium ascorbate to the greatest extent (unpublished  data).  
Among  the  nine  different types  of  cancer  cell  lines,  colon  
cancer  and  leukemia  were the  most  sensitive  on  the  basis  of  
GI50  values,  and  renal,  non-small  cell  lung  cancer  and  
ovarian cancer were the less sensitive (Tables Ila and lib). On 
the  basis  of  TGI  values,  colon  cancer  and  melanoma  were  
found  to  be  more  sensitive  than  prostate,  ovarian  or  renal  
cancer.  Based  on the  LC50 values obtained,  the order  of  the  
sensitivity  :*of  9  cell  lines  against  the  5  compounds  was  
somewhat  similar  in  TGI  values.  LC50  values  were  higher  
than TGI values in any cases.  '  
Considering  these  results,  we  can  conclude  that  an  
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Figure  2.  Structure  of  phenotltiazine  skeleton,  aliphatic  chain  and  urea  site  
on  "half-mustard  type"phenothiazincs  I7-I2f  Urea site  is indicated  hy  box,  
and  2-substituted  group  (R=H,  CI,  CFf)  on phenolhiazines  is  circled.  
interaction  of  the  10th  nitrogen  (N)  of  the  substituted  
phenothiazines  with  DNA,  side  chain  charge  and  the  
conformation,  and  lipophilicity  might  affect  the  anticancer  
effects  of  the  compounds.  Moreover,  the  urea  portion  of  -
N(3)H-CO-N(1)H-  of  "half-mustard  type"  phenothiazines  
synergistically  enhanced  the  lipophilicity  of  phenothiazinc  
skeleton,  making  them  more  permeable  through  cell  
membranes  (Figure  2).  From  these  theoretical  calculations,  
we  have  some  evidence  that  the  selectivity  of  the  "half-
mustard  type" phenothiazines  might  depend  on  the  accessible  
structure(s)  of  cell  surface  membranes  of  target  cells,  and  on  
the  reactivity  to  the  macromoleeules  of  the  cells.  Low  
sensitivity  of ovarian  cancer  cells  might  possibly  be due  to  the  
presence  of  a  particular  mucin  in  the  cell  surface  membrane.  
The  possibility that  P-glycoproteins  might  serve as one  of such 
target  proteins  remains  to be  investigated.  
"Half-mustard  type"  phenothiazines  with  buylene  linker  
showed  higher  antitumor  activity  than  those  with  propylene  
linker.  It  is  possible  that  the  anticancer  effect  of  "half-
mustard  type"  phenothiazines  might  depend  on  a  particular  
membrane  structure  in  the  cancer  cells  or on  the  presence  of  
sensitive  point  in  the  cell  cycle.  The  present  results  
demonstrated  the  "cancer  type-specific"  antiproliferative  
action  of  "half-mustard  type"  phenothiazines  [8-12].  It  is  
obvious  that  the  colon-cancer,  leukemia  and  melanoma  arc  
more  sensitive  than  prostate  or  ovarian  cancer.  The  
compounds  might  act  on  the  cancer  cells  via  alkylurea-
induced  alkylation  of  proteins  or  on  DNA  by  a  particular  
intercalation. 
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Membrane Associated Antitumor Effects of Crocine-,  Ginsenoside-
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Abstract.  In the present work a  systematic study  was  initialed  
with  crocine,  ginsenoside  and  cannabinoid  derivatives  on  
multidrug  resistant  mouse lymphoma cells, viral tumor  antigen 
expression and some human leukocyte functions. Among saffron 
derivatives, crocin  and  picrocrocin,  tiiglucosyl and diglucosyl 
crocetin were ineffective  on  the reversal  of  multidrug  resistance  
of  lymphoma  cells.  Ginsenoside increased drug  accumulation  
and  tumor  antigen  expression  at  2.0-20.0  pg/ml,.  Some  
cannabinoid derivatives  siuh  as  cannabinol, cannabispirol and 
cannabidiol increased drug accumulation,  while  cannabidiolic  
acid,  deita-9-THC  and  lelrahydro-cannabidiolic acid reduced 
drug accumulation  of the human mdrl-gene  transfected  mouse 
lymphoma cells.  The reversal of multidrug resistance is the result 
of the inhibition  of the efflux pump function in the tumor cells. 
Crocetin esters were less potent than crocin itself in the inhibition 
of EBV early antigen expression.  However crocin  and diglucosyl-
crocetin inhibited early tumor antigen  expression  of adenovirus 
infected cells,  but triglucosylcrocetin  tmy less effective at 0.01-1.0 
pg/mL.  The crocin had  no  antiviral effect ¡on  HSV-2  infected  
vero cells/  up to  25 pg/mL  concentration. Ginsenosides had a 
moderate inhibitory effect except  ginsenoside Rbl  (was the  less  
effective) on the drug efflux pump. Among the cannabinoid deri-
vatives the cannabinol and  cannabispirol increased drug  accu-
mulation,  while cannabidiolic acid  and  della-8-THC, della-9-
THC.and tetraliydro-  cannabinol reduced drug accumulation  in  
inultidnig  resistant  mouse lymphoma cells. Jt is interesting  that  
ginsenosides had  a  chemical structure-dependent  imnumomo-
dulating effect  by enhancing the activity of NK-cells and ADCC 
activities. 
Various  components  isolated  from  mcdicinal  plants  have  
different  antitumor  effects:  e.g.,  cytotoxic-,  chcmoprevcntive-,  
apoplosis-  and  differentiation  induction.  Recently  Shoyama  
and co-workers  found  that  saffron derivatives  inhibit  chemical  
carcinogenesis  in mice  (1).  
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versity,  Szeged,  Dóm  tor  10,  H-6720  Hungary.  Tel:  36-62-455-
115,  Fax:  36-62-455-113.  
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Sangwan  et  al  listed  the  edible  plants  with  potential  anli-
niulagcnicity  and  also  reported  thai  various  kinds  of  plant  
products  have  been  studied  as anliniulagens  evidently  related  
to cancer  prevention  (2).  
Among  them  we  selected  three  traditional  medicines,  
saffron,  ginseng  and  marihuana  components  for  this  study.  
The  antitumor  activity  of  saffron  in  mice  transplanted  with  
sarcoma-180,  Ehrlich  ascites carcinoma  and  Dallon's  lympho-
ma  ascites  tumors  was  studied  (3).  The  inhibitory  effects  of  
saffron  on  chemical  carcinogenesis  in  mice  using  a  hvo-stagc  
assay  system  (4)  and  the  effect  of  crocetin  on  skin  papillomas  
and  Rous  sarcoma  (5)  have  also  been  described,  liserihano  el  
al  (6)  reported  that  crocin  inhibits  the  growth  of  I lel.a  cells  
and  suggested  apoplosis  induction.  More  recently  we  found  
that  crocin  and  crocclin  derivatives  inhibit  skin  tumor  
promotion  in  mice  (I) .  It  is  well  known  lhal  the  ginseng  
extracts  prevent  the  cancer  disease  in  Chinese  traditional  
mcdicinc.  Konoshima  and  his  co-workers  investigated  the  
inhibitory  effects  of  a  ginseng  water  extract  and  ginsenoside  
Rgl  for anti-  tumor-promoting  activities  using  an  in  vitro  two-
stage carcinogenesis  assay system  (7).  
The  effects of  marihuana  components  was  described  on  the  
plasmid  mediated  bacterial  resistance  and  pathogenicity  in  
model  experiments  (8)  and  on  E.  coli  adhesion  to  (issue  
culture cells  (9).  
Based  on  the  similarity  of  drug  resistance  mechanisms  in  
bacteria  and  cancer  cells,  it was  worthwhile  to  study  the  acti-
vity of some  cannahinoids,  ginsenoside  and  saffron  derivatives  
on  the  mdr-glycoprotcin  of  cancer  cells  and  tumor  antigen  
expression  of  virus  infected  cells.  Here  we  report  the  effects  
of  crocin,  cannahinoids,  ginsenoside  derivatives.  
Materials  and  Methods  
Chemicals.  Extraction  and  separation  of  aclivc  mil ¡-tumor  compounds:  
Dried saffron (5(H) g) was cxiractcd  with  50 %  EtOI I. The  ElOl I extract 
(ECS)  (311 g) was separated  hy Silica-gel  column  chromatography  using  
an  EtOAc-EtOI I-l 120 gradient  solution  (9:3:1  to  7:3:2)  to  separate  the  
carotcnoid  containing  fraction  (275  g)  and  non-earotcnoid  fraction  (36  
g). The carotcnoid  containing  fraction was repeatedly  purified  hy  Silica-
gel  column  chromatography,  with  an  EtOHAc-ElOH-lEO  gradient  
solution  (9:3:1  to  7:3:2),  and  finally  purified  hy  a  Mel  gel  column  
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chromatography  clution  with  an  H 2 0 - M e 0 H  gradient  solution  (1:0  to  
0:1)  to  yield  crocctin  di-glucose  ester  (0.41  g),  crocctin  gentibiose  
glucosc ester  (5.10 g) and crocin  (5.69 g). 
Ginsenosidcs,  Rbl ,  Rc,  Rd,  Re  and  Rgl  were  isolated  from  white  
ginseng  by  repeated  column  chromatography  on  Silica-gcl  as  previously  
reported  (10). They were  dircctly  identified with authentic  samples.  
Cannabis:  dclta8-.tetrahydrocannabinol  (A8-THC),  delta9-tctrahydro-
cannabinol  (A9- THC),  cannabinol  and  cannabidiol  were  kindly  supplied  
by  Dr.  Kcizo  Watanabc,  narcotics  Laboratory  Scction,  Division  of  
Narcotic  Drugs,  United  Nations,  Vienna  International  Center,  Vienna,  
Austria.  Tetrahydro-cannabidiolic  acid  (THCA)  tricthylamine  was  
prepared  by Alkaloida,  Tiszavasvari,  Hungary.  
The  compounds  were  dissolved  in  DMSO;  final concentrations  were  
1.0, 5.0 and  10 |ig/mL,  in  all  triplicate  lest  cultures.  Both  control  cultures  
and  test cultures contained  DMSO  (Sigma)  in  the same  concentration.  
Cell  cultures.  For  the  cytotoxicity  assay,  Raji  cells  and  Hcp-2  cells  were  
cultivated  in  RPM1  supplemented  with  10  %  foetal  calf  scrum.  The  
L5I78Y  (parent)  mouse  T-ccll  lymphoma  and  its  transformed  subline  
with  mdr  (MDRI/A)  were  grown  in  McCoy's 5A  medium  supplemented  
with  10%  hcat-inactivcd  horse  scrum.  HEp-2  cells  for  immunofluo-
rescence  studies  were  grown  on  glass  coverslip  in  Petri  dishes  in  Eagle  
MEM  supplemented  with  5 %  new horn  calf  serum.  
For  T-antigen  expression  the  highly  oncogenic,  human  adenovirus  of  
serotype  12  was  applied.  Infcctivity  of  the  virus  suspension  was  
determined  and  found to be  10s  s  TCID<,o /'nit. (12). 
Virus  and  cell  culture  for  antiviral  effccts.  Vero  cells  were  cultured  and  
maintained  in  RPM1  1640 medium  supplemented  with  5  %  or  2  %  calf  
scrum  respectively.  The  virus  used  was  a  strain  of  HSV-2  and  it  was  
propagated  in  Vero  cells  and  infcctivity was  measured  in  tile  same  cells  
by  the  dilution  method  on  microtitrc  plates  (Linbro,  Greincr).  The  
infective  litre  was  expressed  as  TCI Dsn  (50  %  tissue  culture  infective  
dose) calculated  by the  formula of  Reed  and  Mucnch.  
Reversal  of  multidrug  resistance.  The  L5178  mouse  T  cell  lymhoma  cell  
line  was  infected  with  the  pHa  MDRI/A  retrovirus  as  previously  
described  (14).  MDR1  expressing  cell  lines  were  selected  by  culturing  
the  infccted  cells with  60 ng/mL colchicine  to  maintain  expression  of  the  
MDR  phcnotypc. The  L5178 MDR  cell  line, and  the  L5178Y  parent  cell  
line were  grown  in  McCoy's  5A medium  with  10% hcat-inactivated  horse  
scrum,  L-glutaminc  and  antibiotics.  The  cell  suspensions  were  adjusted  
to  a  density  of  2xl0h/mL  and  resuspended  in  serum-free  McCoy's  5A  
medium  and  the  cells were  distributed  into 0.5 mL aliquots  to  Eppendorf  
centrifuge  tubes.  Then  the  tested  compounds  were  added  (0.2-100.0  pL  
of  the  1.0 mg/mL stock  solutions)  and  the  samples were  incubatcd  for  10  
mitt  at  room  temperature.  Then  10 pL  (5.2  pM  final  concentration)  of  
the  indicator  Rhodaminc  123  was  added  to  the  samples  and  the  cells  
were  incubated  for  a  further  20  min  at  37'C,  washed  twice  and  
resuspended  in  0.5  mL  phosphate-buffered  saline  (PBS)  for  analysis.  
The  fluorescence  of  the  cell  population  was measured  by  flow  cytometry  
with  a  Beckton  Dickinson  FACScan  instrument.  Verapamil  was  used  as  
a  positive  control  in  the  Rhodaminc  123  exclusion  experiments.  The  
percentage  of  control  mean  fluorescence  intensity  was  calculated  for  
parental  and  mdr  cell  lines  as  compared  to  untreated  cells.  An  activity  
ratio  was  calculated  by  the  following  equation  (13)  on  the  basis  of  
measured  fluorescence  values:  
mdr  treated  / mdr  control  
R  =  
parental  treated  / parental  control  
EVB-EA  activation  in  vitro.  The  inhibition  of  EBV-EA  activation  was  
assayed  using  the  same  method  described  previously  (14). The  Raji  cells  
were  incubated  at  37°C  for  48  It  in  a  medium  supplemented  with  n-
butyric  acid  (4  mol),  TPA  (32  pmol)  and  various  amounts  of  the  test  
compounds.  Smears  were  made  of  the  ccll  suspension,  and  the  EBV-EA  
(1)  Ohreot  
(2) 
Figure  1.  Chemical  structures  of  picrocrocin  (I),  crocin  (2).  crocctin  
gentiobiose  glucose  ester  (3)  and  crocetin  di-glucose  ester  (4)  .  
inducing  cclls were  stained  by  means  of  an  indirect  immunfluorcsccnce  
tcchniquc.  In  each  assay,  at  least  500 cclls were countcd  and  the  number  
of  stained  cells  (positive  cclls)  among  them  was  recorded.  Triplicate  
assays  were  performed  for  each  data  point.  The  EBV-EA  inhibitory  
activity  of  the  test  compound  was  compared  with  that  of  the  control  
experiment  (100%) with n-butyric  acid plus TPA.  In the experiments,  the  
EBV-EA,  activities  were  originaly  around  40  %,  and  these  values  were  
taken  as  the  positive  control  (100  %).  The  viability  of  cells  was  assayed  
against  treated  cclls by the tripan-bluc  staining  method.  
Assay  for  adenovirus  early  T-antigen  expression  by  immunofluorescence.  
HEp-2  cclls  on  the  coverslip  were  infccted  with  adendvirus  at  a  
multiplicity  of  7  x  I0~2  and  incubatcd  at  37°C  for  4  h.  After  1  h  
adsorption,  the  unadsorbed  virus was removed  and  the cclls were  washed  
3 times with  cold  medium  to remove  the unattached  virus. The  cclls were 
then  overlaid  with  a  warm  medium  containing  the  appropriate  
concentration  of  crocin  derivatives.  After  16  h incubation,  the  cclls  were  
washed  twice  with  the  cold  phosphate  buffered  saline  (PBS)  and  fixed  
with  cold  acetone  for  20  min  at  -20°C.  The  freed  cells were  stored  at  -
20°C until  the  immunofluorescence  assays were  performed.  
T-antigcn-producing  cells  were  detected  by  means  of  indirect  
immunofluorescence.  Cclls  were  incubated  with  hamster  anti-T  scrum  
(diluted  1:15  in  PBS)  containing  1  %  foetal  calf  scrum  for  60  min  at  
31'C.  They  were  subsequently  washed  with  cold  PBS  and  incubatcd  for  
45  min  at  37°C  with  fluorescein  conjugated  rabbit  anti-hamster  
immunoglobulin  (diluted  1:30  in  PBS).  T-antigen-positive  cclls  were  
scored  under  LEITZ  UV  microscope,  counting  a  total  of  600  individual  
cclls  (12).  
Assay  of  antiviral  activity.  Antiviral  activity  of  compounds  was  
investigated  by the  yield  reduction  method.  Monolayer  cultures  of  Vero  
•  COO  
HOHjC OH2C HOHjC 
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Figure  2. Caililahiiitnil  derivatives.  
cells  were  grown  in  96-well  microtitrc  plates  and  were  infected  with  
HSV-2  at  a  multiplicity  of  0.5 TCID50  per  cell. After  adsorption  for  I  h  
at  37°C  the  inoculum  was  removed  and  the  cultures  were  washed  
twice  with  PBS  solution  then  supplied  with  RPMI  1640  medium  
containing  2  %  calf  scrum  and  the  drugs  in  different  concentrations.  
Virus  infected  control  cells  were  cultured  in  the  medium  without  
drugs.  After  incubation  for  24  h  at  37°C,  the  cultures were  frozen  and  
thawed.  The  cell  debris  was  removed  by  low-speed  centrifugation.  
The  virus yield  in  the  supernatant  fluids was determined  in  Vcro  cells  
grown  on  microtitre  plates  by  the  dilution  method.  The  inhibitory  
effect  of  drugs  011  the  virus  multiplication  was  evaluated  by  
comparing  the  virus  titres  obtained  in  the  presence  and  absence  of  
the  compounds.  
Assay  for  cytotoxicity.  The  HEp-2  cells,  L5  I 78Y parent  and  multidrug-
resistant  (mdr)  cells  were  seeded  into  Grcincr  96-well  flat  bottom  
microtrays  at  5000  cclls/0.1  mL  of  McCoy's  medium  supplemented  
with  10  %  horse  scrum  (for  L5I78)  or  RPMI  medium  (for  HEp-2)  
containing  10  %  foetal  calf  scrum.  The  cells  were  allowed  to  attach  
and  spread  on  the  bottom  of  the  wells  for  6  h. Then  0.1  mL  of  diluted  
test  compounds  was added  to  the  wells.  Control  cells  received  0.1  mL  
of  growth  medium,  and  medium  control  received  0.2  mL  of  growth  
medium  without  cells.  The  total  volume  of  medium  / well  was  0.2  mL.  
The  trays  were  incubated  further  at  37°C  for  3  days  in  a  CO2  
incubator.  Then,  the  culture  medium  was discarded  and  the  celjs  were  
fixed  with  0.05  ml  of  10  %  formalin  for  10  niin,  followed  by  staining  
with  0.05 mL  of  0.05  %  crystal  violet  for 30  min. The  stained  cells  were  
rinsed  with  tap water  and  air  dried.  The  dye  was  dissolved  in  0.15  mL  
of  50  % cthanol  plus 0.1  %  acetic  acid  and  measured  in  Elisa-readcr.  
Antibody  dependent  cellular  cytotoxicity  (ADCC)  test.  Human  0  Rh-
positive  red  blood  cells were  used  as  a  target  and  PBM  Mo"  cells  as  an  
effector  in  a  1:10  ratio.  The  reaction  was  mediated  by  red  blood  ceil  
specific anti-D  antibodies. The  cultures were  incubated  at  37°C  for  16 h 
and  the  amount  of  released  S1Cr  in  each  supernatant  was  determined  
using  a  gamma  counter.  Front  the  average  of  triplicate  released  values,  
the  percentage  of  cytotoxicity  was  calculated  according  to  the  following  
formula  (15).  
'1 cytotoxicity  =  100 x 
test  s l Cr  release  - spontaneous  s l Cr  release  
maximum M C r  release  - spontaneous  Cr  release  
Spontaneous  release  indicated  cultures  without  anti-D  antibody.  The  
results are expressed  in percent  of control  cultures.  
Natural  Killer  cell  activity  (NK  assay).  51Cr-labelled  K562  cells  (used  as  
the  target),  and  PBM-Mo+  and  PBM-Mo"  (used  as  the  effector)  were  
mixed  in  a ratio  of  1:50. After  incubation  at  37°C for  4  h,  the  amount  of  
radioactivity  released  into  culture  supernatants  was  determined.  The  
results  arc  expressed  as  a  percentage  of  cytotoxicity,  as  described  above  
(16). 
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Tabic  I.  Percentage  of  EBV-EA  induction  in  the  presence  of  crocelin  
derivatives from  Crocus sativus. 
Compounds 
Crocin 
Triglucosyl  crocctin  
Diglucosyl crocctin 
Concentration  (mol  ratio/TPA)")  
EBV-EA 
1  x  I0J  
I9.5h)  (>80)c)  
30.1 (>80) 
37.6 (>80) 
1  x  I0"1  
82.7 (>80) 
100.0 (>80) 
100.0 (>80) 
Table  II.  The  effect  of  crocin and  its derivatives on  the  expression of early 
tumor antigen of adenovirus  12 infected llep-2  cells.  
Compounds 
a )  TPA (20 ng  =  32 pmol). 
h '  Values represent  relative percentage to the positive control value (100 
%). 
•  Values  in the parentheses arc viability percentage of  Raji cells. 
Crocin 
Digtucosyl-crocctin 
Triglucosyl-crocclin 
Concentration 
pg/ml 
0.01 
0.10 
0.01 
0.10 
0.01 
0.10 
1.00 
Expression of adeno  EA in 
percent  of the control 
I  (HI  
5-10 
10 
5 
1(H) 
100 
5 -  10  
Control 100 
Results 
The primary screening  of crocin  was carried  out  with  a short-
term  in  vitro  assay  on  EBV-EA  activation.  The  inhibitory  
effects  of  crocctin  glycosides  on  activation  induced  by  TPA  
and viability of Raji cells are shown  in Table I.  
Table  I  shows the  inhibitory  effect of  compounds  isolated  
from active carotenoid  fraction against EBV-EA induction. In 
the ingredients  of  the cthanol  extract  of Crocus sativus (ECS) 
crocetin  gentibiose  glucose  ester  and  crocetin  di-glucosyl  
ester, were  less potent  than  crocin  in  inhibiting  the  EBV-EA  
induction  effect.  The  comparative  study  among  three  
analogues  clearly  suggests  that  gentibiose  attached  to  the  
diterpenoid  chain  are  important  for  crocin  to  exert  the  
biological  activity.  
The exposure of the  EBV genome carrying  lymphoblastoid  
Raji  cells  derived  from  Burkitt  lymphoma  and  exposure  of  
adenovirus  infected  cells  by  some  compounds  resulted  in  
altered  T-antigen  expression  in  HEp-2  cells  (Table  II).  The  
crocin  and  diglucosyl-crocetin  inhibited  early  tumor  antigen  
expression  in  HEp-2  cells  in  the  presence  of  triglucosyl-
crocctin  the  effect  was  less  significant.  Interestingly,  the  
crocin  had  no  antiviral  effect on  herpes  simplex  virus-type-2  
(Table  III).  These  findings  led  us  to  suppose  that  crocctin  
,  glucoside  may  affect  the  activity  of  membrane  proteins  such  
as mdr p-glycoprotein  (Table IV). 
The  mdr  glycoprotein  located  in  the  membrane  of  tumor  
cells  are  responsible  for  the  decreased  retention  of  a  wide  
variety  of  anticancer  drugs  in  cells.  Therefore,  the  pheno-
menon  is  called  multidrug  resistance,  which  means  cross-
resistance for a large number of antitumor drugs. 
Therefore, the main aim of our studies in this paper was to, 
improve  the  strategies  designed  to  block  the  activity  of  ppg  
membrane  protein  to  circumvcnt  a  form  of  drug-  resistance  
by  membrane  active  compounds  like  ginsenosid  and  
cannabinoid  derivatives.  
The  resistance  reversal  effect  of  crocetin  glycosides  was  
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Table III. The antiviral effect of crocin on  HSV-2.  
Compounds Concentration 
pg/ml 
Inhibition 
(l«>S) 
Crocin 50 0.49 
25 0.24 
12.5 0.(1 
6.25 0.0 
3.12 0.0 
1.56 0.0 
tested  on  mouse  lymphoma  cells  carrying  the  hutpan  mdr I 
gene. The  data  obtained  with  crocetin  glycosides  is  summa-
rized  in  Table  IV.  The  triglucosyl-crocetin  and  diglucosyl-
crocetin  activity  was  marginal  - for  0.1  to  10.0  pg/mL  
concentration;  however,  picrocrocin  and  crocin  were  ineffe-
ctive in this aspect. Even drug accumulation was decreased  in  
the  treated  cells.  Thus,  one  cannot  exclude  the  enhanced  
membrane permeation or apoptosis.  
The interpretation  of multidrug resistance reversal cffcct of 
the  compounds  also  gives  some  information  about  direct  
cytotoxic potential. The morphological changes were analysed 
by measuring the FSC and SSC values on the flow cytometer. 
The  cell  size  increased,  and  at  the  same  time  cellular  
granulation  decreased.  The  viability  of  cells  did  not  change  
during the experiment. As determined  by the trypan blue test, 
the cell viability was between 95 and 98 % (data not shown). 
Some  ginsenoside  derivatives  had  a  remarkable  inhibition  
on  mdr efflux, and the effect also showed  a dose  dependence  
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Table  V.  1'lw reversal  of  multidrug  resistance  of  mouse  lymphoma  cells  hy  
naturally  occurring  glycosides.  
Giusenosidc 
Rb, 
Re 
Rd 
Re 
Rg. 
R i 
Gle—Glc-
Glc—Glc-
GIc—Glc-
H 
Gle—Glc-
R2 
II 
H 
H 
Rha—Glc-O-
Glc-O-
Ra 
Gle—Gle— 
Ara(f)—Glc-
Glc-
Glc-
Glc-
Figurc  3. Ginsenoside  derivatives.  
Table  IV.  The  reversal  of  multidrug  resistance  of  mouse  lymphoma  cells  by  
crocetin  glycosides  and  picrocrocin.  
Compounds Concentration 
(ig/ml 
FSC SSC FL-1 Fluorescence 
Activity  Ratio  
PAR  control  548.98 170.71 743.22 
MDR  control  649.28 259.87 36.03 
Verapamil 8 651.43 255.02 185.33 5.14 
Crocin 10 695.35 235.23 23.25 0.65 
20 684.18 230.62 17.14 0.48 
too 687.09 231.37 13.54 0.38 
Triglucosyl 10 708.07 220.63 40.79 1.13 
crocctin 
20 678.15 219.71 43.18 1.20 
too 682.96 219.59 37.77 1.05 
Diglucosyl 10 697.47 230.71 22.45 0.62 
crocetin 
20 698.58 225.24 44.74 1.24 
100 695.02 239.36 32.68 0.91 
Picrocrocin 10 693.62 224.73 27.28' 0.76 
20 689.09 225.03 25.78 0.2 
100 665.07 219.06 25.12 0.70 
Compounds  Concentration  
(ig/ml 
FSC SSC FL-1 Fluoresccncc 
Activity  Ratio  
PAR  control  522.20 260.98 1010.84 
MDR  control  581.72 311.94 47.57 
Verapamil 8 578.25 312.83 374.40 7.87 
Ginscnosidc  Rgl  2 589.12 315.78 99.32 2.09 
20 585.34 307.60 113.27 2.38 
Ginscnosidc  Rbl  2 585.29 304.65 75.78 1.59 
20 585.02 298.95 87.95 1.85 
Ginscnosidc  Rc  2 586.11 300.44 142.80 3.00 
20 588.32 301.59 145.84 3.07 
Ginscnosidc  Rc  2 589.62 308.93 245.17 5.15 
20 584.74 299.28 182.13 3.83 
Ginscnosidc  Rd  2 582.43 300.19 278.08 5.85 
20 585.17 307.34 363.94 7.65 
Table  VI.  The  reversal  of  multidrug  resistance  of  mouse  lymphoma  cells  by  
some  cannabis  derivatives.  
Compounds  Concentration  
(ig/ml 
FSC SSC FL-1 Fluorcsccnce 
Activity  Ratio  
Verapamil 5 528.86 253.87 62.89 3.15 
Cannabinol 2 502.23 262.80 221.29 11.08 
Cannabidiol 2 502.93 235.87 57.79 2.89 
Cannabidiolic  acid  2 490.11 248.36 10.91 0.55 
A 8 T H C 0.5 497.26 246.43 13.58 0.68 
A 9  T H C 0.5 491.21 244.91 14.45 0.72 
for  2.0  to  20.0  |.ig/mL.  The  ginsenoside  Re  and  Rd  had  the  
highest  effect  by  reducing  the  activity  of  drug  efflux  pump.  
These  two  ginsenosides  had  nearly  the  same  effect  without  
any apparent  cytotoxicity (Table V). 
Some  of the cannabinoid  compounds  showed  a  remarkable  
inhibition  on  the  Rhodamine  accumulation  of  tumor  cells  at  
0.5-5.0 pg/mL concentrations  (Table  VI). We could  not  detect  
any  inhibitor'  effect  in  case  of  the  hallucinogenic  A8-A9  
THC. 
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Tabic VU. Effect of tliu drugs ou NK cells activity. 
Compounds  NK cell  activity (% of control  value)  
I pg/ml  10 pg/ml 
Ginsenosidc  Rgl  91  117*  
Ginsenosidc  Rbl  106*  114*  
Ginsenosidc Re  93  85  
Ginsenosidc  Re  85  103*  
Ginsenosidc  Rd  97  116*  
Control values DMSO  17.9  15.2  
Table  Vlll.  ADCC  uctivity in the presence of the drugs. 
Compounds  ADCC activity ( o f  control)  
1 Hg/ml  5|tg/ml  lll|\g/ml  
Ginsenosidc  Rgl  53  0.1  05  
Ginsenosidc  Rbl  63  71  88  
Ginsenosidc  Re  55  51  4o  
Ginsenosidc  Rc  53  84  07  
Ginsenosidc  Rd  48  63  70  
Control values DMSO  66.2  52.4  4.1.0  
The  A8-THC  had  a  marginal  effcct  at  cytotoxic  
concentration  while  A9 had  a remarkable  effect at  the  same,  
2.0 pg/ml, concentration,  which  lead  to  10 percent  reduction  
of the cell size without  any apparent changes in SSC values or 
cell viability. It is interesting that the two effective compounds 
enhanced  the  NK  ccil  activity  (Table  VII).  That  means  that  
ginsenosidc Rd and Rgl  may have a beneficial effcct in tumor 
bearing  animals.  However,  the  ADCC  activity  of  lcukocytes  
was hardly-enhanced  by ginscnoside Rc, Rgl  and Rbl  (Table  
VIII). 
Discussion 
Crocus sativus  grows  in  South  Asia  and  South  Europe.  Its  
medical  value  was  recorded  in  traditional  Chinese  medicine  
and  was  used  to  improve  blood  circulation  (17).  The  
compounds  of  saffron  are  able  to  inhibit  chemical  carcino-
genesis  as chemopreventive  agents  and  had  direct  antitumor  
action  in  animal  experiments  (3,  18).  Crocus  sativus extracts 
were  effective  in  the  treatment  of  central  nervous  system  
diseases including depression,  anxiety, and  improved  memory  
functions (19). 
It  was  shown,  that  the  saffron  extracts  contain  chara-
cteristic  compounds  such, as  carotenoids;  crocin  and  mono-
terpene  aldehydes;  picrocrocin  and  safranal  (20).  The  
majority of crocetin  glycosides were able to inhibit  the growth 
of human cancer cells in vitro  (6). 
In  addition,  some  plant  phcnolics  were  able  to  enhance  
the  survival  time  of  mice  inoculated  with  NK/LY  ascites  
tumor  cells  (21,  22);  others  affected  the  genetic  base  of  
bacterial  resistance,  including  plasmid  transfer,  which  was  
inhibited  by  psychoactive  and  inactive  derivates  as  well  
(8). 
Crocine  had  an  inhibitory  effect  on  two  stage  carcino-
genesis  with  DMBA  as  an  initiator  and  TPA as  a  promoter.  
When  crocin  was applied  before the TPA  treatment  only  10  
% of animals had papillomas and the formation of papillomas 
was  delayed  (1).  Konoshima  assumed  that  there  are  two  
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possibilities  by  which  crocin  inhibits  tumor  formation:  a.,  
prevention  of  DNA  damage  and  b.,  working  as  an  activator  
for DNA excision repair enzyme. 
There  were  no  data  about  the  effects  of  these  plant  
compounds  on  drug  resistant  cancer,  although  the  molccular  
mechanism  of  the  membrane  effect  was  analysed.  Abe  el al 
(23)  suggested  that  crocin  antagonizes  the  cthanol  effect-on  
N-methyl-D-aspartale  reccplor  activated  membrane  current  
(23).  It  was  interesting  that  EBV  and  adenovirus  induccd  
tumor-  antigen  expression  was reduced  by crocin  derivatives,  
despite the lack of the antiviral  effect on the  DNA containing 
herpesvirus. 
It  is  possible  that  gene  expression  is  blocked  due  to  the  
reduccd  promoter  activity  in the presence  of crocin, or  that  a  
T-antigcn  shift  can  be  the  consequence  of  physicochcmical  
changes  in the membrane lattice induccd  by a charge transfer 
complex  formation  between  particular  membrane  compo-
nents and crocin  derivatives.  
The  effcct  of  ginsenosidc  derivatives  was  dependent  on  
their  chemical  structure.  The  compounds  in  general  had  a  
moderate  effect  on  the  inhibition  of  multidrug  resistance  
efflux  pump  of  the  human  mdr-1  transfcclcd  mouse  
lymphoma  cells.  The  ginscnoside  Rbl  was  an  exception,  
having the lowest effect possibly due to the bulky substitution 
at  the  C-3 site. This hypothesis was supported  by the  highest  
activity  of  Rd  derivative.  In  the  latter  compound  the  space-
filling  of  the  C-3  substituent  is  much  smaller  than  in  Rbl.  
However,  the  moderate  action  of  the  Rgl  may  be  due  to  
steric hindrance problems at the C-6 position. 
In  the  case  of  cannabinol,  the  electrophilic  nature  of  the  
molecule may be responsible for the reversal  of the multidrug 
resistance efflux-pump. However, the extreme  hydrophobicity  
and  broken  pi-conjugation  in  the  molecules  of  the  two  
hallucinogenic compounds  such as A8 and  A9 THC might  be  
responsible  for  their  ineffectiveness. The  tested  compounds  
can  change  the  membrane  structure  and  only  a  few of  them  
are able to block the mdr-efflux pump. 
In  addition, cannabinol  can  enhance  the  phagocytic  index  
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and  TPA-induced  chcmiluminesccnt  reaction  of  human  
polymorphonuclear  leucocytes  by  enhancing  oxidative  bursts'  
(9).  The  relevant  immuno-modulating  effect  of  the  most  
active  ginsenoside  was  studied  in  two  functions  of  the  human  
leucocytes  such  as  NK  cell  activity  and  A D C C .  The  
ginsenosides  were  able  to  enhance  the  natural  killer  cell  
activity,  however  the  A D C C  activity  changed  to  a  lesser  
extent. 
In  conclusion,  we  suggest  that  the  reduced  T-antigcn  
expression,  increased  natural  killer  cell  activity  and  inhibition  
membrane  efflux  pump  responsible  for  the  multidrug  
resistance can be exploited  in antitumor  chemotherapy.  
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Abstract. Drug resistance  to chemotherapy  is rapidly emerging. 
Resistance  to  one  drug  carries over  resistance to unrelated 
anticancer drugs leading to  multidrug resistance  (MDR).  A  
major factor  of  MDR is  P-glycoprotein  (P-gp) mediated ABC 
transport found  in many eukaryotic  cells. P-gp acts as  a drug 
eMux pump.  The  mdrl  gene  involved  in  P-gp  170 protein 
production is localized in the human chromosome 7 band  p21.0  
- 21.1. Point mutations alter cross-resistance patterns.  A variety 
of  stimuli  increase the  expression  of  the  mdrl  gene:  lowered  
extracellular pH,  heat  shock,  arsenile,  cytotoxic  agents,  
anticancer drugs,  transfection  with oncogenes,  H1V-I,  and UV-
irradiation.  An  alternative hypothesis  to the efflux pump claims 
that  P-gp  modifies  the  intracellular environment  to  reduce  
accumulation of  anticancer  drugs in  cancer cells by  creating  
ionic or proton gradients.  Chemosensitizers that block P-gp drug 
extrusion are generally lipid-soluble at physiological pH,  possess 
a  basic  nitrogen  atom  and  at  least two  co-planar rings.  P-gp  
blocking does not depend on drug chirality.  This  opens the  way 
of  treating P-gp  related MDR  with  chiral  versions of drugs 
relatively harmless  in  terms  of  side-effects. We  believe that 
resistance  modifiers  combined  with  cytostatics  will  
chemotherapeutically be more effective for cancer patients. 
Cancer  is  the  second  most  frequent  disease  globally.  The  
hope  for  cures  of  most  cancers  are  probably  systemic  
treatments  such  as  chemotherapy  and  immunotherapy.  
Chemotherapy  has  proven  to  be  effective and  has  led  to  the  
cure  of  many  cancers  such  as  leukemias,  lymphomas  and  
sarcomas.  The  common  clinical  problem  in  the  successful  
treatment  of  cancer  is  the  resistance  of  tumor  cells  to  
chcmotherapeutic drugs. 
Resistance  to  chemotherapeutics  has  recently  been  
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observed  to  be  emerging  among  viruses,  bacteria,  fungi,  
protozoa  and  cancer  cells.  The  basic  reason  for  the  
development of this resistance is a Darwinian selection, which 
ensures the  accommodation  of  living organisms to an  altered  
environment  (1).  During  the  last  20  years  drug  resistance  
mediated  by  a  membrane  glycoprotein  has  been  studied  in  
detail.  This  type  of  resistance  has  a :  special  importance  
because cancer cells exposed to one cytostatic results not only 
in a specific resistance to the inducer, but  also to  many other 
chemically  unrelated  anticancer  drugs  representing  a  non-
specific cross-resistance. 
The ABC superfamily of membrane transporter  proteins  
P-glycoprotein belongs to a large group of functional proteins 
that  share  common structural  and functional properties. This 
superfamily  of  proteins  has  been  named  the  ABC  (ATP  
Binding Cassette) family of membrane traffic ATPases. There 
are  at  least  40 members  of  this'ABC superfamily of  proteins  
in bacteria,  including nutrient,  peptide,  polysaccharide,  toxin  
and  drug  transporters.  There  are  many  examples  of  these  
ABC  proteins  in  eukaryotic  cells:  a  pigment  transporter  in  
Drosophila  melanogaster (2), a pump that  appears to  mediate  
chloroquine  resistance  in  Plasmodium  falciparum,  pfmdr  
(3,4), a transporter for a peptide mating factor of yeast called 
STE6  (5,6);  CFTR,  the  product  of  the  cystic  fibrosis  gene  
(7,8), a peroxisomal membrane pump in the liver (9) which, if 
it  is  mutated  results '  in  a  fatal'  cerebro-hepato-renal  
dysfunction  (10);  and  two  linked  genes'associated  with  the  
transport  of peptides into the endoplasmic reticulum for class 
I antigen presentation, recently named-Tap-l and Tap-2 (11). 
-The general structure of these/transporters includes a set of 
six  transmembrane  domains^whichsi-'are  'generally  not  
homologous  to others  sharing  amino  acids  with'-hydrophobic  
properties,  followed  by  an  ATP^binding'casette.J  In  the  
bacterial  systems,:  the . • subunit R with'¿the rc transmembrane 
domains  and  the'ABC proteins-may be separate o r fused! In 
eukaryotic systems;'a  set  of  six transmembrane  domains  may  
be  fused  to  a  single  ABC  protein,- as  for -the- peroxisomal -
membrane  •  protein,  •  endoplasmic-^ reticulum- '/ peptide • 
transporters, Drosophila  pigment  transporter'and  the  antigen  
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Tabic  I. Mammalian  multidrug  resistance genes. 
Species Class 1 Class  II  Class III 
Human MDRI MDR3 (MDR2) 
Mouse nidr3 (mdrl  a)  mdrl (mdrl  b)  mdr2 
Hamster Pgpl Pgp2 PgP3 
Rat I'gP" Pgp2 (mdrl  b)  pgp3 (mdr2) 
peptide transporters,  or  two of  these  may be fused to give  12  
transmembrane  domains  and  two  ATP  sites,  such  as  the  
CFTR,  STE6  and  MDR  proteins.  Although  this  family  has  
not  yet  been  fully  described,  it  appears  that  the  ABC  
transporters localised to intracellular membranes contain only 
one  set  of  six  transmembrane  domains  and  one  ATP  site,  
whereas  the  transporters  localised  to  the  plasma  membrane  
have  12 transmembrane  domains  and  two ATP sites.  Several  
secondary  transporters  such  as  the  glucose  carrier,  anion  
exchanger and Na/H exchanger, which do not  have ATP sites, 
when  localised  to  the  plasma  membrane  also  contain  12  
transmembrane  domains,  but  homologous  intracellular  
organelle  transporters  contains  six  transmembrane  domains  
and  function  as  dimcrs  (12,13).  Based  on  this  analogy,  it  is  
tempting  to  suggest  that  the  minimal  functional  unit  of  the  
ABC  transporters  may  also  require  12  transmembrane  
domains and two ATP sites. 
Broad-spectrum  resistance  to  chemotherapy  in  human  
cancers  has  been  called  multidrug  resistance  (MDR).  This  
resistance  is due  to decreased  accumulation  of  drugs  in cells,  
and  the  efflux  of  cytostatics  is  mediated  by  an  energy-
dependent  drug  transporter  protein  (2).  One  of  the  
biochemical  aspects  by which  tumor  cells  manifest  multidrug  
resistance  is  the  overexpression  of  an  integral  plasma  
membrane  P-glycoprotein  or  P-170,  the  product  of  an  SOS  
gene.  This  is  the  multidrug  resistance  1  (MDRI)  gene.  P-
glycoprotcin  (P-gp)  acts  as  a  drug  efflux pump  that  actively  
extrudes  drugs  from  tumor  cells,  thereby  decreasing  the  
concentration  of chemothcrapcutic  agents  in  resistant  cancer  
cells or HIV-1 protease inhibitors (14). 
The  overexpression  of  the  MDR1,  MRP  and  LRP  genes  
explains  only  a  subset  of  multidrug  resistance.  More  studies  
have  identified  resistance-related  abnormalities  of  the  
enzyme  topoisomcrasc  II  (15,16)  with  respect  to  
overexpression  of  the  genes  involved  in  the  glutathione  S-
transferase system  (17,18)  and  the  expression  of  other  genes  
(19,20).  These  studies  have  provided  additional  mechanisms  
by which multidrug resistance  can be conferred. Even  though  
these  phenomena  are  associated  with  multidrug  resistance,  
the  breadth  of  the  resistance  associated  with  each  is  not  as  
broad as the MDR  now often encountered  in the clinic. 
Table  II.  Potential  physiological  functions  of  l'-gi>s  in  mammuls  ((mm  
Borst and Schinkel,  1996).  
1.  Protection against exogenous toxins ingested with food: 
Expression  in small intestine, colon, Wood-tissue barrier sites. 
2.  Excretion  of metabolites or  toxins:  
Expression  in liver canalicular membrane,  kidney.  
3.  Transport  of steroid  hormones:  
Expression  in adrenal gland, demonstrated  transport  of  
Cortisol, corticostcronc,  aldosterone.  
4.  Extrusion  of (poly-)pcptidcs (cytokines)  not exported  from the cell 
via the classical signal/cleavage  pathway:  
Compare yeast St6, E. coli  1-llyB, mammalian  endoplasmic  
reticulum peptide  transporters.  
5.  Ion transport and cell volume  regulation:  
Activation of an endogenous  CI" channel  activity.  
6.  Lymphocyte  cytotoxicity:  
Possible involvement  in NK-ccll-incdiatcd  cvtotoxicily.  
7.  Transport  of prcnylcystcinc methyl  esters.  
f 
8.  Intracellular vesicular transport of  cholesterol.  
Genes responsible for MDR 
Different  P-gp  isoforms  have  been  identified,  and  these  arc  
encoded  by  a  family  of  closely  related  genes.  They  arc  
referred  to  as  pgp genes  in  hamsters  and  rats,  mdr  genes  in  
mice  and  MDR  genes  in  man  (21).  Based  on  their  3'-
untranslatcd  regions  the  mammalian  multidrug  resistance  
genes  are  divided  into  three  classes  of  genes,  termed  class  I,  
class II and class III as in Table I (22). 
The  rodent  class  I  and  class 'ITgenes  appear  to  be  more  
closely  related  to  each  other'in  structure  and  function  than  
either gene to  the class III gene. Overexpression  of class I  or 
class II  P-gps renders cells multidrug resistant; while class III 
P-gps  is  not  capable  of  conveying'multidrug  resistance.  The  
structural  similarities  between''  two  ''  halves1  of  the  
transmembrane  P-gp molecule  led  to  the  hypothesis  that  the  
P-gp gene  family arose  from the  duplication  of  a  primordial  
gene  (23).  However,  detailed"  analysis  of  the  MDR1  
exon/intron  structure  indicated  that  this  is  probably  not  the  
case (24). 
The  MDRI  gene  has  been  localized  in  the  human  
chromosome 7 band p21-21.1 (25) on a 600-kb NruI fragment 
and !the entireMDRr'coding'regio'niis  containecf oiiV120-kb 
Xhol fragment (26). This gene extends over more than  100 kb 
and  encompasses  28  introns,  26  of  which  interrupt  the  
protein-coding  sequence.  Its • messenger  RNA  has  a  size  of  
4.7kD so its coding region therefore represents  less than 5 % 
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Figure  1. Schematic  model  of  the  structural  organization  of  human  multidrug  transporter,  based  on  amino  acid  sequence.  
of  its  total  length.  The  human  MDR2  gene  has  the  same-
number  of  28  exons,  27  coding,  but  is  shorter  and  only  
extends  for  74 kb. The  function  of  the  closely  related  MDR2  
genes  is  not  known  and  its  substrates  have  not  yet  been  
i  identified  (27).  
One  of  the  most  intriguing  aspects  of  P-gp  biology  is  the  
broad  substrate  specificity  of  the  molecule,  which  can  be  
altered  by  point  mutations.  Spontaneous  base  pair  
substitutions  in  the  human  MDR1  gene,  resulting  in  a  glycine  
to valine change at  amino acid  185, located  at  the  cytoplasmic  
border  of  the  third  transmembrane  domain,  change  the  
pattern  of  resistance  by  their  increased  ability  to  pump  
colchicine  and  etoposide,  with  a  decrease  in  the  ability  to  
pump  vinblastine  and  actinomycin  D  (28).  Both  intact  halves  
of  the  P-gp  molecule,  as  well  as  the  two  nucleotide  binding  
sites, seem  to be essential  for drug transport  (29).  Evidence  is  
accumulating  that  transmembrane  domains  of  P-gp  are  
important  for  the  interaction  of chcmotherapeutic  drugs  with  
P-gp  (30).  For  example,  predicted  transmembrane  domain  3,  
6  and  11  are  likely  to  play  a  role  in  substrate  recognition,  
binding  or  release.  Point  mutations,  either  spontaneously  
occurring  or  genetically  engineered,  within  or  in  close  
proximity  to  these  putative  transmembrane  domains,  alter  
cross-resistance  patterns.  An  important  role  for  the  
transmembrane  domains  of  the  P-gp  molecule  for  drug  
transport  fits with  the  hydrophobic  vacuum  cleaner  model  of  
the  function  of  P-gp  (31).  As  a  consequence  of  its  broad  
substrate  specificity, the  function of the  P-gp molecule  can  be  
inhibited  by  non-cytoloxic  compounds  that  also  have  a  high  
affinity for the drug binding site on the  P-gp.  
Sequence, structure, expression andfunction of P-
glycoprotein 
P-gp  is  1280  amino  acids  in  length.  The  primary  amino  acid  
sequence  predicts  a protein  with  12 transmembrane  domains  
in  two  homologous  halves,  each  containing  six  
transmembrane  regions  and  two large  intracytoplasmic  loops  
encoding  an  ATP-binding  site.  P-gp  consists  of  two  
homologous  halves,  with  43  %  amino  acid-sequence  identity  
between  the  amino-  and  carboxy-terminal  halves  (32,33). The 
degree  of the  homology varies throughout  the sequence  being  
much  stronger  near  the  C-tcrminus  than  in  the  rest  of  the  
protein.  Each  half  of  P-gp  consists  of  a  short,  highly  
hydrophilic,  N-terminal  region,  a  long  hydrophobic  region  
and  a  long,  relatively  hydrophilic  cytoplasmic  C-terminal  
region.  The  mass  predicted  from  the  deduced  amino  acid  
sequence  is  140  kDa  (34),  but  size  fractionation  by  
polyacrylamide  gel  electrophoresis  indicates  a  size  of  ~  170-
180  kDa.  This  discrepancy  seems  due  to  glycosylation  and  
phosphorylation  of  the  P-gp  (35).  This  general  structure  
appears  to  be  indicative  of  membrane  channels  and  
transporters  (e.g.,  in  the  human  voltage-sensitive  Na + 
channel,  cystic  fibrosis  transmembrane  conductance  
regulator)  and  is a consistent  motif  throughout  evolution  (36).  
P-gp  uses  energy  in  the  form  of  ATP  to  transport  drugs  
through  a  channel,  formed  by  the  transmembrane  segments  
(37,38). 
P-gp  is  also  found  generally  in  polarized  epithelial  cell  
layers,  where  it  generally  localizes  to  the  apical  (or  luminal)  
surface  of  the  cell.  This  localisation  indicates  that  a  major  
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function of  P-gp  is the  protection  of  organisms  against  many  
of  the  toxic  xenobiotics  to  which  they  can  be  exposed  in  
nature (39). 
Lowered  extracellular  pH  (40),  heat  shock  and  arsenite  
(41),  cytotoxic  agents  (42),  transfection  with  oncogens  (43)  
and  with  human  immunodeficiency  virus-1  (44)  and  UV  
irradiation  (45), increase the expression of the MDR1 gene in 
both human and rodent cell lines. 
Expression  of  mul t idrug  t ranspor te r  in  normal  tissues,  the  
normal  function of  "MDR"  
The  highest  level  of  human  MDR1  protein  and  mRNA  
expression  arc  found  in  the  adrenal  gland,  kidney, jejunum, 
colon  and  endothelial  cells  of  the  blood-brain  barrier,  
whereas human MDR2 is strongly expressed  in the liver. 
Immunohistochemical  analysis  with  specific  anti-P-gp  
antibodies  reveals  that  P-gps  are  expressed  in  a  polarized  
manner  on  the  apical  membrane  of  secretory  epithelial  cells  
lining luminal  spaces  such  as the  glandular  epithelial  cells of 
the endometrium  in the pregnant  uterus, the biliary canaliculi 
of  hepatocytes,  the  brush  border  of  renal  proximal  tubules,  
pancreatic ductules, columnar  epithelium  of the intestine and 
in  endothelial  cells  of  the  blood-  brain  barrier  and  in  the  
testes (13). Expression of P-gp at the surface of epithelial cells 
lining  the  luminal  spaces  of  the  intestine,  kidney  and  liver  
suggest  that  P-gp  plays  a  protective  role  at  these  sites.  
Additional experimental evidence suggests that: 
1.  endothelial  cells  from  the  blood-brain  barrier  can  cany  
out  unidirectional  drug  transport  in vitro (46)  to  protect  
the brain from toxic natural products (12); 
2.  pluripotent  stem  cells  of  the  hemopoetic  system  can  
transport  the  P-gp  substrate  fluorescent  dye  rhodamine  
123 (47); 
3.  the  cardiac  glycoside  digoxin,  which  is  eliminated  by  
glomerular  filtration  and  tubular  excretion, -  is  a  P-gp  
substrate  (48).  On  the  other  hand,  expression  of  P-gp  at  
other  sites  such  as  the  pancreatic  ductules,  the  adrenal  
cortex and the endometrial  glands of the pregnant  uterus,  
suggest that P-gp may play a role in hormone transport. P-
gp  can  transport  steroid  hormones  such  as  aldosterone,  
dexamethasone, cortispl  (49) and  corticosterone.  
The tissue-specific expression  of the MDR1 gene  indicates  
that  levels  of  MDR1  RNA  may  be  regulated  in  mammals.  
Several  studies  have  demonstrated  increases  in  RNA  levels  
for  P-gp  after  partial  hepatectomy  (50,51),  treatment  with  
cheniotherapeutic  drugs  and  cytotoxic  stress  such  as  heat  
shock  (41).  These  studies  demonstrating  increased  P-gp  
mRNA levels in response to cell injury support a role for P-gp 
in protecting cells against damage by toxic products. 
Glycosylation  of  P-glycoprotcin  
P-gps  arc  post-translationally  modified  by  glycosylation  and  
phosphorylation. P-gp is N-glycosylated at one position on the 
first  extracellular  loop  of  the  C-terminal.  Experiments  in  
which  multidrug  resistant  cells  were  grown  in  the  
glycosylation  inhibitor  of  tunicamycin  (52,53)  and  mutant  
multidrug resistant cclls greatly reduced  glycosylation  of  P-gp  
demonstrating that glycosylation of P-gp is not required for its 
multidrug  transport  function  (54,55).  However,  it  has  been  
suggested  that  N-glycosylation  may contribute  to  the  correct  
folding, proper routing and stabilization of the  molecule.  
Phosphorylation  of  P-glycoprotcin  
Early studies suggested that the phosphorylation  slate  of P-gp 
affects  its  function.  P-gp  is  phosphorylatcd  on  serine  and  
threonine  residues and  is a substrate for a number  of  cellular  
kinases  (56,57).  Studies  in  which  protein  kinase  C  has  been  
specifically overexpresscd,  activated  by phorbol  esters  (58,59)  
or  inhibited  by staurosporine  (60-62), have demonstrated  that  
P-gp  is  a  substrate  for  protein  kinase  C  phosphorylation  
(63,64).  In  human  P-gp,  protein  kinase  C  phosphorylation  
sites  are  Ser-661,  Ser-671  (65);  cAMP  dependent  protein  
kinase phosphorylation  sites are Ser-667, Scr-671 and  Ser-683  
(66).  These  phosphorylation  sites  are  confincd  to  a  ccntral  
cytosolic segment that connects the two homologous halves of 
P-gp.  It  is  interesting  that  some  of  the  multidrug  resistance  
reversing agents, such as verapamil  and trifluoperazine, which 
bind  and  inhibit  P-gp,  also  increase  P-gp  phosphorylation  
(67,68).  These  studies  suggest  that  different  kinases  arc  
involved  in  P-gp  phosphorylation;  namely,  cellular  drug  
resistance  is  increased  which  is  correlated  with  decreased  
intracellular drug accumulation. 
i  ,  
Interact ion  of P-glycoprotein  with drug  molecules  
The hypothesis that  P-gp protects multidrug resistant  cells by 
pumping, cytotoxic  drugs  through  the ¡plasma, membrane  out  
of  the  cell,  suggests  that  the.P-gp  contains  specific  binding  
sites  for  these  drugs  and  their ¡sites  could  be  labeled  by  
photoaffinity  drug  analogs.  ¡Many/ different , photoaffinity 
derivatives of multidrug resistant drugs have been  synthesized  
and  shown  to  bind  to  P-gp; the most  frequently used  are  the  
drug analog 3H-vinblastine (69), the P-gp modulator  calcium-
channel  blocker  3H-azidopine'(70),•verapamil  (71),  an  al-
adrenergic  receptor  iigand  -u-iodoarylazidoprazosin  (72)  
and others  like colchicin  (73),  iodomycin  (74),  cyclosporin  A  
(75), and forskolin (76).  •  •  r  
More  studies  have  established  that  at  least  two regions  of  
the  membrane-associated-portion  of .P-gp  are "involved  in  
binding photoactivable ligands:one  minor, site  located  within  
the  amino  terminal  half,,and  a  major .site  mapping  to  the  
carboxy terminal half (77,78). ¡1.1-'  .-:•  ••  
A  further  study on  a  series  of  antibodies  directed  against  
discrete  P-gip  peptides  .demonstrated  .that  .prazozine. and 
azidopine bound  to the same site on P-gp, which was limited 
mostly,  to  two  4  and  5  kDa  ; cryptic»peptides  mapping  
immediately  downstream  of  the  last! membrane  domains  of  
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F igure  2. Mechanism  of  action  of  llw  nnlr  efflux  pump.  
each  half  of  the  P-gp  (79).  This  study  suggested  that  
symmetrical  regions  in  each  half  of  P-gp arc  involved  in  drug  
binding and  transport.  
Cornwell  et  al.  (80)  prepared  two  different  photoaffinity  
vinblastine  analogs  and  showed  that  these  compounds  
specifically  labeled  P-gp.  The  specificity  of  labeling  was  
defined  by three  criteria:  the photoaffinity vinblastine  analogs  
labeled  a  170  kD •  protein  in  the  plasma  membrane  of  
multidrug  resistant  cells,  but  did  not  label  any such protein  in  
the  plasma  membrane  vesicles  prepared  from  the  drug  
sensitive  parent  cells;  it  was  possible  to  inhibit  the  action  by  
adding excess vinblastine  to  the reaction;  the  170 kDa  labeled  
protein  was  immunoprecipitated  by  antibodies  raised  against  
P-gp  (81).  
Excess  vinblastine  competed  succesfully  to  prevent  H-
vinblastin  from  binding  to  plasma  membrane  vesicles  
prepared  from  multidrug  resistant  cells.  These  results  show  
that  vinblastin  binding, and  labeling  is a saturable  process  and  
from this one  may infer that  vinblastin  binds  to  a specific site 
on  P-gp.  Other  drugs,  which  are  also  presumed  to  be  
substrates  for  P-gp  transport,  did  not  inhibit  vinblastin  
binding  and  labeling.  For  instance,  daunomycin  inhibited  
vinblastin  binding  or  tomato  lectin  inhibited  promethazine  
binding  to  P-gp,  but  colchicine  and  actinomycin  D  did  not,  
even  though  the  multidrug  resistant  cells are  crossresistant  to  
all of these drugs  (38).  
Many  different drugs are  able  to  interfere with  the  activity  
of  the  multidrug  transporter  and  also  reverse  the  multidrug  
resistance  phenotype  of  cultured  cells.  These  include  the  
calcium  channel  blocker  verapamil,  the  antiarrhythmic  
quinidine,  the  antihypertensive  reserpine  and  the  immune  
Tabic  III.  Methods  of  ¡¡election  MDR.  
Analysis of  RNA  Analysis of  protein  
Northern  blot,  slot  blot  Western  blot  
RNAse  protection  Immunohistochemistry  
In  situ  hybridization  Flow  cytometry  
Polymerase  chain  reaction  (PCR)  
suppressant  cyclosporin  A  (82).  Since  verapamil  is  also  a  
substrate  for P-gp (83) and  inhibits ATP-dependent  transport  
of vinblastin  into vesicles containing  P-gp (38),  it  is likely  that  
verapamil  works  as  a  competitive  inhibitor  of  the  multidrug  
transporter. 
Photoaffinity analogs of verapamil  (84), colchicine  (85) and 
daunomycin  (74)  have  since  been  prepared  and  used  to  label  
specifically  P-gp.  The  results  demonstrate  that  these  drugs  
have  binding  sites on  P-gp and  support  the  hypothesis  that  P-
gp  is  responsible  for  pumping  them  out  of  the  multidrug  
resistant  cells.  Probably  all the drugs share  a single site for the 
transport  by  P-gp,  but  there  are  more  than  one  site  on  the  
transporter  for binding. 
Expression  of multidrug transporter in human  cancer  
A  preliminary  survey  of  more  than  400  different  human  
cancers  demonstrated  the  widespread  expression  of  the  
MDR1  gene  in  human  cancers  with  both  intrinsic  and  
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Tabic IV. Clieinosensitizers: agents capable of inhibiting l'-g/> in vitro. 
Agents that reverse drug  resistance  
Calcium channci  blockers (verapamil, nifedipine, azidopinc,  dihydroplcridincs)  
Anli-arrhythmics  (quinidinc,  amiodaronc)  
Antihypertensives  (rcscrpine)  
Antibiotics (hydrophobic  cephalosporins)  
Antihistamines  (tcrfcnadinc)  
Immunosuppressants  (cyclosporin A,  FK506,  rapamycin)  
Steroid  hormones  (progesterone)  
Modified steroids (tamoxifen,  tirilazad) 
Lipophilic cations  (tctraphcnylphosphoniurn)  
Ditcrpcncs (forskolin) 
Detergents  (Twccn-80)  
Antidepressants  (thiopcridonc)  
Antipsychotics  (phcnothiazincs)  
Many other  hydrophobic, amphipalhic drugs and  their  analogs  
Anticancer  drugs  
Vinca alkaloids (vinblastine,  vincristine)  
Anthracyclincs  (doxorubicinc)  
Epipodopliyllotoxins  (ctoposidc)  
Antibiotics (actinomycin  D)  
Others (mitomycin C, taxol, milhramycin,  topotccan)  
Other cytotoxic  agents  
Antimicrolubulc  drugs (colchicine,  podophyllnloxin)  
Protein synthesis inhibitors (puromycin,  emetine) 
DNA intcrcahitors (cthidium  bromide)  
Toxic peptides (vtilinoniycin, gramiciilin,  D.N-jieeyllcucyl-
Icucyl-norlcucinal  (AI.I.N))  
acquired  multidrug  resistance  (86).  Cancers  of  the  liver,  
colon,  kidney,  pancreas  and  adrenal,  which  are  generally  
drug-resistant,  express  high  levels  of MDR1 RNA  equivalent,  
to  levels  found  in  four-fold  to  six-fold  multidrug  resistant  
tissue culture cells (86). Similar  levels of expression arc found 
in  a  minority  of  human  leukemias  and  non-Hodgkin's  
lymphoma,  chronic  myelogenous  leukemia  in  blast  crisis,  
astrocytoma  before chemotherapy  and  in  higher  percentages  
of  treated  leukemias,  lymphomas,  neuroblastomas,  sarcomas,  
cancer  of  the  breast  and  ovary  from  patients  who  have  
received  chemotherapy.  The  process  of  malignant  
transformation  in  cancer  derived  from  tissues  that  do  not  
normally  express  P-gp  can  activate  expression  of  the  MDRI  
gene  (43).  Increased  expression  of  the  MDRI  gene  is  
commonly  seen  in  tumors  treated  with  chemotherapy  that  
have  relapsed  during  the  course  of,  or  after  chemotherapy.  
For  example  breast  cancer,  ovarian  cancer,  lymphoma,  
leukemia,  neuroblastoma,  phcochromocytoma,  rhabdomyo-
sarcoma and  multiple myeloma. In these cases, it  is presumed 
that  small  numbers  of  MDRl-expressing  cells  were  present  
when  therapy  was  initiated  and  that  this  population  survived  
chemotherapy  and  caused  the  relapse.  But  a  direct  effect of 
chemotherapy  to induce mdrl gene expression  is also possible 
(87). 
Mechanism  of action 
The  early  studies  of  P-gp-positivc  multidrug  resistant  cells  
clearly  demonstrated  that  the  emergence  of  multidrug  
resistance  in  these  cells  was  linked  to  a  marked  decrease  in  
the  intracellular  accumulation  of  the  various  drugs  to  which  
the  cells  expressed  resistance.  The  reduced  cellular  drug  
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accumulation  was  strictly  energy  (ATP)  dependent  and  was  
concomitant  with  an ATP-dcpendcnl  increase  in drug release 
from these cells. Two major hypotheses for the mechanism of  
P-gp action  to  explain  such  reduced  drug accumulation  have  
been put forward (3 1,54,88). 
The  first  hypothesis  is  that  P-gp  functions  as  a  drug  
transporter  (efflux pump)  which  can  act  on  a broad  range of  
structurally  unrelated  molecules  and  uses the  energy  of  ATP 
hydrolysis  to  mediate  drug  efflux.  Experimental  data  
supporting  the  notion  that  P-gp  functions  as  a  drug  
transporter  include the observations that: P-gp binds the ATP 
analog,  has  ATPasc  activity  and  mutations  in  either  of  its  
predicted ATP-binding domains to abrogate  its function; P-gp 
binds  drug  analogs  and  mutations  in  its  predicted  
transmembrane  domains  and  modulates  substrate  specificity  
by altering drug binding to the protein; P-gp shares  homology  
with  a  number  of  prokaryolic  and  eukaryotic  membrane  
proteins  implicated  in  the  ATP-dcpcndcnt  transport  of  
various  types  of  substrates  across  the  membrane;  transport  
studies  in  intact  cells and  plasma  membrane  vesicles  from P-
gp  expressing  cells  indeed  suggest  that  P-gp  mediates  
increased  ATP-dcp'cndcnt  drug 'binding  and  transport  into  
these vesicles (38,80,89)."  ' '  
The  second  hypothesis  proposes  that  P-gp  itself  is  not  a  
drug  transporter',  but  has  an  indirect  role  in  modifying  the  
intracellular  environment  to create  cither  an  electrochemical  
- or  a pH  - gradient.  In  turn,  these  graclients would  act  in  an 
indirect  fashion  to  drive  the  movement'of  charged  drugs  
across the  membrane. The  major appeal  of  this  hypothesis  is  
its explanation  of  the  unusual  ability  of  P-gp to  act  on  a vast 
number  of structurally  unrelated  substrates which yet'share  a  
high  degree  of  hydrophobicity  and"are  positively  charged  at  
:  .."  "t  '<  « '  '  '«• . . 
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neutral  pH.  In  this  model,  P-gp was  proposed  to  function  as  
an  outwardly  directed  ATP  channel,  creating  an  
electrochemical  ATP-gradient  and  possibly  providing  a  
driving  force  for  drug  efflux.  Another  model  for  the  P-gp  
nrcchanism  is  based  on  the  observation  that  P-gp-positive  
cells  demonstrate  an  altered  intracellular  pH  (90).  In  this  
model  P-gp  would  function  either  directly  or  indirectly  to  
increase  intracellular  pH  and  lower  the  electrical  membrane  
potential,  in  consequence  of  which:  charged  hydrophobic  
compounds  such  as  anticancer  cytostatics  or  multidrug  
rcsistancc  reversing  drugs  (lipophilic  cations)  might  be  
differently  retained  in  P-gp-positive  and  negative  cells;  the  
pH-depcndcnt  binding  of  drug  molecules  to  their  respective,  
but  structurally  unrelated  targets,  might  also be altered  by P-
gp overexprcssion. 
These  hypotheses  suggest  that  the  P-gp action  may  have a 
dual function. 
A  model  for  the  action  of  P-gp,  which  incorporates  these  
ideas,  is  shown  in  Figure  2.  (32).  The  first  feature  of  this  
mcchanism  is that  drugs can  be detected  and expelled  as they 
enter  the  plasma  membrane  in  the  manner  of  a  hydrophobic  
vacuum cleaner. Anticancer drugs with a hydrophobic domain 
and  a  positively  charged  domain  demonstrate  diffusion  into  
and  across  the  plasma  membrane,  where  they  encounter  the  
multidrug  transporter  by  lateral  diffusion. The  transporter  
uses energy  transduced  from two essential  ATP binding sites  
to  pump  the  drug  out  of  the  membrane  (91).  The  
hydrophobic metabolic product, produced  in the cytoplasm or 
in  the  membrane,  is  shown  as  a  potential  substrate  for  the  
e  transporter.  One  pathway  of  drug or  metabolic  efflux within 
the transporter  is shown for simplicity, but there  may be more 
than one (92).  
Methods  of MDR1  detection  
The  dctcction  of  multidrug  rcsistancc  has  both  thcorctical  
and  clinical  significance. These  approaches  include  assessing  
MDRI  gene  amplification,  measuring  MDR1  mRNA  levels  
and  delecting  P-gp.  General  methods  for  detecting  MDRI  
genes in tissues are shown in Table III. 
A  number  of  monoclonal  antibodies  are  available  for  the  
dctcction  of  P-gp. The  monoclonal  antibodies  C219  used for 
both  immunoblot  analysis  and  immunochistochcmical  
dctcction  of  P-gp  is  nonspecific.  Another  antibody  C494  is  
specific for P-gp. This antibody  also  rccognizcs a  cytoplasmic  
epitope  and  thus  requires  fixation  prior  .  to  
imtnunohislochemical  staining.  Antibody  MRK-16  has  high  
affinity for  P-gp.  MRK-16  rccognizcs  an  external  epitope  on  
the outer  surface of  the  plasma membrane  of  living cells  and 
it  does  not  require  prior  fetation. The  primary  advantages  of  
inimunohistochcmistry  in  the  clinical  setting  include  the  
ability  to  discriminate  P-gp  expression  in  normal  cells  
compared  to  tumor  cells.  Immunohistochemistry  is  sensitive  
enough  to  detect  low-level  expression  of  P-gp.  Polymerase  
chain  reaction  is  probably  the  most  sensitive,  rapid  and  easy  
means  of  delecting  MDRI  mRNA.  It  is  possible  lo  analyze  
the most minute clinical specimens for diagnostic purpose. 
Clinical  relevance of reverse multidrug  resistance  
After  the  discovery  that  the  P-gp  molecule  can  be  expressed  
in  human  tumors,  clinical  trials  have  been  initialed  with  (he  
aim to block the P-gp drug efflux pump and  in thai  way make 
anticancer  drugs  more  effective  (93).  Large  numbers  of  
compounds  have  been  noted  to  overcome  P-gp  mediated  
multidrug rcsistancc (Table  IV).  
Chcmoscnsitizers  in  general  arc  lipid-soluhlc  at  
physiological  pH  and  possess  a  basic  nitrogen  atom  and  two  
planar  aromatic  rings  at  least.  The  calcium  channci  blocker  
verapamil  is  able  to  overcome  P-gp  mediated  multidrug  
rcsistancc  to  vincristine  and  doxorubicin,  both  in vitro and in 
vivo.  Verapamil  is  capable  of  overcoming  clinical  drug  
rcsistancc,  but  .  cardiotoxicily  has  heen  close-limiting.  
Cardiotoxicity  induccd  by  verapamil  may  he  rcduccd  by  
specific stereoisomers.  Both  the  R  and  S  optical  isomers  of  
verapamil  arc  equally  cffcclivc  jn  reversing  multidrug  
resistance,  but  the  R  isomer  is  10 times  less cardiotoxic  that  
the  S isomer.  Clinical studies arc currently  underway with  R-
vcrapamil  as a chcmoscnsilizcr,  and  likewise the  immunosup-
pressive  drug  cyclosporinc  and  its  non-immunosupprcssivc  
analogue SDZ PSC 833. 
The role of stereoselectivity 
Chiral  anticancer  drugs  exist  „since  pharmacological  
differences  have  been  found  between  stereoisomers.  The  
single  isomers  of  leucovorin,.  isophosphamidc  buthioninc  
sulfaximine  and  verapamil  are  used  in  medical  practice  with  
better  results  than  the  raccmic  forms,  however  the  role  of  
chirality  was  not  properly  analysed  (94,95)  in  the  reversal  
effect of drugs on the mdr. Despite similar drug targets  in the 
cancer  cells,  the  50  %  inhibitory  concentration  ,of  various  
anthracyclines,  vinca  alkaloids,  podophyllotoxins,  topoisomc-
rasc  inhibitors  and  antibiotics  varied  to  a  great  extent  in  
multidrug resistant  and sensitive cancer cells (96). 
In  the  multidrug  resistant  cancer  cells  the  efflux-pump  
mechanism  is  responsible  for  treatment, failures,  therefore  
inhibition  of  the  efflux mcchanism  may  result  in  an cffcclivc 
anticancer  chemotherapy.  However,  we have to consider  that  
normal  cells  also  contain  ABC  transporters  e.g., to  function  
for  detoxification.  To  avoid „toxic;  side  effects  of  novel  
resistance  reversal  compounds, we, need  drugs  with  selective  
'  •  -  I •  *  •  »  111»"  lAf  •  r  4  .  (  
inhibition  of  the  mdr  efflux-without, any  cffects .on-ABC 
transporters  with  physiological Junction  in  cancer  cells.  To  
achieve  this  effect thrce  classes  of  known  neuroleptic  drugs  
with  active  and  inactive  stereoisomers  were  tested  for .mdr 
efflux inhibition  and  antiproliferative effects on  sensitive, and 
multidrug  resistant  cancer  cell  cultures,and.the  results  were  
compared  with  verapamil  as .a  classic,,resistance  modifier.  
Before the reversal of multidrug resistance, the  ID50 values of 
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1: Verapamil  5  pg/mL; 2:  (-)Butaclamol  0.5; 5 pg/mL; 3:  (+)Butaclamol  0,5;  5 pg/mL;  4:  L-methotrimeprazine  
0.5;  5  pg/mL;  5:  D-methotrimeprazine  0.5;  5  pg/mL;  6:  Trans(E)-clopcntixol  0.5;  5  pg/mL;  7:  Cis(Z)-
clopenthixol  0.5; 5 pg/mL 
Figure  3.  The  effect  of  butaclamol,  methotrimeprazine  and  clopenthixol  isomers  on  the function  of  MDR  efflux  pump  in mouse  lymphoma  cells.  
the  compounds  were  determined  and  it  was  found  that  the  
parent  cell  line,  having 30 % higher  IDso, was less sensitive  to  
the  stereoisomer  pairs  than  the  multidrug  resistant  cell  line.  
However,  we  have  to  consider  that,  for  the  determination  of  
antiproliferative  effect,  a  much  smaller  number  of  cells  is  
treated  for  a  much  longer  time  than  for the  determination  of  
reversal  of the MDR efflux-pump. 
The  effect  of  three  different  pairs  of  stereoisomers  was  
studied  on  the  activity  of  MDR-glycoprotein  of  mouse  
lymphoma  cells  (Figure  3.).  The  levo-  and  dextro-
methotrimeprazine  enantiomers  had  nearly the same effect by 
inhibiting  the  efflux-pump  activity  of  mdr  P-gp  in  mouse  
lymphoma  cells.  The  results  show  that  the  two  enantiomers  
do  not  differ  significantly  in  the  reversal  of  multidrug  
resistance. 
The  second  pair  was  the  butaclamols  derivatives.  An  
interesting  relationship  was  found  between  mdr-reversing  
effect  and  molecular  configuration  of  the  butaclamol  
stereoisomers.  In  the  experiments  the  concentration  
dependent  inhibition  of  stereoisomers  on  the  efflux  pump  
were  compared.  (-)Butaclamol  was  more  effective  than  the  
biologically  important  (+)butaclamol  enantiomer.  The  data  
indicated  that  there  are  no general  rules for  structure-activity  
relationships  in  the  inhibition  of  mdr  efflux pump  activity  by  
tricyclic compounds. 
The  third  stereoisomer  pair  concerns  the  clopenthixols.  
The  cis-  and  trans-clopenthixol  had  similar  inhibitory  effects  
on  the  mdr  efflux-pump  of  mouse  lymphoma  cells  if  results  
were compared  to verapamil  as a control.  
The  (-)  isomer  of  verapamil  is  10-fold  more  potent  as  a  
calcium  antagonist  than  the  (+)  isomer,  however  both  
enantiomers  were  reported  as  equally  effective  in  increasing  
cellular  accumulation  of  anticancer  drugs  (97).  The  
enantiomers  of  phcnylalkylamines  are  equally  potent  in  
inhibiting  drug  transport  by  P-gp  (98).  However  the  potency  
of  vinca  stereoisomers  in  both  wild  type  and  mdr  cells  was  
dependent  on  the  substituents  of  stereoisomeric  form  due  to  
modulations  of  cytotoxicity  of  vinblastine  (99).  When  the  
stereoisomers  of  verapamil  and  cyclosporins  were  compared  
on  P-gp  mediated  efflux and  NK  cell  mediated  cytolysis,  the  
verapamils  were  more  potent  inhibitors  of  cytolysis  than  the  
cyclosporin.  On  the  contrary,  cyclosporins  were  more  
effective for  inhibiting  P-gp  mediated  rhodamine  efflux than 
the verapamil  isomers  (100).  
The  CNS  active  and  inactive  members  of  butaclamol  
enantiomers  differed  in  MDR-reversal  very  much,  that  
means  that  the  drug  binding  has  some  cnantioselectivity  
on  the  P-gp.  On  the  other  hand,  the  similar  effects  of  
levo-  and  dextromethotrimeprazine  provide  evidence  
against  the  enantioselective  inhibition  of  the  drug  efflux  
pump. 
How can  the  two different examples  of  enantiomer  effects  
be  exploited  ? The  CNS  inactive  enantiomers  were  inhibitory  
in the  case  of  methotrimeprazine  and  butaclamol.  Therefore,  
the  mdr  reversing  effects  of  CNS  inactive  members  of  
enantiomers  can  he  exploited  in  neoadjuvant  chemotherapy  
of  cancer  to  increase  the  effectiveness of several  cytostatics  in  
multidrug  resistant  cancer.  The  remarkable  inhibitory  effect  
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of (-)butaclamol may be due to the higher log-P value, i.e., the 
increased  lipophilicity.  
. Surprisingly,  the  stable  stereoisomers  of  clopenthixol  had  
similar concentration-dependent  inhibition on the mdr efflux 
mcchanism;  again cvidcncc for the  lack of stereospccificity in 
drug  binding  of  cancer  cells  (101).  On  the  contrary,  the  
normal  cells  in  the  CNS  (  102),  in  the  heart  (97),  bacterial  
plasmid  replication  inhibition  of  ATPase  or  cholincsterase  
enzymes  (103), stereoselectivity  and  configuration  of  tricyclic  
compounds is essential  (102).  
Cis-clopenthixol  inhibited  the  dopamine stimulated  adenyl  
cyclase  10-fold compared  to  the  trans  isomer.  In  the  case  of  
mcthotrimeprazine  enantiomers  a  significant, stereoselective 
effect  was  observed  on  dopamine  and  5-hydroxytryptaminc  
receptors,  whereas  the  opiate  receptors  did  not  discriminate  
between the levo- and dextrorotatory isomers (104). 
The  basis  of  selectivity  of  some stereoisomers  may be  due  
to a rigid configuration of the reccptor sites. Another  concept  
is  that  the  individual  members  of  stereoisomer  pairs  have  
different  energy  levels  for  binding.  Indeed,  the  cis-
stcrcoisomer  has  a  more  stable  configuration  with  a  lower  
energy  level  than  the  trans-form  of  clopenthixol.  The  
differences  in  the  energy  levels  in  the  excited  state  can  be  
even higher  (105).  
Based on the relatively  high concentration  of drugs used in  
our  experiments,  potential  non-specific effects was  suggested  
via  interactions  at  various  drug  receptors.  As  an  example,  
sigma  rcccptors  have  high  affinity  binding  sites  for  several  
psychotropic  drugs.  Similar  sites  arc  located  not  only  in  the  
CNS  but  also  occur  in  various  peripheral  tissues.  The  
overexpression  of  these  receptors  is found  in  human  tumors  
(106).  Different  neuroleptic  compounds  affecting  sigma  
receptors  produced  changes  in  cell  morphology.  Some  
neuroleptics lacking sigma affinity such as (+)butaclamol  and  
clozapine  had  no  effect  on  ccllular  morphology  (107).  
However,  (-)butaclarnol  exhibited  morphological  changes  
resembling apoptosis. The binding sites are distinguishable by 
their affinity for stereospecific ligands (108). 
The  (+)butaclamol  has  a  high  affinity binding  site  on  the  
dopamine  D2 receptor  (109)  while  the  (-)butaclamol  was  30 
times  less  active.  Interestingly,  the  (-)enantiomer  was  more  
active  in  the  reversal  of  the  MDR  efflux-pump  than  the  
(+)butaclamol,  which  means  that  the  MDR  reversal  effect  
was  not  mediated  by  D2-like  structures,  but  probably  
mediated  by sigma  rcccptors.  5-Hydroxytryptamine  reccptors  
are  suggested  to  play  a  role  in  certain  neuroleptic  disorders;  
the  therapeutic  effect  of  (+)butaclamol  and  clozapine  is  
localized on 5HT receptors  by inhibiting some effects of 5HT. 
However  the  (-)butaclamol  and  (-)propranolol  were  less  
effective (1,10). 
Considering the role of D4 reccptors or D ~ -like structures 
on  the  mdr  glycoprotein,  we can  exclude  D4 specific binding 
on the P-gp because dopamine receptor antagonists showed a 
high affinity to  the reccptor  with  a rank order  of  haloperidol  
>  chlorpromazine  >  (+)butaclamol  >  (-)butaclarnol.  The  
Tabic  V. Influence  of  anti-psychotic  tlrugs on 
as P-g/> substrate, into PBL  of patients. 
the  uptake  of  daunombicin.  
Antipsychotic Cone. Relative fluorescence  intensity  
drugs |ig/ml Patients: 
SzL PL  NV  
Amitriptilinc 1 - -
5 1.48 1.39  1.1(1  
Fluphenazine 1 - -
5 1.24 1.53  0.90  
Maprotiline 1 - -
5 1.86 1.32  1.03  
Trimipramine 1 
5 1.53 
-
Dcsipraminc 1 
5 1.65 
0.90 
Imipramine 1 - -
5 1.42 1.00  I.0Ü  
Haloperidol J - -
5 1.44 1.37  0.98  
Cyclosporin  A  .5 1.39 1.32  0.90  
(+)butaclamol  bound  to  D4  receptors  in  a  stereoselective  
manner,  showing  higher  affinity  than  its  respective  (-)  
enantiomer.  The (+)  enantiomer  was found  to be  nearly  20-
fold  more  effective  than,  (-)butaclamol  (111).  The  lack  o,f  
dopamine  receptor  specific  stereospecificity  of  mdr-reversal  
excludes  the  involvement  of  D2 and  D^like  binding  sites  on  
the  P-gp;  rather  our  results  refer  to  the  sigma  receptor  
involvement  for  drug  binding  responsible  for  inhibition  of  
drug efflux in the tumor cells. 
When  mdr  cells  were  exposed  to  tricyclic  stereoisomers  
with lipophilic characteristics the drug resistance was reversed 
due  to  the  inhibition  of  the  efflux-pump  system.  However,  
down-regulation  of  the  mdr  gene  was  also  found  in  some  
cases (112,113). It was interesting that  the effect of verapamil 
stereoisomers  had  no  substantial  difference in  the  potencies  
of (+)  and  (-) enantiomers  in reversing the mdr efflux pump 
(98), and  in accelerating clearance (114).' 
The  enantioselective  mdr-reversal  effect  of  the  pharma-
cologically  inactive  (-)butaclamol '  may  be  exploited  in  
combination  chemotherapy:  based  on  the  different  lipo-
philicity of the two stereoisomers. 
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Anti-psychotic  drugs  reverse  multidrug  resistance  of  tumor  
ccll  lines and human AML cells  ex  vivo  
Several  compounds  arc  in  clinical  trials  for  modulation  of  P-
gp related  resistance  in cancer  (27). It  is now not  uncommon  
to  use  antipsychotic  drugs  in  canccr  patients  (115,117).  The  
concomitantly  used  canccr  chcmothcrapcutic  and  anti-
psychotic  drugs  may  alter  each  others  pharmacokinetics  in  
canccr  patients.  If  the  anti-psychotic  drug  also  affects  P-gp  
function  then  the  pharmacokinetics  of  the  anticancer  drugs  
may change  in canccr  cells,  and  also pass through  the  blood-
brain barrier  (118).  
Tricyclic antipsychotic  drugs were  shown  to  exert  a variety 
of  biological  effects at  the subcellular  and cellular  levels.  For  
example,  chlorpromazine  (CPZ),  trifluoperazine  and  
clozapine  inhibit certain  proteases, acetylcholine esterase  and  
affect Ca2+  metabolism  (119).  
Fluphcnazinc,  a  phcnothiazinc  type  antipsychotic  drug,  
some  of  its  analogues  (120),  butaclamol  stereoisomers  (101)  
and  the  chemically  related  thioxanthene  type  compounds  
(121),  were  shown  to  inhibit  P-gp  function  in  some  MDRI  
gene  expressing  ccll  lines.  Most  of  these  tricyclic-  and  other  
antidcprcssivc  drug  molecules  arc  lipophilic  and  possess  a  
positive  charge  due  to  their  terminal  chain  nitrogen  atom.  
These  chemical  characteristics  were  shown  to  be  important  
for  agents  which  affect  the  function  of  P-gp  (14,31).  
Prochlorperazine,  the  tricyclic antiemetic  drug, was shown  to  
be effective as a resistance modifier  in phase  I clinical  studies  
(122). 
c  For  the  above  reasons  we  studied  the  effect  of  some  
antipsychotic  drugs  on  the  function  of  P-gp.  In  our  study,  
wc  used  the  transfecled  leukemia  cell  lines  L1210  MDR,  
L5178 MDR  and  the  human  adenocarcinoma  ccll  line  KB-
V-l  and  peripheral  blood  lymphocytes  obtained  from  
leukemic  patients.  Treatment  of  L1210  MDR  cells  with  
cyclosporin  A  (CsA),  (5  pg/mL),  a  known  P-gp  blocker,  
increased  the  relative fluorescence intensity about  7-fold in 
the  L1210  MDR  cells.  All  tested  antipsychotic  drugs  
increased  the  relative  fluorcsccncc  intensity  in  L1210  
MDR  cells,  halopcridol  and  fluphcnazinc  being  the  most  
active.  In  the  L5178  MDR  ccll  line  fluphcnazinc  and  
maprotilinc  were  the  most  effective compounds.  None  of  
the  tested  drugs  changed  significantly  the  rhodaminc  123  
uptake  into  the  parental  cells.  Similar  results  were  
obtained  with  KB cells  when  daunorubicin  (DR)  was  used  
as a fluorescent substrate  (123).  
In  these  experiments  DR  was  used  as  fluorescent  
substrate  of  P-gp,  since  it  was  also  used  as  chcmo-
thcrapcutic  agent  in  patients.  The  antipsychotic  drugs  
increased  the  relative  fluorescence  of  KB-V-1  but  not  of  
the  KB-3-1  parental  cells.  The  increase  .was  close  to  that  
with  CsA,  the  known  P-gp  blocker,  for  amitriptyline,  
fluphcnazinc  and  halopcridol.  However,  efflux of DR from 
KB-V-1  cells  was  not  blocked  to  the  same  extent  as  in  the  
L1210  MDR  and  L5178  MDR  cells  relative  to  CsA.  We  
attributed  this  lack  of  correlation  between  the  three  ccll  
lines  to  the  fact  that  wc  used  different  substrates,  
rhodaminc  123 and  DR with  the  L5178,  LI 210 and  the  KB  
cells,  respectively,  which  fact can  contribute  to differentia! 
sensitization  with  CsA.  It  was  shown  previously  that  some  
P-gp blockers  may exert  their  effects indircctly  through  the  
plasma membrane without  being a substrate  (124).  Because  
of  the  demonstrated  blocking  effect  of  the  tested  
antipsychotic  drugs  on  P-gp,  these-drugs  were  tested  in  
peripheral  blood  lymphocytes  (PBL)  of  drug  treatment  
resistant  patients,  using  DR  as  fluorescent  substrate.  
Relative  to  LI210 MDR,  L5178MDR  and  to  KB-V-1  cells,  
CsA had  a small  effect on  DR efflux in  PBL of  the  patients  
SzL  and  PL.  However,  most  of  the  tested  antipsychotic  
drugs  had comparable  effects to CsA  in  PBL  in  both  of  the  
patients  (Table  V).  
Cells  from  acute  myeloid  leukemia  (AML)  patient  NV,  
although  resistant  to  treatment  in  the  clinic,  could  not  be  
sensitized  by  CsA  or  with  the  antipsychotic  drugs  for  
uptake  of  DR  (Table  V).  The  reason  for  the  difference  
among  the  three  PBL  for  sensitization  could  not  be  
established.  However,  some  basic  information  can  be  
obtained  for  example  by  mAb  staining.  Future  inve-
stigations  arc  planned  to  include  more  detailed  chara-
cterisation  of  clinically  resistant  AML  cells,  which  do  not  
respond  to P-gp blockers. 
Antipsychotic  drugs arc  used  at  blood  levels  of  10 to  500  
ng/mL,  depending  on  the  drug  used  and  on  the  sensitivity  
of  the  patient  (121,125).  A  double  concentration  of  the  
highest  clinical  blood  level,  1  )ig/mL,  showed  small  but  
significant  blocking  of  P-gp  in  L1210  MDR,  L5178  MDR  
and  KB-V-1 cells.  PBL  of  the  patients  could  not  be  tested  
at  a  1 pg/mL  dose  level,  due  to  an  insufficient  amount  of  
blood  samples.  However,  based  on  results  with  CsA  at  a  
comparable  dose  level,  5.  pg/mL,  it  was  expected  that  
uptake  of  DR  into  PBL  wpuld  be  enhanced  by  1 and  0.5  
pg/mL of some  of the antipsychotic  drugs.  
Taken  together,  the  results  obtained  with  the  use  of  the  
model  ccll  lines  L1210  MDR,"L5178  MDR  and  KB-V-1  
and  the  fluorescent  indicator  R  123  and  DR,  we.showed  
that  the  clinical  anti-psychotic  drugs  , may  significantly  
modulate  the  uptake  of  substrates  ofrP-gp into MDR  cells.  
We  have  also  tested  this  possibility  in  a:pilot,study,  using  
PBL  prepared  from  the  blood  of  drug  resistant  leukemic  
patients.  Resistance  was  based  on  clinical  experience  and  
was verified on  PBL  by the effect of  CsA on  the  uptake  of  
DR.  In  these  PBL  cells  wc  epmpared  the  effects  of  the  
antipsychotic  drugs with  that  of,CsA for the  uptake  of.DR,  
the drug  used  for the treatment  of  two of  the patients.  The  
ex- vivo  results  indicated  that  treatment  with  some  of  the  
antipsychotic  drugs changed  as much  in DR  uptake  as  CsA 
does in  two out  of three patients'. PBL. Our  results point  in  
the  direction  of  necessary ( pharmacological  studies  when  
antipsychotic  drugs  and  cancer, chemotherapcutic  agents  
are  used  together  in  multidrug  resistant  cancer  patients.  
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Other  possibilities  may  exist  to  overcome  multidrug  
resistant  malignancies  such  as  the  administration  of  
differentiation  inducers,  apoptosis  inducers,  vaccination  
against  the  tumor  cells  or s o m e  thermodynamic  approaches.  
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Effects of Naturally Occurring Glucosides,  Solasodine  Glucosides,  
Ginsenosides  and Parishin Derivatives on Multidrug Resistance  of  
Lymphoma Cells and Leukocyte  Funtions  
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Abstract.  Solamargine,  solasonine, ginsenosides and parishin-
related  compounds  were  investigated  for  their  effects on  mdr  
efflux pump  of lymphoma cells,  and their effects on  T cell proli-
ferative assays and  cell mediated  immune functions, antibody-
dependent cellular cytotoxicity  (ADCC)  and natural killer (NK) 
cell  activity  of  human  peripheral  mononuclear  cells.  Sola-
matgine and solasonine were the only drugs which inhibited all 
of the tested immune functions; however, ginsenoside Rc and Rd 
enhanced T cell proliferative assays and marginally increased the 
NK cell activity.  The majority of the compounds  were not able 
to  reverse the  multidrug resistance of  mouse  lymphoma cells. 
However,  ginsenosides Rc,  Rd  and  parishin  C  were  able  to  
moderately reduce the activity of the ejflux pump.  Parishin, pari-
shin  C  and  crude  extract significantly enhanced  the  ADCC  
reaction. 
The  combination  of  different  in  vivo  and/or  in  vitro  assay  
systems  was  recently  recommended  for  enhancing  the  
screening  of  bioactivc  compounds  and  for  the  quick  and  
reliable  deduction  of  pharmacological  mechanisms.  Pre-
viously,  we  found  several  pharmacological  activities  of  
naturally  occurring  compounds  such  as  an  inhibitory  activity  
against skin tumor promotion  (crocin  and crocctin  derivatives  
from  Crocus saliva)  (1)  and  membrane  associated  antitumor  
activity (ginsenosides,  crocin and  marihuana  compounds)  (2).  
In  continuation  of  our  investigation  of  bioactivc  natural  
resources,  we  did  a  preliminary  survey  of  several  glycosides  
with  the  use  of  a  multidrug  resistance  assay  system  using  
lymphoma  cells  and  leukocyte  functions (3)  and  focused  our  
interest  in  three  kinds  of  glycosides:  solasodine  glycosides,  
Correspondence  to:  Livia  Berek,  Blood  Transfusion  Center,  
Albert  Szcnt-Gyorgyi  Mcdical  University,  Pecsi  u.  4/b,  Szeged  
6721,  Hungary.  
Key  Words:  mdr-rcvcrsal,  glycosides,  immunomodulating  cffcct,  
ADCC,  NK  reaction, blast  transformation.  
ginsenosides  and  parishins.  These  three  types  of  glycosides  
arc  important  traditional  Chinese  medicines  used  as  tonics  
which  also  possess  some  antitumor  activities  (4,5)  although  
some  of  the  derivatcs'  biological  and  pharmacological  activi-
ties arc not yet  known.  
So  far, no  data  has  been  reported  in  the  literature  on  the  
effect on  transmembrane  signal  and  cancer  cells.  Therefore,  
we  studied  the  effects  of  solamargine,  solasonine,  ginse-
nosides  and  parishin-rclatcd  compounds  on  several  leuko-
cytes functions and on  the  reversal  of  multidrug  resistance  in  
lymphoma  cells.  The  immunomodulating  effects of  the  three  
different  types  of  glycosides  mentioned  above  were  investi-
gated  on  human  peripheral  blood  mononuclear  cells  (PBM).  
The  criteria  we  used  were  lymphocyte  blast  transformation  
activity, antibody dependent cellular cytotoxicity (ADCC) and 
the natural  killing activity. 
Materials and  Methods  
Compounds.  Ginsenosides  Rc,  Rd,  Re  and  Rgl  were  isolated  front  the  
white  ginseng  by  repeated  column  chromatography  on  silica  gel  as  
previously  reported  (6).  They were directly  identified with  the  authcnic  
samples.  Fruit  of  S.khasianum  was  obtained  from  the  herbal  garden  of  
the  Faculty  of  Pharmaceutical  Scicnccs,  Kyushu  University,  Japan,  and  
solasonine  and  solamargine  were  isolated  as  previously  described  (7)  
(Figure  1).  Tuberous roots of  Gaslrodia etala were ground and  extracted  
3 times with 70% McOH.  The combined solution  was evaporated  under  
released  pressure  to  give  the  crude  cxtract.  After  partition  of  crude  
extract  between  I-f20  and  organic  solvent,  the  aqueous  layer  was  
repeatedly purified on MCI gel CHP 20P using H 2 0-Mc0H  mixture us a 
solvent  to  give  parishin,  parishin  B  and  parishin  C,  respectively  (Figure  
2).  All  chemicals were  of  analytical  grade  and wr;e  supplied  by  Merck  
(Darmstadt,  Germany),  Pharmacia  (Uppsala,  Sweden)  and  Sigma-
Aldrich  Kft.  (Budapest,  Hungary).  The  compounds  were  dissolved  in  
DMSO and  final concentrations were 1 .0 ,5 .0 ,10  pg/ml, respectively  in  
all  triplicate  test  cultures.  Both  control  cultures  and  test  cultures  
contained DMSO in the same  concentration.  
Isolation  of  mononuclear  cells.  Human  peripheral  blood  mononuclear  
(PBM) cells were  isolated  from healthy  blood donors  by  Ficoll-Uromiro  
gradient  ccntrifugation.  The  cells  were  washed  and  resuspended  in  
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Figure  1. The  chemical  structures  of  solasodine  derivatives.  
RPMI-1640 medium  supplemented  with  10%  fetal  calf  serum,  100  IU/ml  
penicillin,  100  nig/ml  streptomycin  and  2 mM  L-glutamine.  To  provide  
monocytc-free (PBM-Mo-)  samples,  the  freshly drawn  heparinized  blood  
was  treated  with  carbonyl  iron  powder  at  37° C  for  5  minutes  and  then  
the  lymphocytes  were  isolated  on  Ficoll-Uromiro  gradient.  
The  viability  of  the  cells  with  the  drugs  was  determined  by  trypan  blue  
indication  after 4 hours  incubation  (8).  
Lymphocyte  blast  transformation  (T  lymphocyte  proliferation  assays).  
Mononuclear  cells  were  routinely  cultured  in  flat-bottomed  Greiner  
microliter  plates  at  2xl05  cells  (0.2  ml/well).  The  triplicate  cultures  
containing  the  drugs  were  incubated  in  the  presence  or  absence  of  
mitogens:  P l lA  1:200  diluted  stock  solution,  Con  A  5  pg/ml  in  a  CO2  
incubator  for  72  hours.  For  the  determination  of  lymphocyte  DNA  
synthesis,  0.5  pCi  H-thymidine  was  added  to  all  cultures  for  the  last  5  
hours  and  the  cells were  collected  on  GFC  filter  paper.  The  amount  of  
radioactivity  incorporated  was  determined  in  a  liquid  scintillation  
counter.  The  results  were  calculated  as  the  difference  in  cpm  between  
the  incorporated  activity  of  transformed  cells  and  control  cells  (without  
mitogens)  and  the  results were  expressed  as the  %  of control values  (9).  
Antibody  dependent  cellular  cytotoxicity  (ADCC)  test.  Human  O  Rh-
positive  red  blood  cells were  used  as  a  target  and  PBM  Mo"  cells  as  an  
effector  in  a  1:10  ratio.  The  reaction  was  mediated  by  red  blood  cell  
specific anti-D  antibodies.  The  cultures  were  incubated  at  37  °C  for  16  
hours  and  the  amount  of  released  Cr  in  each  supernatant  was  
determined  using  a  gamma  counter.  From  the  average  of  triplicate  
released  values,  the  percentage  of  cytotoxicity  was  calculated  according  
to  the  following formula  (10):  
j cytotoxicity =  lOOx  
test  51 Cr  release  -  spontaneous  5 1Cr  release  
maximum " C r  release  - spontaneous  5 l Cr  release  
;H2—COORj 
HO^ -C—C00R2 
3  ,H2—COOR3  
1.  Rj-R2"R,R3-H  ( P a r i s h i  
2.  R i " R 2 h R , R 2 » H  ( P a r i s h i  
3.  R ^ - R a - R  ( P a r i s h i  
Figure  2.  The  chemical  structures  of parishin  derivatives.  
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Spontaneous  release  indicated  cultures  without  anti-D  antibody.  The  
results were expressed  in percent  of control  cultures.  
Natural killer cell activity (NKassay).  3,Cr-labellcd  K562 cells (used as the 
target)  and  PBM  cells  (used  as  the  effectpr)  were  mixed  in  a  ratio  of  
1:50.  After  incubation  at  37*C for 4  hours,  the  amount  of  radioactivity  
released  into the culture supernatants  was determined.  The  results  were 
expressed as the percentage  of cytotoxicity, as described above (11). 
Reversal of  multidrug  resistance.  The  L5178 mouse T  cell  lymphoma  cell  
line  was  infected  with  the  pHa  MDR1/A  retrovirus  as  previously  
described  (12).  MDR1  expressing  cell  lines  were  selected  by  culturing  
the  infected  cells with  60 ng/ml  colchicine  to  maintain  expression  of  the  
MDR  phenotypc.  The  L5178 MDR  cell line and  the L5178Y parent  cell  
line were grown  in McCoy's 5A medium with  10% heat-inactivated  horse  
scrum,  L-glutamine  and  antibiotics. The cells were  adjusted  to  a  density,  
of  2xl0A/ml  and  resuspended  in  scrum-free  McCoy's 5A  medium.  The  
cells  were  then  distributed  in  0.5  ml  aliquots  to  Eppendorf  centrifuge  
tubes. The  tested  compounds were added  in various concentrations  (0.2,  
20.0 pi)  from the  1.0 mg/ml  stock  solutions and  samples were  incubated  
for  10  minutes  at  room  temperature.  Then  10  pi  (5.2pM  final  
concentration)  indicator  Rhodamine  123 was added  to  the  samples  and  
the cells were incubated  for a further 20 minutes  at 37  *C, washed  twice  
and  resuspended  in 0.5 ml phosphate-buffered saline (PBS) for  analysis.  
The  fluorescence  of  cell  populations  was  measured  by  flow  cytometry  
using  a  Bcckton  Dickinson  FACSscan  instrument.  Verapamil  was  used  
as  a  positive control  in  the  Rhodamine  123 exclusion  experiments.  The  
percentage  of  control  mean  fluorescence  intensity  was  calculated  for  
parental  and  mdr  cell  lines  as compared  to  untreated  cells.  An  activity  
ratio  was  calculated  using  the  following  equation  (13)  on  the  basis  of  
measured fluorescence values: 
mdr treated  / mdr control 
R= 
parental treated / parental  control  
Results 
Cytotoxic  effccts  of  the  compounds  were  determined  by  
trypan  blue  exclusion  tests.  The  biological  effects  were  
studied at non-toxic concentrations. 
The  cell  viability  was more  than  95%  with  all  compounds  
(data  not  given)  and  the  reactions  were  calculated  on  viable  
cell  number.  The  immunological  effects  of  the  compounds  
were  tested  on  human  peripheral  blood  mononuclear  cells  
from different blood  donors  and  all compounds were  used  in  
different  concentrations.  The  data  obtained  from  four  
different  blood  donors  represented  a  single  experiment  and  
donor  to  donor  variation  was  not  significant.  Some  of  the  
compounds,  namely  ginsenoside  Rgl,  ginsenoside  Re,  
ginscnosidc  Rd  and  parishin,  were  able  to  reverse  the  
multidrug  resistance  of  tumor  cells  due  to  the  inhibition  of  
the rndr-1 mediated membrane efflux pump activity (Table I). 
The  inhibitory  activity  of  the  drugs  tested  on  T  cell  
proliferative  assays  was significantly stimulated  by PHA  and  
ConA  in  the  presence  of  1,  5  and  10  pg/ml  doses.  The  
exception  was  in  the  case  of  ginsenoside  Re  and  Rd,  which  
had  a  considerable  enhancing  effect  when  tested  on  blast  
transformations  and  this  effect  exhibited  dose-dependence  
(Figure 3). 
Results  of  the  ADCC  reaction  showed  slight  inhibitory  
Table  I.  Reversal  of  multidrug  resistance  by  solasodine  glycosides,  
ginseiwsides and ¡rarishins. 
Compounds  •  Cone, (pg/ml)  Fluorescence  activity  ratio  
PAR 
MDR 
VERAPAMIL 5 4.36' 
SOLAMARGINE 2 1.26 
20 (1.96 
SOLASONINE 2 1.19 
20 0.6 
GINSENOSIDE  Rc  2 3.03 
20 2.33 
GINSENOSIDE  Rd  2 3.19 
20 4.18 
GINSENOSIDE  Rc  2 1.83 
20 1.88 
GINSENOSIDE  Rgl  2 1.38 
20 1.57 
PARISHIN 2 1.54 
20 2.93 
PARISHIN  B  2 1.49 
20 1.17 
PARISHIN  C  2 2.10 
20 .1.34 
activities  in  the  case  of  1  |ig/ml  concentration  of  the  drugs  
(Figure 4).  Parishin,  parishin  C and crude  extract  had  a  low  
dose- dependent enhancing effect. 
The  immunomodulating  effect  of  solasoninc,  measured  
on  NK  cell  activity,  exhibited  a  dose-dependent  inhibitory  
effect  (Figure  5),  but  we  could  not  detect  any  real  immu-
nomodulating effect in the case of the other  compounds.  
Discussion 
In  the  present  study we  investigated  the  immunomodulating  
activities  of  three  types  of  glycosides,  dammarane-type  gly-
cosides:  (ginsenosides),  steroidal  glycoalkaloids  (solamarginc  
and solasonine)  and phenolic glycosides (parishin  and related  
compounds).  The  crude  drugs  which  contain  the  above  
glucosides  have been  used  as traditional  medicines,  but fun-
damental  questions  remain  unanswered  concerning  the  
nature  of  the  compounds,  and  their  roles  in  the  protective  
mechanisms.  Regarding  their  direct  effects  in  immune  
reactions, we  found that  all compounds affected the  immune  
functions of  human  peripheral  blood  mononuclear  cells,  but  
that effect was selective. 
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Figure  3.  A:  solamargine,  B:  solasoninc,  C:  ginsenoside  Rc,  D:  ginsenosideRd,  E:  ginsenoside  Re,  F:  ginsenoside  Rgl,  G:  crude  extract,  II:  parisliin,  1:  
parisliin  B, J: parisliin  C l)NA  synthesis  of  PHA-  and  Con  A-  stimulated  lymphocytes  were 25,300±  9/600  and  21,200±8,800  cptn,  respectively.  
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Figure  4.  A:  solamargine,  B:  solasonine,  C:  ginsenoside  Rc,  D:  ginsenoside  Rd,  E:  ginsenosideRe,  F:  ginsenoside  Rgl,  C:  crude  extract,  II:  pans/tin,  1:  
parishin  B,  J: parishin  C  The  taiget-effector  ratio  was  1:10.  The  basic  ADCC  activity  without  DMSO  was  43  %.  
Figure  5.  A:  solamargine,  B:  solasonine,  C:  ginsenoside  Rc,  D:  ginsenoside  Rd,  E:  ginsenoside  Re,  F:  ginsenoside  Rgl,  G:  crudeextract,  H:  parishin,  I:  
parishinB,  J: parishin  C.  The  target-effector  ratio  was  1:50.  The  basic  NK  cell  activity  without  DMSO  was  17%.  
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Solamarginc  and  their  related  compounds  were  
investigated  in  our  laboratory  lor  immunmodulatory  
functions and  the  reversal  of  multi  drug resistance (MDR)  in  
cancer  (14).  Solasonine  and solamarginc were the only drugs 
which  inhibited  all  tested  in  vilro  reactions  (  T  and  B  cell  
proliferations,  ADCC  and  NK  reactions)  and  the  effect was 
dose-dependent. 
Previous  studies  have  reported  that  ginseng  is  one  of  the  
most  important  Chinese  medicines.  It  is  used  to  enhance  
stamina,  increase  the  capacity  to  cope  with  fatigue  and  
physical  stress  and  as  a  tonic  for  cancers  and  immune  
functions.  The  mechanisms  of  ginseng's  actions  remain  
unclear, although  its pharmaceutical  properties arc  attributed  
to  the. ginsenosides  in  the  plant  (5,  6).  In  our  study  the  
ginseng  derivatives,  in  particular  ginsenoside - Re  and  Rd,  
enhanced  the T cell proliferative assays considerably.  Among  
the  studied  compounds,  ginsenoside  Rd  was  the  most  
effective compound with respect to MDR. The results suggest 
that  these  enhancing  effects  play  an  important  role  in  the  
mechanism of ginseng action. 
In  the  ADCC  reaction,  real  enhancing  effect  could  be  
detected  in the case of  parishin,  parishin  C and crude  extract.  
The  phenolic  glycoside  types  of  parishins were  isolated  from 
Gastrodia elata,  which  is  an  important,  traditional  Chinese  
medicine, used as a tonic.  Previous studies have reported  that  
some  of  these  compounds  inhibit  the  multiplication  of  plant'  
and  human  pathogenic  bacteria  (15)  and  viruses  (16,  17).  
These  enhancing  effect  of  parishin,  parishin  C  and  crude  
extract  in  the  ADCC  reaction  are  in  accordance  with  the  
natural defense mechanism against infectious diseases (18). 
In  our  experiments,  the tested  drugs  only slightly modified 
the  NK  cell  reaction,  which  plays  a  significant  role  in  
immunological  defense  reactions  against  malignancy.  The  
majority  of  compounds  had  some  toxic  effect  on  cancer,  
while,  some,  were  able  to  reverse  the  MDR  of  mouse  
lymphoma  cells.  The  weakest  compounds  in  these  respects  
were  solamarginc  and  solasonine  althougt  solamargine,  
solasonine, ginsenoside Re, parishin  B , parishin  C and  crude  
extract  had  sonic  toxic  effect  in  the  highest  applied  
concentration. 
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Abstract 
Two  3-benzazepines  ([5],  [10])  were  able  to  form  complex  with  replicative  form  of  
plasmid  DNA.  The  multidrug  resistance  {mdr)  P-glycoprotein  efflux  pump  of  mouse  
lymphoma cells  was inhibited  by three compounds  ([5],  [8],  [10]). The inhibitory  effects of 
compounds  on reverse  transcriptase  (RT) of Moloney  leukáemia  had  shown  a great  variety,  
however, the most effective compounds were [7], [8] and  [9].  
Introduction 
Antibiotic  resistance  of  bacteria  is  encoded  by  extrachromosomal  
DNA,  called  plasmids.  There  are plasmids  encoding ATP binding  cassette  
(ABC)  transporter  protein  which  have  a great extent  of  similarity  with  a P-
glycoprotein  (P-gp)  responsible  for  multidrug  resistance  {mdr)  of  cancer  
cells (Endicott  and  Ling,  1989).  The  emerging  drug  resistance  is  known 
Abbreviations:  7,8-Dimethoxy-2-methyl-3-methanesulfonyl-2,3,4,5-tetrahydro-3-benzazepin-l -one [1],  
7,8-dimethoxy-2-methyl-3-trifluoromethanesulfonyl-2,3,4,5-tetrahydro-3-benzazepin-I-one  [2],  3-
trifluoromethanesulfonyl-2,3,4,5-tetrahydro-3-benzazepin-l-one  [3],  7,8-dimethoxy-3-trifluoro-
methanesulfonyl-2,3,4,5-tetrahydro-3-benzazepin-l -one  [4],  7,8-dimethoxy-2-isopropyl-3-trifluoro-
methanesulfonyl-2,3,4,5-tetrahydro-3-benzazepin-l-one  [5], 7,8-dimethoxy-2-phenyl-3-trifluoro-
methanesulfonyl-2,3,4,5-tetrahydro-3-benzazepin-l-one  [6],  7,8-dihydroxy-2-trifluoromethyl-2,3,4,5-
tetrahydro-lH-3-benzazepine  [7],  7,8-dihydroxy-3-methyl-2-trifluoromethyl-2,3,4,5-tetrahydro-lH-3-
benzazepine  [8],  7,8-dihydroxy-2,3,4,5-tetrahydro-lH-3-benzazepine  [9],  7,8-dimethoxy-2-
trifluoromethyl-2,3,4,5-tetrahydro-lH-3-benzazepine  [10], dopamine  [DA, 11]; norepinephrine  [NE.  
12]. 
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among  viruses,  bacteria,  protozoa  and cancer cells  including drug  resistant  
retroviruses  such  as  human  immunodeficiency  virus  (HIV)  (Hamada  and  
Tsuruo,  1986;  Zamora  et  al.,  1988;  Kovács  et  al.,  1991;  Schäfer  et  al.,  
1993;  Swartz,  1994; Taylor  et al.,  1994; Artico  et al.,  1996;  Ecker  et  al.,  
1996; Hewlett  et al.,  1997; Suzuki etal.,  1997).  
In  addition,  retroviruses  can  exist  in  an  autonomous  state  and  behave  
like plasmids-before the integration into host cell chromosomal DNA. 
There  are evidences  that  antiplasmid  compounds  can form a  complex  
with plasmid DNA topoisomerase  and már P-gp, resulting in the reversal  of  
resistance. However, the majority of compounds do not block replication  of  
HIV  retrovirus  although  the  reverse  transcriptase  (RT)  and  integrase  were  
considered  potential  targets  for  inhibition  of  retrovirus  replication.  The  
search for novel agents has led to the synthesis  of some rare  phenothiazines  
(Motohashi  et al.,  1996) and 3-benzazepines  (Kawase  et al.,  1997;  Kawase 
etal.,  1998b).  
To  identify  the  standard  features  of  3-benzazepines  required  for  the  
biological  activities,  the  tetrahydro-3-benzazepines  were  subjected  to  
interact  with E. coli plasmid  DNA, már P-gp of lymphoma cells  and RT of  
Moloney leukaemia in model experiments.  
Materials and Methods 
Chemicals-The  following  six 2,3,4,5-tetrahydro-3-benzazepinones  [1-
6]  and  three  2,3,4,5-tetrahydro-17/-3-benzazepines  [7,  8,  10]  were  newly  
synthesized  as  recently  published  (Kawase  et  al.,  1997;  Kawase  et  al.,  
1998b).  Compound  [9]  was  synthesized,  vide  literature  (Pecherer  et  al.,  
1971).  [1]  (m.w.  313.38,  mp  165-166°C),  [2]  (m.w.  367.34,  mp  102-
103°C),  [3] (m.w. 293.26, mp 76°C),  [4] (m.w. 353.32, mp  158-160°C),  [5]  
(m.w.  395.40,  crystals),  [6]  (m.w.  429.42,  mp  175-178°C),  [7]  (m.w.  
328.13,  mp  223°C  (dec)),  [8]  (m.w.  297.70,  mp  215°C  (dec)),  [9]  (m.w.  
206.12, mp 241°C (dec)),  [10] (m.w. 275.24, oil). 
DA hydrochloride  [11] was purchased  from Sigma Chemical  Co.  (St.  
Louis,  MO,  U.S.A.).  NE  [12]  and  rhodamine  .  123  hydrate  (R123,  
lot#28394-0)  were purchased from Aldrich  Chemical Co. (Milwaukee,  WI,  
U.S.A.) (Table  1).  
DA  [11]) and NE  [12]) were used as controls and the compounds  were  
dissolved in 20% dimethylsulfoxide (DMSO) solution. 
Bacterial  strains.  
E.  coli  K12  pBR  322  bacterial  strain  was  applied  for  isolation  of  
plasmid DNA by agarose gel-electrophoresis  (Fig.  1).  
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Table  1. Structures  of  2,3,4,5-tetrahydro-l//-3-
benzazepines  [1-10]  and  two catechols  [11,12]  
used  in this studya).  
Ri 
Ri 
Ri 
N-R2  II  
Ri 
o 
DA  [11]  
NE [12]  
N-R2 
r 3 
[1-6] [7-10] 
Compound R. r 2 r 3 
[1] MeO Ms Me 
[2] MeO Tf Me 
[3] H Tf H 
[4] MeO Tf H 
[5] MeO Tf Me2CH 
[6] MeO Tf Ph 
[7] HO H c f 3 
[8] HO Me c f 3 
[9] HO H H 
[10] MeO H c f 3 
a)  abbreviations.  Me: CH3 Ms:  S02CH3;  
Tf:  S02CF3.  
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Fig.  1.  Effect  of  tetrahydrobenzazepines  on  pBR322  plasmid  DNA  from  E.  coli.  
(C-control;  ccc-covalently  closed  circular  form;  oc-open  circular  form;  lin-linear  
form; and  Frg-fragment of DNA 
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Antiretroviral  effect. Moloney murine leukaemia virus  (M-MuLV) RT 
assay. 
Trifluoperazine-metal  coordination  complexes  and  3'-azido-3'-
deoxythymidine  triphosphate  (AZT-TP) as a control  were assayed for their 
ability to inhibit M-MuLV RT (New England BioLabs). The assay  is based 
on  following:  the  poly-adenosine  phosphate  (rA)n,  oligo  deoxythymidine  
(dT) 12-18 (New England BioLabs) directed incorporation  of  deoxythymidine  
triphosphate  (dTTP)  (Amsterdam)  into complementary  DNA (cDNA). The 
10 x  RT buffer contains  500  mM Tris-HCl  (pH  8.3),  80  mM MgCl2,  300  
mM  KC1,  and  100  mAf dithiothreitol  (DTT).  In  all  experiments,  the final 
volume of the reaction assay was 20 jjL. This contained water, 2 pL of  10 x 
RT buffer, 20 pg/mL template-primer, 5 \iM dTTP precursor (New England 
BioLabs),  0.2  pCi  tritiated  precursor,  the  compounds  to  be  tested  
(administrated  into the medium before adding the enzyme)  and 5 units  (U)  
RT  initiating  the  reaction.  This  procedure  was  followed  by incubation for  
40  min  at  37°C.  15 pL  of  the  mixture  was  then  transferred  to  Whatman  
DE81 filter paper disc,  washed  by  5% disodium-hydrophosphate  buffer (3 
x  3 min), water,  then  96% ethanol,  and after drying  and putting  into  5 mL 
scintillation  cocktail  (OptiPhase  HiSafe 3',  Wallac),  the  radioactivity  was  
measured  by  Packard  Tri-Carb  2200  CE  liquid  scintillation  counter.  The  
residual enzymatic activities were compared to the control (no drug added).  
The  IC50 of AZT-AT was 0.12 pM in our experiments. 
Cell and fluorescence uptake, mdr reversal effect. 
The  L5178  mouse  T  cell  lymphoma  cell  line  was  infected  with  the  
pHa  MDR1/A  retrovirus  as  previosuly  described  (Aszalos  et  al.,  1995).  
MDR1  expressing  cell  lines  were  selected  by  culturing  the  infected  cells  
with  60 ng/mL colchicine  to  maintain  expression  of  the MDR  phenotype.  
The L5178 MDR cell  line  and  the L5178Y parent  cell  line were  grown  in  
McCoy's 5A tissue culture medium with  10% heat-inactivated horse serum, 
L-glutamine  and  2,3,4,5-tetrahydro-l//-3-benzazepines  [1-10].  The  cells  
were adjusted to a concentration  of 2 x  106/mL and resuspended  in  serum-
free  McCoy's  5A  medium  and  the  cells  were  distributed  into  0.5  mL  
aliquote  to  Eppendorf  centrifuge tubes.  Then,  the  tested  compounds  were  
added  in  various  concentrations  (0.2-20.0  pL)  of  the  1.0  mg/mL  stock  
solutions  and the  samples  were  incubated for  10 min  at  room temperature.  
Next,  10 pL (5.2 pM final concentration)  indicator  of rhodamine  123 were 
added  to  the  samples  and  the  cells  were  incubated  for further  20  min  at  
37°C, washed twice and resuspended  on 0.5 mL phosphate-buffered saline 
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(PBS)  for  analysis.  The  fluorescence  of  cell  population  was  measured  by  
flow cytometry  using Beckton  Dickinson  FACScan  instrument.  Verapamil  
was used  as a positive control  in the rhodamine  123 exclusion  experiments  
(Weaver  et  al.,  1993).  The  percentage  of  control  mean  fluorescence  
intensity  was  calculated  for  the  following  equation  on  the  basis  of  
measured fluorescence values. 
mdr  treatedImdr control R  —  
parential treated/parental control 
Complex formation  between benzazepines and plasmid DNA 
The  E.  coli  pBR322  strain  was grown  in  5 mL  yeast-extract-tryptone  
broth  (YTB)  in  presence  of  tetracycline  (100  pg/mL)  and  ampicillin  (25  
pg/mL)  at  37°C for  16 hours. The overnight  culture  was distributed  into 1 
mL aliquote  in  Eppendorf  tubes.  Benzazepines  were  added  to  the  plasmid  
containing  bacterial  suspension  in  200  pg/mL  final  concentration,  the  
samples  were  centrifuged  for  5  min  (3000  rpm)  and  the  supernatant  was  
discarded. The pellet was resuspended  in  100 pL of Sol I (lAf Tris-HCl, 0.5 
M glucose,  0.25 M ethylenediaminetetraacetic  acid (EDTA)),  homogenized  
in  vortex,  and  incubated  at  room temperature  for  5  min. Then,  200  pL  of  
Sol II (10 N NaOH, 20%  sodium dodecyl  sulfate (SDS))  was added  to the 
bacterial  suspensions, homogenized and incubated in water bath (0°C) for 5 
min.  Then,  150  pL  of  ice  cold  5  M  potassium  acetate  was  added  tq  the  
samples.  After  mixing,  samples  were  incubated  further for  5  min  at  0°C,  
then  centrifuged for  10 min  (3000 rpm). The  supernatant  was  treated  with  
200 pL  phenol  solution  and  200 pL  of chloroform: isoamyl  alcohol  (1:1).  
The  samples  were centrifuged for  1 min  (3000  rpm)  and  the  supernatants  
were precipitated  with  96% ethanol  and incubated  at room temperature for 
5  min  and  then precipitated  plasmid DNA was centrifuged for 5 min  (3000  
rpm).  The  supernatant  was  discarded  and  the  plasmid  DNA  was  washed  
with 70% ethanol. Then, ethanol  was discarded  and the samples  were dried 
at  37°C.  The  extracted  plasmid  DNA was  dissolved  in  20 pL  Tris-EDTA  
(TE)-buffer containing  RNAse  (20 pL/mL,  Sigma).  10 pL  of  the  RNAse  
treated  plasmid  DNA  solution  were  applied  to  1%  agarose  gel  (with  0.5  
pg/mL  ethidium  bromide).  Agarose  gel  electrophoresis  was  performed for 
20  min  (200 V).  The  various  forms of  plasmid  DNA  were detected  under  
UV lamp (Fluo-link).  
Results and Discussion 
In  the control  sample  [C], the covalently closed circular  (ccc) form of 
plasmid  DNA  runs  faster  than  the  linear  (lin)  form  and  the  two  
conformations  can  be  seen  near  to  each  other  (Fig.  1).  The  open  circular  
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(oc)  form  ran  slower,  relatively  far  from  linear  (lin)  form.  In  case  of  
2,3,4,5-tetrahydro-l//-3-benzazepine  treated  plasmid-containing  cells,  the  
oc form can be found in each sample. Similar  situation exists with  lin form. 
However,  compounds  ([5],  [10])  were able to form complexes  with the ccc 
form  of  plasmid  DNA.  The  results  showed  an  evidence  for  the  selective  
complex  formation  of  two  active  benzazepines  ([5],  [10])  with  the  
superhelical  form  of  plasmid  DNA,  meaning  that  this  biological  effect  is  
dependent  on the substituents of the benzazepine molecule.  
The  ccc  form  of  plasmid  DNA  is  maintained  by  bacterial  gyrase  
(topoisomerase)  which  can  be  inhibited  by  benzazepines.  Theoretically,  it  
is  also  possible  that  a  simple  interaction  of  two  benzazepines  ([5],  [10])  
leads  to  the  unwinding  of  ccc  form  into  the  oc  form,  which  is  due  to  a  
single nick introduced into one strand. 
Two compounds  ([5],  [10])  selectively  inactivate  the replicative form 
of plasmid  DNA that encode the antibiotic resistance (tetracycline (Tc)  and 
ampicillin  (Ap))  in bacteria. The DA  [11] and NE  [12] had no effects (data 
not shown). 
When  the  substituted  benzazepines  were tested  on the  P-glycoprotein  
efflux-pump of tumour cells, only a few compounds were active (Table 2). 
Mdr reversal on tumour cells 
The  mdr  reversing  effects  of  benzazepines  [1-10]  by  their  chemical  
structures  were  compared  to  that  of  verapamil,  using  a  mouse  leukaemia  
cell  line  (L-5178  cells).  The  effects were  measured  by  fluorescence  ratio  
between  treated  and  untreated  group  cells.  Compound  [8]  has  the  highest  
activity  on  mdr  reversal  (Fluorescence  activity  ratio  8.38)  among  12  
compounds used in this research  and compound  [8] was 2-fold more potent 
than  verapamil  (fluorescence  activity  ratio  4.18).  Then,  compound  [8]  
might  be  an  anti-mdr inducing  agent  of  great  interest,  because  the affinity 
of  [8] to two dopamine Di  and D2 receptors  was reduced by introduction  of  
trifluoromethyl  (CF3) group at 2nd position  of benzazepine ring (Kawase et 
al,  1998b).  
We  have  reported  that  benzazepines  [7],  [8]  and  [9]  induced  apoptic  
cell death  in human promyelocytic  leukaemia HL-60 cells and the cytotoxic 
activities  of  [7]-[9] were  1.3,  1.3 and 2.0 times higher than that  of DA  [11],  
respectively.  Additionally,  it  is  found  that  apoptosis  induced  by  these  
benzazepines  [7]-[9]  is  coupled  with  their  radical  generation  (Kawase  et  
al,  1998a).  
The  retroviruses  have  a  key  enzyme,  which  called  RT  that  is  
responsible for maintaining the virus multiplication,  the  transformation  of  
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RNA  encoded  information  into  DNA.  This  intermediate  stage  of  
retroviral  replication  was  effected  by  three  compounds  ([7],  [8],  [9],)  
(Table 3) (Figure  1).  
The  results  obtained  show  a  chemical  structure-dependent  effect  on  
RT  again.  The  active  benzazepines  inhibit  the  RNA-directed  DNA  
synthesis, however, the majority of the derivatives did not show remarkable 
Table 2.  The effect of 2,3,4,5-tetrahydo-l //-3-benzazepines [ 1-10]  and two analogues 
[11,12] on lymphoma 5178 cells with  multidrug resistance. 
Compound 
[No.] 
pare) control 504.86 184.75 775.68 3.03 1060.98 49.98 
mf/r+R123° control 552.95 211.52 340.48 1.33 -  21.23  1.00 
(±) verapamil  5  545.74 216.62 499.20 1.95 88.72 4.18 
Benzazepines: 
[1] 5 473.30 188.91 253.44 0.99 9.85 0.46 
[2] 5 425.16 205.05 325.12 1.27 18.69 0.88 
[3] 5 494.57 193.54 284.16 1.11 12.97 0.61 
[4] 5 467.29 188.79 309.76 1.21 16.39 0.77 
[5] 5 491.72 190.79 422.40 1.65 44.77 2:11 
[6] 5 507.50 197.30 291.84 1.14 13.89 0.65 
[7] 5 469.78 187.09 314.88 1.23 17.01 0.80 
[8] 5 447.77 191.53 576.00 2.25 177.91 8.38 
[9] 5 477.28 189.43 309.76 1.21 16.12 0.76 
[10] 5 507.71 198.41 373.76 1.46 "  28.68  1.35 
Dopamines: 
DA [11] 2 579.02 251.38 343.04 1.34 21.77 0.84 
20 571.20 251.12 350.72 1.37 23.47 0.93 
NE [12] 2 569.10 256.09 340.48 1.33 21.32 0.82 
20 564.14 254.11 330.24 1.29 19.53 0.80 
a) Ref: Kessel,1989; Weber et al.,  1994.  
b) x: Measured fluorescence value at linear scale [mg, uptake of R123]. 
c) The R-123 accumulation was calculated from fluorescence of one height value using 
1st equation 
log(y)=logI0  256  
then the fluorescence activity ratios were calculated according to the formula given below; 
£atj0  _  ([mdr  treated/mz/r control) 
(parental treated/parental control) 
d) (±)verapamil: a control for mdr reversal 
e) par: parental without multidrug resistant gene. 
f) mdr. parental with multidrug resistant gene. 
Concen-  Forward  Side scatter  Fluorescence one height3  Fluore-
tration  scatter  height  value  scence  
(Ug/mL)  height  [granulation  
[cell size of cell ratio]  xb  y  *  l o g ( y H o g  ^  
ratio]  4)6  10  "  ratio  
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Table 3. Inhibition  of Moloney murine leukaemia virus  rever  
transcriptase by 2,3,4,5-tetrahydro-l//-3-benzazepines  [1-10]  
In concentration  (10"sAi).  
Compound  Concen-  Activity  Activity  in  
(No.)  tration  ofcDNA  percentage  
(Pg/mL) (DPM)a) of  DMSO control  (%)  
DMSO  (control)  67401 100 
0.5 pL  DMSO/  54887 
20 pL  assay  50297 
.64784 
+  Control  83245 -
57408 
[1] 50 39352 88.2 
60832 
[2] 50 49649 89.1 
54104 
[3] 50 48949 80.4 
45591 
[4] 50 63098 112.6 
66862 
[5] 50 56214 98.7 
58153 
[6] 50 31249 72.1 
52950 
[7] 50 23728 32.6 
13754 
[8] 50 17873 29.5 
17305 
[9] 50 15536 21.8 
10126 
[10] 50 60242 102.6 
56805 
aDPM:  decomposition per minute  [alternative to 
count per minute (cpm) values]. 
effects in the system. These derivatives  possibly  might  modify the  enzyme 
activity by binding to benzazepine binding sites on RT-enzyme. 
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